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FOREWORD 
 
In 2004 the Institute of Bioinorganic and Radiopharmaceutical Chemistry, one of six institutes in the 
Research Centre Rossendorf, continued to focus its basic and application-oriented research on the 
use of radiotracers as molecular in vivo probes, especially in the human body, on three main fields: 
 
- radiotracers in tumour and metabolism research 
- radiometal therapeutics 
- PET in drug and food research 
 
In the field of radiopharmaceutical chemistry, the Institute is predominantly engaged in research on 
PET nuclides as well as on radiometals. 
 
In the latter field, our engagement in the coordination chemistry and radiopharmacology of technetium, 
rhenium and other metals has been further pursued. Here, chemical and radiopharmaceutical studies 
increasingly confront the radiotherapeutic aspect. This involves both the search for stable chelators for 
radiometals as well as attempts to optimize the in vivo behaviour of the molecule into which the che-
late unit is integrated. 
 
In the PET field, the improvement of labelling methods for carbon-11 and fluorine-18 continue to re-
main an area of considerable endeavour. The same is true for the task of increasing the range of PET-
radiopharmaceuticals produced according to GMP regulations. 
 
The Institute’s chemically and radiopharmacologically oriented activities were complemented by more 
clinically oriented activities in the Positron Emission Tomography (PET) Centre Rossendorf, which 
closely links the Institute with the Department of Nuclear Medicine of the Medical Faculty of the Uni-
versity Dresden. 
 
For these investigations, the lack of dedicated data processing tools has been identified as a potential 
bottleneck. Within the PET Centre, the Institute therefore is engaged in algorithm development for and 
implementation of such tools, notably in the area of accurate individual movement correction in PET 
investigations. 
 
Generally, the activities in the PET Centre were further extended. In this context, the decision to install 
a dedicated 7 T micro-MRI apparatus to augment the imaging capabilities for small animal investiga-
tions should especially be mentioned. The machine was delivered in December 2004 and will be op-
erational early in 2005. 
 
The studies on bioactive substances in food, which may cause health risks or exert other, not yet iden-
tified effects on the body have been continued. 
 
During the period under review, cooperations with external partners, particularly from the pharmaceu-
tical industry, could be further extended. 
 
After retirement of Dr. Spies, Prof. van den Hoff took over as Acting Director on April 1, 2004 until 
assumption of office by the successor of Prof. Johannsen, expected to take place in 2005. 
 
The Institute would like to thank all partners from universities, industry and research institutes who 
supported its progress, as well as all members and guests of the Institute for their active contributions 
in 2004. The Institute wishes to acknowledge in particular the support and assistance received from 
the Executive Board of the Research Centre Rossendorf, from the competent authorities and funding 
agencies. 
 
 
 
Prof. Dr. Jörg van den Hoff 
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Impact of Clinical Characteristics on the Pattern of the Regional Cerebral 
Glucose Metabolism in Patients with Major Depression  
B. Beuthien-Baumann, G. Zündorf, S. Lüdecke, A. Triemer, K. Schierz, K. Herholz,  
V. A. Holthoff 
 
Introduction 
In the acute phase of Major Depression im-
pairment of regional cerebral glucose metabo-
lism is localized mainly in the frontal cortex [1]. 
The aim of this investigation was to assess the 
additional impact of clinical characteristics like 
age, gender, number of prior depressive epi-
sodes, severity and duration of the current 
depressive episode on the cerebral glucose 
pattern.  
 
Patients and Methods 
Patient group: 84 patients with Major Depres-
sion in acute phase, 64 female, 20 male; mean 
age 49.6±15.9 years; Hamilton Depression 
scale 21-items: 27.6±4.66 points. 
Normal controls: 54 volunteers, 22 female, 32 
males, mean age 51.7±13.7 years. The control 
group was derived from the European Data-
base of the EU-project ”Network of Efficiency 
and Standardization of Dementia Diagnosis” 
(NEST-DD).  
FDG-PET: ECAT Exact HR+ (Siemens/CTI), 
300 MBq [18F]FDG, measured attenuation 
correction, acquisition 40-60 min post injection. 
Data analysis: SPM99 (Statistical Parametric 
Mapping) [2], ANOVA, covariate: age at the 
time point of PET measurement. We retained 
as significant those clusters with a corrected 
p<0.05. 
 
Results and Discussion 
Comparing the group of patients in acute 
phase of Major Depression with the control 
group shows the impairment of regional cere-
bral glucose metabolism in the dorsolateral 
prefrontal cortex -more pronounced on the left 
side-(Brodmann area (BA) 9, BA 44-47; 
p<0.0001), impairment bilaterally in the orbi-
tofrontal cortex (BA 10; p< 0.0001) and bilater-
ally in the superior temporal cortex (BA 41; 
p<0.0001) (Fig. 1). 
Focussing on the clinical characteristic “age” 
one can observe a correlation between the 
increasing age at onset of the depressive epi-
sode and the degree of reduction of the dorso-
lateral prefrontal cortex (p<0.001) (Fig. 2), a 
pattern that does not correspond to the reduc-
tions due to age seen in a normal population 
[3]. 
No influence on the cerebral glucose pattern 
was seen from the other clinical characteris-
tics: gender, number of prior depressive epi-
sodes, severity and duration of the current 
depressive episode. 
 
 
 
Fig.1. Brain areas marked in red indicate a reduction of 
brain glucose metabolism in patients with depression 
compared to the control group. 
  
 
Fig. 2. Influence of age (marked in red) on the cerebral 
glucose pattern in patients with depression. 
 
One substantial factor influencing the cerebral 
glucose pattern of patients with Major Depres-
sion in the acute phase seems to be the age of 
the patients, indicated by the regional reduc-
tion of metabolism in the dorsolateral prefrontal 
cortex, which is part of the pattern distinguish-
ing patients and controls. It can be therefore 
hypothesized that the age is a risk factor for 
the development of Major Depression.  
 
References 
[1] Beuthien-Baumann, B. et al., Acta Psych-
iatr. Scand. 110 (2004) 184-194. 
[2] Friston, K., Hum. Brain Mapping 1 (1994) 
214-220. 
[3] Herholz, K. et al., Neuroimage 17 (2002) 
302-318. 
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Trigeminal Activation Measured with [15O]H2O-PET 
B. Beuthien-Baumann, T. Hummel, L. Oehme, M. Heinke, J. Kotzerke, J. van den Hoff 
 
 
 
Introduction 
During their life time more than 5 % of the 
population will loose their sense of smell, me-
diated through the olfactory nerve, due to 
trauma or disease. In these patients the 
trigeminal nerve represents the only intranasal 
chemosensory modality. Up to date, most in-
vestigations studying olfactory processing ap-
ply mixed olfactory-trigeminal stimuli. The aim 
of this study was to investigate the cerebral 
processing of discrete trigeminal nerve activa-
tion in normal controls without olfactory im-
pairment with [15O]H2O-PET.  
 
Methods 
Normal control group: 15 males (age 30-58 
years, mean age 36 years) without neurologi-
cal and internal diseases and without impair-
ment of the olfactory senses.  
Trigeminal activation: Application of short CO2 
pulses via intransal tube into the left nasal 
cavity (pulse length 1 s, interval between 
pulses 3 s) starting 20 s before injection of 1.7 
GBq [15O}H2O.  
PET: ECAT Exact HR+ (Siemens/CTI), dy-
namic acquisition over 5 min. Total of 4 PET 
scans per person, alternating activation and 
non-activation studies. Iterative reconstruction 
of the acquired data with measured attenuation 
correction. Parametric flow maps were calcu-
lated, applying a standard input function. 
These parametric flow maps were taken for the 
comparison of activation and non-activation 
studies. The analysis was performed with the 
software package SPM99 [1]. The study proto-
col was approved by the local ethics commit-
tee and the Federal Agency of Radiation Pro-
tection.  
 
Results and Discussion 
In 12 persons investigated, a total of 2 activa-
tion studies and 2 non-activation studies were 
successfully acquired. In the other 3 persons, 
due to technical problems, at least one pair of 
activation and non-activation was acquired. 
The first result of the ongoing data analysis of 
all studies performed shows a bilateral activa-
tion of the projection area of the trigeminal 
nerve, located in the lower part of the post-
central gyrus. This activation is more pro-
nounced in the right hemisphere than in the left 
hemisphere (Fig. 1).  
 
 
 
Fig. 1. SPM analysis, comparing activation versus non-
activation of all subjects investigated. There is a clear 
bilateral activation in the projection field of the trigeminal 
nerve of both hemispheres with accentuation on the right 
side, contralateral to the activation side. 
 
 
The evaluation of the stability of the intraindi-
vidual activation is one subject of the ongoing 
data analysis. 
 
 
References 
[1] Friston, K., Hum. Brain Mapping 1 (1994) 
214-220. 
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4 h FDOPA Protocol for the Investigation of Parkinson’s Disease with PET 
P. Bühler, A. Strumpf, B. Beuthien-Baumann, R. Bergmann, J. Kotzerke, J. van den Hoff
 
 
Introduction 
Positron Emission Tomography with the radio-
tracer [18F]-fluorodopa (FDOPA) can be used 
to investigate deficiencies of the dopaminergic 
system in the brain. It is therefore a powerful 
tool in diagnosing Parkinson’s disease (PD) 
and to differentiate it from other movement 
disorders. FDOPA is intravenously adminis-
tered. After transport through the blood-brain-
barrier it is metabolized into [18F]-fluorodop-
amine (FDA), which is then trapped in the pre-
synaptic vesicles in the striatum. Parts of the 
FDOPA and also FDA are metabolized to other 
products which are capable of leaving the 
brain. The uptake of FDA into the striatum, 
which can be quantified with PET, is used as a 
discriminator for PD. A reduced uptake is in-
dicative for PD. At the PET centre of the FZR, 
the uptake is normally quantified by kocc = 
k2k3/(k2+k3) (see Fig. 1) which is determined 
using the data of the first 60 minutes post-
injection of a dynamic PET scan and a refer-
ence tissue model. During this period FDOPA 
behaves practically like a irreversibly bound 
tracer (kloss = 0). 
 
 
 
 
Fig. 1. Compartment model used to analyse FDOPA-PET 
data. In PD k3 is supposed to be reduced and kloss, to be 
enhanced. C: activity concentration, k: coupling constant. 
 
This is no longer the case at later times, at 
which the effects of kloss ≠ 0 become important. 
As was demonstrated by Sossi et al. [1], data 
taken at later times can be used to measure 
the dopamine turnover kocc/kloss which they 
argue is the better discriminator for PD than 
kocc. To determine the dopamine turnover they 
introduced a dynamic PET protocol with a total 
duration of 4 hours. With some assumptions 
the system of equations describing the com-
partment model can be reduced to the linear 
relation 
 
 
 
 
and kocc/kloss is determined with a linear fit. 
Here we report on the recent implementation 
of a similar protocol at the PET centre of the 
FZR and first results of a trial study with 10 
patients. 
 
Method 
The protocol comprises 3 dynamic PET scans 
of 90 and 2×40  minutes which are acquired 
within 4 hours. The data are acquired in 3D list 
mode. Prior to each emission scan a transmis-
sion scan is acquired and blood samples are 
taken in regular intervals throughout the entire 
investigation. Between the scans the patient is 
allowed to stand up and walk around. In order 
to allow an accurate coregistration of the 3 
scans, the position of the patient head is con-
tinuously monitored with an infrared tracking 
system. This information is not only used for 
coregistration but can also be used for move-
ment correction [2]. After sorting and recon-
struction of the acquired list mode data, circu-
lar regions of interest (ROIs) are selected in 
the striatum (represent Cf+Cb) and the occipital 
cortex (represents Cr) which are used to com-
pute the time course of the activity concentra-
tions. 
 
 
Results and Discussion 
So far we have carried out the procedure with 
10 patients. The values obtained for kocc/kloss 
are comparable with the values published by 
Sossi et al. [1] as shown in the upper panel of 
Fig. 2. Each of the open diamonds represents 
a patient. The values for the dopamine uptake 
and turnover are highly correlated as is shown 
in the lower panel of Fig. 2, which suggests 
that both quantities are similarly good in differ-
entiating PD. However, in order to judge the 
methods a discriminating analysis must be 
carried out with sufficiently large groups of PD 
and non-PD patients. Such a study will be 
started next year. 
 
 7 
  
Fig. 2. Comparison of kocc/kloss values from study patients  
(open diamonds) with results published by Sossi et al., 
2002 [1] (inset) and correlation between kocc and kocc/kloss.
 
 
References 
[1] Sossi, V. et al., J. Cereb. Blood Flow Me-
tab. 22 (2002) 232. 
[2] Bühler, P. et al., IEEE Trans. Med. Imag.  
23 (2004) 1176. 
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FDG, OMFD and DOPA in the Diagnostic Work-up of Patients with Medullary 
Thyroid Carcinoma and Increasing Calcitonin Levels 
B. Beuthien-Baumann, A. Strumpf, J. Zessin, J. Bredow, J. Kotzerke 
 
 
Introduction 
In patients with medullary thyroid carcinoma 
(MTC) the only chance of cure is through sur-
gery. Therefore the detection of local recur-
rence or metastases is mandatory for a cura-
tive intent, otherwise the diagnostic aim is the 
identification of malignant sites which can 
cause local problems like, i.e., bone metasta-
ses causing fractures or local recurrences 
invading vital structures of the neck. Compar-
ing different nuclear medicine procedures in 
the diagnostic of MTC, FDG-PET shows a 
moderate detection rate [1]. Since MTC exhib-
its histologically neuroendocrine features it 
was described that [18F]DOPA can identify 
metastases or local recurrence in patient with 
MTC [2]. [18F]OMFD is a metabolite of DOPA 
which behaves in vivo like an amino acid and 
is used in the diagnostic of malignant brain 
tumours. In previous investigations it was 
found, that OMFD has only little accumulation 
in the muscles and is excreted via the urinary 
tract [3]. It was hypothesized, that MTC could 
be visualized by this amino acid tracer.  
 
Patients and Methods 
Patient group: 14 patients with MTC and in-
creased calcitonin levels (range 48–4233 
pg/ml) were investigated with FDG-PET (370 
MBq FDG i.v., acquisition 60 min post injec-
tion). 10 out of these 14 patients were investi-
gated with OMFD (300 MBq i.v., acquisition 
from 15 min p.i.). 12 out of these 14 patients 
were scanned with DOPA (premedication with 
100 mg carbidopa 60 min pre-injection of 300 
MBq DOPA, acquisition from 60 min p.i.).  
PET: ECAT Exact HR+ (Siemens/CTI), itera-
tive reconstruction with measured attenuation 
correction.  
 
Results and Discussion 
In 5 patients FDG revealed small focal in-
creased areas (about 1 cm in diameter) in the 
neck, thorax or upper abdomen, highly suspi-
cious for metastases and local recurrence 
respectively. 1 patient showed focal uptake at 
the left hip joint. 4 patients showed focal up-
take with DOPA, in some areas corresponding 
to the FDG uptake in neck and thorax. In three 
of these patients uptake sites with DOPA were 
more numerous and some correlate findings 
were detected with ultrasound (neck) and CT 
(thorax). In 2 patients with DOPA uptake FDG-
PET, CT or ultrasound was negative. With 
OMFD uptake was seen in 2 patients (1 x dor-
sal of the urinary bladder, 1 x in the liver) with-
out correlate with FDG, DOPA or conventional 
diagnostic. 
With FDG and DOPA focal increase uptake 
was noted in a total of 8/14 patients, highly 
suspicious for metastatic spread or local recur-
rence, although no histological verification was 
performed up to now. Therefore it can be con-
cluded that there is a chance to detect MTC 
via increased glucose metabolism and in-
creased neuroendocrine uptake of DOPA, but 
not via increased amino acid transport with 
OMFD.  
 
 
 
Fig. 1. 63-year old patient, initial stage pT4N1Mo, increa-
sed calcitonin level of 2151 pg/ml at time of PET. Focal 
increased uptake in the neck with FDG (2 spots) and 
DOPA (1 spot), no uptake with OMFD. 
 
 
Correlate with ultrasound: Calcified structure in 
the left ventral cervical region. 
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User Guided Segmentation and Quantification of Three-Dimensional Structures 
in Oncological Whole Body PET - Continued 
C. Pötzsch, J. van den Hoff 
 
 
Introduction 
Oncological positron emission tomography 
(PET) studies typically contain several hundred 
tomographic images, which have to be ana-
lysed to derive informations such as the de-
gree of metastatic spread of a tumour disease. 
To fully exhaust the quantitative information 
provided by PET with respect to tracer accu-
mulation and volume of target structures it is 
necessary to provide means for analysing 
these large data sets with manageable user 
interaction. Available programs, both, commer-
cially as well as in the public domain do not 
offer the necessary functionality because 
quantitative evaluation is generally limited to 
processing of individual tomographic images. 
Therefore, it was the aim of this work to de-
velop and implement volume oriented methods 
for quantification and provide a dedicated tool 
for the described situation. In the last report we 
described the basic functionality of the applica-
tion. Here we will discuss the developments of 
this year and further aims. 
 
Results and Discussion 
One of the aims in the last report was the rou-
tine usability of the application for oncological 
studies performed in the PET center. To ar-
chive this, additional functionality was imple-
mented and verified. In addition to the previ-
ously available orthogonal viewer mode two 
new views of the tomographic volumes are 
integrated. The first, is an overview of all slices 
in a specific angle (e.g. transaxial, coronal, 
sagittal), see Fig. 1. The user has the possibil-
ity to decide how many slices are displayed. 
The key functionality of defining masks and the 
threshold based search of VOI’s is kept in this 
view.  
 
 
Fig. 1. Multiple planes view of a human brain 
The second new view is a so-called maximum 
intensity view (MIPS) (see Fig. 2). Within this 
view two modes are possible. The first mode is 
the standard MIPS view where the whole vol-
ume is rotated over a user definable range of 
angles and the maximum projection computed 
for all angles and displayed afterwards. So the 
user has the impression of a rotating object 
where in all angle positions the hottest parts 
remain visible. In the second method a gaus-
sian weight can be used to modify the projec-
tion, enhancing interior structures. 
 
Fig. 2. Maximum Intensity Projection of an oncological 
study 
 
A new image export with various setup pa-
rameters (e.g. a colorbar) is available for all 
three views. For distance and size determina-
tions a ruler mode was implemented (see Fig. 
2). To physically archive the results of the ap-
plication a new print functionality is imple-
mented where the user has the ability to define 
a header/footer to meet the in house design 
and layout standards.  
Future developments will aim to improve the 
threshold based segmentation of the tomo-
graphic data. For follow up studies coregistra-
tion methods will be developed in cooperation 
with ABX (Advanced Biochemical Compounds, 
Radeberg). These coregistered volumes can 
be used to compare VOIs at different times to 
assess treatment success or failure. 
 10
Development of an Algorithm for Respiratory Motion Correction in Gated PET 
Investigations of the Thorax 
D. Möckel, U. Just, J. van den Hoff  
 
Introduction 
Respiratory motion has a negative influence on 
the image quality of PET investigations of the 
human thorax. In the PET Centre Rossendorf 
a method was developed to register the respi-
ratory motion and correlate the dataset with 
the PET data [1]. It is possible to create gated 
images of defined respiratory phases, thus 
reducing the effects of respiratory motion. Ho-
wever this method has a disadvantage. The 
statistics in respiratory motion gated images is 
decreased and the noise is increased, which 
results in a more difficult detection of struc-
tures with low activity concentration.   
An algorithm was developed correcting the 
respiratory motion on the one hand and using 
the whole statistics on the other hand. 
 
Methods 
The developed algorithm transforms each of 
the single volume images of a respiratory mo-
tion gated study to a selected target image out 
of the gated sequence. The corrected image is 
finally created by averaging the image se-
quence. The transformation value for each 
voxel of the volume matrix is calculated by 
using a transformation function. The transfor-
mation function is modelled in consideration of 
the anatomy and physiology of the respiratory 
system. Only motions in craniocaudal direction 
are corrected because the main part of the 
respiratory motion proceeds in this direction. 
The transformation function depends on the 
craniocaudal position since motion amplitude 
changes dependent on it. Further, the trans-
formation function can be dependent on lateral 
and ventrodorsal position to address additional 
anatomical dependencies.  
The calculation of the transformation function 
requires input parameters such as the position 
of diaphragm and other moving structures. A 
graphical user interface was developed for the 
input of the transformation parameters. 
The method was evaluated on eleven respira-
tory motion gated patient studies of the thorax. 
In these studies seven hearts and eight tu-
mours were investigated. 
 
Results 
The measured tumour volumes in the cor-
rected images are similar to those derived from 
the gated images for motion amplitudes 
greater than 0.5 cm (Fig. 1). For three tumour 
lesions with an amplitude of >0.9 cm the 
measured volume after correction was 6 %,     
4 % and 12 % greater than the averaged vol-
ume of the gated images, in contrast to 19 %, 
26 % and 21 % in images created without gat-
ing. 
For low motion amplitudes (<0.5 cm) there was 
no difference between the measured tumour 
volumes in the corrected and uncorrected im-
ages. However in cases of small motion ampli-
tudes the imaged tumour volume is little influ-
enced and a respiratory motion correction is 
less needed. 
With the developed correction method small 
tumours with high motion amplitude and low 
activity concentration may be detected that are 
not visible in non gated studies because of the 
respiratory motion and in the single gated im-
ages because of the high noise.  
Images of the heart could be improved by the 
respiratory motion correction (Fig. 1). Espe-
cially for combined respiratory and heart gated 
investigations the use of the developed 
method is advantageous. Thus it is possible to 
study the heart cycle with the influence of res-
piration largely reduced and without the loss of 
statistics in single respiratory motion gated 
images.  
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 Fig. 1. Coronal slices of two FDG-PET studies of the thorax showing a tumour (top) and a heart (bottom). The displayed images 
of each row illustrate (from left to right )one single respiratory phase, the non gated study and the corrected image, respectively.  11
Correction of Body Motion Artifacts in PET - Optimized 
J. Langner, P. Bühler, E. Will, J. van den Hoff 
 
Introduction 
Patient motion during PET investigations is 
unavoidable and can result in a noticeable loss 
of resolution and/or introduce artifacts in the 
final PET image. In a previous report [1] we 
presented that an event (list mode) based 
movement correction method, which is capable 
of minimizing such influences, results in an 
improved image quality. However, the applica-
tion of the method showed that the processing 
times are large which hinders its introduction in 
routine operation. Therefore our recent work 
concentrated on developing methods to opti-
mize the correction algorithm by making use of 
modern multiprocessor systems. Here we re-
port on the progress and implementation and 
demonstrate how these methods allow to inte-
grate list mode based movement corrections in 
routine operation by reducing the processing 
time considerable. 
 
Method 
The correction algorithm, which spatially reori-
entates each registered line of response (LOR) 
depending on movement information supplied 
by an external motion tracking system, under-
went a parallelism analysis. In several steps 
the data dependencies of the algorithm were 
identified and independent areas encapsulated 
into separate threads. This also includes the 
time consuming “Out-of-FOV” corrections as 
well as the final sorting and binning into a si-
nogram file. These threads are then automati-
cally distributed among the available proces-
sors during the correction. In addition, to sup-
port the idea of a routine use of motion correc-
tion procedures during neurological PET ac-
quisitions, an implemen-tation of a graphical 
user interface was also part of the develop-
ment. During the research on the user inter-
face we decided to use the “Qt” development 
framework [2] that allows to keep applications 
portable over several platforms, aiming at a 
GUI usable by the technicians performing the 
PET acquisitions. Furthermore, this application 
also has the possibility to directly acquire the 
motion data from the ARTtrack1 tracking sys-
tem with which the head motion is measured. 
 
Results and Discussion 
The speed improvement and the accuracy of 
the optimized correction algorithm was valida-
ted with several test setups and measure-
ments. Here we show results of a comparison 
between the sequential and the parallel im-
plementation of the algorithm. For a selected 
study (21 frames) the sequential version re-
quired ~21 h for correcting list mode data 
based on an 1 h PET study while the parallel 
implementation only required ~1.5 h thanks to 
its multithreaded design. 
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           sequential     parallel 
Fig. 1. Speed measurement where list mode data based 
on an one hour PET acquisition was first corrected by the 
sequential implementation and afterwards by the parallel 
version of the correction algorithm, showing a considerable 
speed up of the computations. 
The capabilities of the method are demon-
strated in Fig. 2. The data show a phantom 
study, in which the phantom was first kept at 
rest and during the second half of the acquisi-
tion was moved in axial direction. Comparison 
of images from the first and second half of the 
study prove, that the movement correction 
notably reduces the movement artifacts. 
 
Fig. 2. Results of a test measurement with movement in 
axial direction (z). Sagittal views at the top row show re-
constructed images in different positions (at rest, w/o, and 
w/ correction, respectively). 
 
Our future work will focus on validation of 
these methods for the application in routine 
operation. In addition, further optimizations 
should eliminate still existing problems and 
also probably allow to correct motion artifacts 
in real time. 
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Tomographic Image Reconstruction Software for the MicroPET P4 Scanner 
H. Moelle, U. Just, P. Bühler, J. van den Hoff 
 
A program to reconstruct tomographic images from the data delivered by our microPET scanner (CTI Concorde 
Microsystems) has been developed. It allows an easy and  fast image reconstruction in batch mode and supports 
the evaluation of the reconstruction parameters. The possibility to systematically assess reconstruction properties 
offers new opportunities to improve the image quality. 
 
Introduction 
The PET Center Rossendorf is equipped with 
a microPET P4 scanner (CTI Concorde Micro-
systems, LLC, Knoxville, TE., USA). The re-
construction software provided with the scan-
ner has various limitations which hamper the 
efficient processing of the data. It is available 
only for MS-Windows and provides no oppor-
tunity for batch processing. So user interaction 
is needed for every single reconstruction. Fur-
thermore, only one instance of the software is 
allowed on a system. This limits the usage to 
one person. The software works unstable if 
data is not located on a local drive, which ma-
kes copying of huge files over the network 
necessary. The reconstruction of a normal 
study with 35 frames takes about 12 hours with 
the OSEM / MAP method provided with the 
software. Iterative reconstruction procedures in 
PET require specification of various recon-
struction parameters upon which the number 
of iterations is crucial for the quality of the re-
constructed image. Optimization of the recon-
struction parameters is a heavily time consum-
ing procedure with the standard software. The 
goal of this work was to develop a simple to 
use tool for reconstruction of microPET data 
and to facilitate optimization of the reconstruc-
tion parameters. 
 
Methods 
Two reconstruction methods of the open 
source reconstruction software STIR [1] have 
been implemented (OSMAPOSL, FBP2D). The 
reconstruction process is controlled by a set of 
parameters which can be set either in the 
graphical user interface (GUI) written with Qt 
or on the command line. For evaluation of the 
optimum number of iterations an iteration se-
quence method has been implemented. It pro-
duces a volume file which consists of one 
frame for each iteration step applied to a se-
lected frame of a study. The calibration factor 
to calculate the absolute activity can be added 
or can be selected from a list of stored values. 
All reconstructions are executed in a batch 
mode which makes human interaction unnec-
essary after having started the process. The 
frames of a study are distributed to the proces-
sors available on the system during the recon-
struction. This speeds up the reconstruction. 
The progress of the reconstruction of a whole 
study and its frames is visible to the user in the 
GUI and on the command line. The recon-
structed images are stored in ECAT7 volume 
format to allow use of existing postprocessing 
software. 
 
Results 
Identification of the best set of reconstruction 
parameters for a specific study is possible in a 
justifiable amount of time. Multiple instances of 
the software are possible and the data is not 
limited to a local drive. The software is avail-
able for SUN OS and Linux. 
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Fig. 1. [18F]FDG microPET images of a line phantom: all images are produced with OSMAPOSL method (7 subsets, all 
segments, no filter) but different number of iterations, left most slice image is the result after two iterations. Next image is 
produced after four iterations, the next after eight iterations and the last after 16 iterations. The contrast increases with the 
number of iterations. 
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Protein Oxidation in Human Disease: a Minireview 
J. Pietzsch 
 
Oxidative modification of enzymes and structural proteins plays an essential role in the etiology, manifestation, 
and progression of an important number of human diseases. During the past two decades, considerable evidence 
has implicated oxidative stress, e.g., in rheumatoid arthritis, sepsis, atherosclerosis, diabetes mellitus, chronic 
renal failure, Alzheimer’s disease, and amyotrophic lateral sclerosis, as well as in ageing. Recent advances in our 
understanding of oxidative stress have included: identification by mass spectrometry of the chemical nature of 
specific oxidative modifications in various proteins; identification of oxidized proteins in several disease-related 
tissue compartments; establishing the role of specific receptors that recognize oxidized proteins; and characteri-
zation of redox signaling pathways and of transcription factors that respond to oxidative stress. In this line, the 
minireview summarizes recent results of the Pathological Biochemistry Group providing further evidence that 
oxidative modification of human low density lipoproteins (LDL) plays a pivotal role in the pathogenesis of athero-
sclerosis. Better understanding of mechanisms generating oxidized LDL (oxLDL) and their metabolic conse-
quences should help the development of new strategies for the prevention of cardiovascular diseases. 
 
Atherosclerosis and chronic vascular diseases 
remain a major health problem in industrialized 
countries. Recent evidence suggests that oxi-
dized LDL (oxLDL) play an important role in 
atherogenesis [1]. However, whether oxLDL is 
an initiator or accelerator of disease and what 
is the diagnostic significance of circulating 
oxLDL in human blood, is subject of debate 
and intensive study. The atherogenicity of LDL 
is increased by oxidative modification of both 
its protein and lipid moiety, occurring within the 
vascular wall and other inflammatory sites. 
Many pathways are known to oxidize LDL, at 
least in vitro [2, 3]. These include the myelop-
eroxidase pathway, the reactive nitrogen path-
way, and the glycoxidation pathway, which 
generate various potent oxidants, e.g., the 
hydroxyl radical (•OH), the superoxide radical 
anion (O2•-), hypochlorite (OCl-), and peroxyni-
trite (ONOO-) [1]. However, the specific path-
ways that are responsible in the atherogenic 
process have not been conclusively identified. 
Modification of apolipoprotein (apo) B-100, the 
major structural protein of LDL, can occur di-
rectly by these oxidants, or indirectly by cova-
lent binding of lipid hydroperoxide breakdown 
products, such as 4-hydroxy-nonenal. Addi-
tionally, there is evidence supporting the hy-
pothesis that among important mechanisms of 
apoB-100 oxidation are also metal-catalyzed 
processes. These processes involve binding of 
either free or, physiologically more relevant, 
complexed (porphyrin-bound) redox-active 
ferric iron to discrete binding sites of LDL and 
apoB-100, respectively, thus forming centers 
for redox cycling and repeated radical produc-
tion [3]. For apoB-100 these modifications 
finally result in the formation of new epitopes. 
The latter are specifically recognized by scav-
enger receptors, followed by an excessive 
uptake and accumulation of oxLDL in macro-
phages, vascular smooth muscle cells, and 
endothelial cells in an unregulated fashion that 
can lead to foam cell formation [4]. The pres-
ence of foam cells in the vascular wall is con-
sidered to be the first morphological substrate 
of atherosclerosis. In contrast, native LDL 
(nLDL) will not promote the formation of foam 
cells under most circumstances, as uptake of 
nLDL by the LDL receptor pathway results in 
down-regulation of endogenous cholesterol 
synthesis and LDL receptor expression. Very 
recently, direct oxidation of apoB-100 has been 
measured in LDL recovered from human aortic 
vascular lesions [5]. Moreover, direct oxidation 
of apoB-100 has been measured in circulating 
LDL in vivo in conditions, which are accompa-
nied by accelerated atherosclerosis including 
rheumatoid arthritis, impaired glucose toler-
ance, and overt diabetes mellitus [6, 7]. The 
role of these circulating oxLDL in disease is 
poorly understood. One reason for this is the 
lack of suitable sensitive and specific radio-
labeling methods, which would allow direct 
assessment of metabolism of oxLDL in vivo. 
Thus, the development of novel methodologies 
for radiolabelling of both nLDL and oxLDL with 
18F and the use of small animal PET to investi-
gate the metabolism of several species of 
oxLDL in vivo is currently in progress [9]. 
The author wishes to thank Mareike Barth, Uta Lenkeit, 
and Susan Hoppmann for their expert technical assis-
tance. 
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Analysis of 6-Hydroxy-2-Aminocaproic Acid (HACA) as a Specific Marker of 
Protein Oxidation: the Use of N(O,S)-Ethoxycarbonyl Trifluoroethyl Ester    
Derivatives and Gas Chromatography/Mass Spectrometry 
J. Pietzsch, R. Bergmann 
 
α-Aminoadipyl semialdehyde (αASA) is sup-
posed to be a primary product of transition 
metal catalyzed oxidation of protein lysine side 
chain residues [1]. αASA may arise via initial 
hydrogen abstraction at carbon six and forma-
tion of a reactive lysyl radical. The latter is a 
target for hydroxylation and subsequent loss of 
the ε-amino group. By reduction with sodium 
borohydride, αASA forms the non-protein 
amino acid 6-hydroxy-2-aminocaproic acid 
(HACA). For other proteins than apolipopro-
teins (apo), the formation of HACA has been 
measured in vitro and in vivo [1]. In this re-
spect, the value of HACA as a specific marker 
of metal catalyzed oxidation of apoB-100 has 
not been established. The mature apoB-100 
(Mr 516,000; without carbohydrate content) 
consists of a single polypeptide chain of 4536 
amino acids, and there is only one copy of the 
protein on each LDL particle. ApoB-100 con-
tains 357 lysine residues that are supposed to 
be partially susceptible to direct oxidative 
damage. The objective of this report is the 
investigation of the feasibility of the use of 
N(O,S)-ethoxycarbonyl trifluoroethyl ester 
(ECEE-F3) derivatives and gas chromatogra-
phy/mass spectrometry (GC/MS) to quantify 
low-abundance αASA residues in isolated LDL 
apoB-100. Isolation, delipidation of human 
LDL, and enzymatic hydrolysis of apoB-100 
were performed as previously described [2]. 
The free amino acids were isolated from pro-
tein hydrolysates, derivatized to their ECEE-F3 
derivatives, and analyzed by electron-impact 
ionization stable isotope dilution GC-MS as 
described elsewhere [2]. 
 
Results and Discussion 
Initial studies of the ECEE-F3 derivatives of 
protein amino acids by GC/MS showed them to 
be well separated under the conditions em-
ployed, with retention times being very repro-
ducible [2-4]. The derivative studied yielded 
diagnostically useful fragment ions for use in 
HACA determination (Fig. 1). The limit of de-
termination of HACA was 1 nmol/L (1 
fmol/injection). The physiological level of 
HACA found in native circulating LDL obtained 
from normolipidemic, young male volunteers 
was 7.1 ± 10-4 mol/mol apoB-100 (0.02/10,000 
lysine residues). 
Furthermore, the data show that lysine side 
chain residues of apoB-100 are highly sensi-
tive to form αASA and HACA, respectively, if 
LDL is exposed to low concentrations of iron or 
copper as pro-oxidants by using established 
oxidation systems in vitro. As an example, Fig. 
2 shows the formation of HACA in human LDL 
particles exposed to various oxidation systems 
in vitro. 
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Fig. 1. EI ionization (70 eV) mass spectra of the ECEE-F3 
derivatives of HACA (Mr 301). Spectra show the prominent 
[M-89]+• and [M-127]+ ions, due to the losses of NH2CO2Et 
and •CO2CH2CF3, respectively, from the ionized molecules. 
GC/MS conditions have been described elsewhere [2]. 
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Fig. 2. Formation of HACA in human LDL particles expos-
ed to various oxidation systems in vitro  (n = 3) [2].  
 
The approach is currently being applied to 
studies dealing with mechanisms of protein 
oxidation in vitro and in vivo.  
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Analysis of Non-Protein Amino Acids as Specific Markers of Low Density Lipo-
protein Apolipoprotein B-100 Oxidation in Human Atherosclerotic Lesions 
J. Pietzsch, R. Bergmann 
 
There is effectual evidence supporting the hypothesis that among important mechanisms of apoB-100 oxidation 
are metal catalyzed processes. Two highly specific products of metal catalyzed protein oxidation are γ-glutamyl 
semialdehyde (γGSA) and α-aminoadipyl semialdehyde (αASA). γGSA is a product of oxidation of arginine and 
proline, and αASA, of oxidation of lysine. By reduction γGSA forms 5-hydroxy-2-aminovaleric acid (HAVA), and 
αASA, 6-hydroxy-2-aminocaproic acid (HACA). Sensitive gas chromatography-mass spectrometry methods allow 
their quantification in LDL recovered from human atherosclerotic lesions. 
 
Direct oxidation of apolipoprotein (apo) B-100, 
the major protein of low density lipoprotein 
(LDL), is thought to finally result in the forma-
tion of new epitopes that are specifically rec-
ognized by scavenger receptors followed by an 
excessive uptake and accumulation of LDL 
particles in macrophages and vascular smooth 
muscle cells that can lead to foam cell forma-
tion [1]. The latter appears to be the earliest 
morphologic substrate of atherogenesis. With 
respect to the pathogenesis of atherosclerosis, 
it has been emphasized that the analysis of 
specific products protein oxidation in LDL iso-
lated from atherosclerotic tissue could provide 
quantitative chemical and clinical evidence for 
metal catalyzed oxidative processes in the 
human artery wall [2]. We performed a sys-
tematic investigation on determination of levels 
of HAVA and HACA in LDL apoB-100 recov-
ered from human aortic vascular lesions. Le-
sional LDL were isolated from the intima of 
normal and atherosclerotic specimen of human 
thoracic aortas as published elsewhere [3]. 
Isolation of apoB-100, enzymatic hydrolysis of 
apoB-100, and determination of HAVA and 
HACA, respectively, followed the protocols 
described previously by us [4, 5]. The content 
of both γGSA and αASA was significantly 
higher in LDL recovered from all types of le-
sion (including fatty streaks that represent the 
earliest lesion of atherosclerosis) when com-
pared with normal aortic tissue (paired Stu-
dent`s t test). Fig. 1 shows the content of 
HAVA and HACA in the intima from various 
stages of lesion evolution as determined by 
sensitive and specific GC-MS analysis. These 
results clearly support the hypothesis that 
metal catalyzed processes contribute to LDL 
oxidation both early and late in the atheroscle-
rotic process [6]. The overall yield of HAVA 
and HACA, respectively, that has been found 
in lesion LDL (mean HAVA content: 
10.45±0.66 mol/mol apoB-100, equally to 
328/10,000 proline plus arginine residues; 
mean HACA content: 8.55±2.06 mol/mol apoB-
100, equally to 243/10,000 lysine residues) is 
remarkably high and indicates that proline, 
arginine, and lysine residues are good targets 
for metal catalyzed oxidative attack. The con-
tent of HAVA and HACA in both atherosclerotic 
and normal aortic tissue exceeded the physio-
logical level of HAVA (0.012±0.004 mol/mol 
apoB-100 (0.4/10,000 proline plus arginine 
residues)) and HACA (7.1 × 10-4 mol/mol 
apoB-100 (0.02/10,000 lysine residues)) found 
in native plasma LDL obtained from healthy 
normolipidemic, normoglycemic subjects [4, 5]. 
However, additional work is needed to under-
stand both the nature of the original oxidative 
insult and the specific consequences of γGSA 
and αASA formation for the metabolic fate of 
apoB-100-containing lipoproteins in vivo. 
 
Fig. 1. Box plots showing low density lipoprotein 
apolipoprotein B-100 (apoB-100) 5-hydroxy-2-aminovaleric 
acid (HAVA; white boxes) and 6-hydroxy-2-aminocaproic 
acid (HACA; grey boxes) content in intima from various 
stages of lesion evolution in human thoracic aorta. 
Samples were obtained from 20 male accident victims 
(aged 26 to 45 years, no signs of severe acute diseases) 
within 10 hours of sudden death [6]. Normal and 
atherosclerotic tissue (fatty streaks, intermediate, and 
advanced plaques) was classified according to the criteria 
of the Pathobiological Determinants of Atherosclerosis in 
Youth Study. 
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Analysis of Specific Markers of Protein Oxidation in Rheumatoid Arthritis 
Plasma and Synovial Fluid LDL 
J. Pietzsch, R. Bergmann, S. Kopprasch1
1Department of Internal Medicine III, Medical Faculty, University of Technology Dresden, Germany 
 
Rheumatoid arthritis (RA) is a chronic inflammatory disease in which reactive oxygen species have been impli-
cated. The antioxidant capacity of synovial fluid is impaired. We hypothesized that LDL in the inflamed synovial 
joint of patients with active RA undergo pronounced oxidation. To better understand mechanisms of LDL oxidation 
in RA a novel GC-MS methodology using N(O,S)-ethoxycarbonyl trifluoroethyl amino acid esters (ECEE-F3) has 
been applied for sensitive determination of 3-chlorotyrosine (3-Cl-Tyr), 5-hydroxy-2-aminovaleric acid (HAVA), 
and 6-hydroxy-2-aminocaproic acid (HACA) in apoB-100 of plasma and synovial fluid LDL subfractions. 3-Cl-Tyr 
is a specific marker of myeloperoxidase-catalyzed protein oxidation, whereas HAVA and HACA are specifically 
formed by metal-catalyzed protein oxidation.  
 
In subjects with seropositive rheumatoid arthri-
tis (RA) LDL particles accumulate in an acces-
sible inflammatory site, the inflamed synovial 
joint, and are supposed to be susceptible tar-
gets of oxidative attack. Oxidized LDL are 
likely to serve as mediators for joint damage, 
further exacerbating the inflammatory process. 
Furthermore, there is clinical and experimental 
evidence that subjects with RA show higher 
cardiovascular mortality when compared with 
the general population [1].  
Paired knee synovial fluid and plasma samples 
were collected from 30 patients with active RA 
(12 men/18 women; 21-63 years) and 30 con-
trol subjects (15 men/15 women; 20-51 years). 
The diagnosis of RA was based on criteria 
proposed by the American College of Rheuma-
tology [2]. Patients were considered to have 
active RA because they had subjective symp-
toms, objective tender/swollen joints, and 
erythrocyte sedimentation rate (ESR) >20 
mm/h or C-reactive protein (CRP) >0.6 mg/dL. 
All subjects were free of renal, hepatic, hema-
tological, and thyroid abnormalities. Nobody 
was taking medications which influenced lipid 
metabolism. All subjects were normoglycemic. 
Nobody was a smoker. Determination of 3-Cl-
Tyr, HAVA, and HACA content of LDL1 and 
LDL2 apoB-100 was performed as published 
elsewhere [3-5]. 
Results suggest that amino acid side chain 
residues of apoB-100 are highly reactive to-
ward oxygen radicals in both plasma and sy-
novial fluid in RA. Particularly small dense 
LDL2 particles were prone to direct oxidation of 
apoB-100. Strong correlations between con-
tent of oxidation markers in plasma and syno-
vial fluid LDL in RA may allow the use of 3-Cl-
Tyr, HAVA, and HACA as clinical markers of 
antioxidant barrier impairment in RA. Results 
further suggest that oxidized synovial fluid LDL 
contribute to increased human monocyte 
chemotaxis and adhesion (not shown in detail). 
In summary, these data support the hypothesis 
of a pathophysiological link between RA and 
atherogenesis [6-7].  
 
 
Fig. 1. Box plots showing LDL apoB-100 3-Cl-Tyr, HAVA, 
and HACA content in plasma LDL1 (A), plasma LDL2 (B), 
synovial fluid LDL1syn (C), and synovial fluid LDL2syn (D) in 
patients with active RA and controls, respectively. 
Oxidation marker content is expressed as mol/mol apoB-
100. 
 
Table 1. Correlation analysis (Spearman‘s rank correlation 
coefficient) in both patients with RA and controls 
 RA Control 
LDL1syn vs. LDL1   
3-Cl-Tyr 0.400 (.010)  - 
HAVA 0.545 (.009)  0.325 (.037) 
HACA 0.623 (.000)  - 
LDL2syn vs. LDL2   
3-Cl-Tyr 0.578 (.004)  - 
HAVA 0.739 (.000)  0.554 (.009) 
HACA 0.714 (.000)  0.617 
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Radiohalogenation of Lipoproteins: Limitations and Implications 
J. Pietzsch, S. Hoppmann, J. van den Hoff  
 
 
In the past, radiohalogenation of peptides, 
proteins, and lipoproteins has been estab-
lished as an essential tool for assessment of 
their biological function in vitro and in vivo [1, 
2]. Halogen radioisotopes are attractive since 
they exhibit nuclear properties suitable for 
various applications. At the same time, their 
chemistry shows great similarities, which en-
ables the use of similar labeling procedures for 
different nuclides. Among radiohalogens, the 
use of iodine radionuclides, principally iodine-
125 and iodine-131, for labeling of peptides, 
proteins, and lipoproteins is of widespread use 
[1, 2]. However, several authors showed that 
most commonly used oxidative radioiodination 
procedures such as the iodogen, chloramine-
T, or iodine monochloride procedures lead to 
severe structural modifications of various pro-
teins dramatically affecting their biological ac-
tivity and functionality [3-6]. Recently, for lipo-
proteins, particularly low density lipoproteins 
(LDL) the significant oxidative modification of 
both the lipid and the apolipoprotein moiety by 
radioiodination has been demonstrated [7-9]. 
As strongly emphasized in these studies, it has 
to be considered that radioiodinated LDL no 
longer reflect the native LDL particle or, when 
obtained from in vitro oxidation experiments, 
the initially characterized modified LDL particle 
[7-9]. Therefore, the valid use of radioiodinated 
LDL to reflect kinetics and behaviour of native 
LDL as well as to differentiate kinetics and 
behaviour of native and oxidized LDL are es-
sentially limited [9]. However, the relevance of 
these limitations varies greatly depending on 
the type of studies being done and the types of 
modified lipoproteins being studied [10-14]. In 
relation to this subject, several attempts have 
been made to overcome adverse modification 
of proteins and lipoproteins by iodination pro-
cedures such as the use of mild oxidizing re-
agents [15], the use of antioxidants [7], and the 
use of conjugative labeling employing Bolton-
Hunter-type reagents [16-18]. For the majority 
of proteins, the use of iodinated Bolton-Hunter-
type reagents such as N-succinimidyl-3-(4-
hydroxy-5-[125I]iodophenyl)propionate, N-suc-
cinimidyl-4-[125I]iodobenzoate or N-succinimid-
yl-3-[131I]iodo-4-phosphonomethyl-benzoate is 
supposed to be a promising approach, be-
cause these n.c.a. systems for protein radioio-
dination prevent direct exposure of the protein 
to excess oxidizing and reducing agents [16-
18]. However, high incorporation of radioactiv-
ity into the LDL lipid moiety (>30%) limits the 
use of the majority of iodinated Bolton-Hunter-
type reagents for radiolabeling of lipoproteins 
[1, 2, 16, 17]. To overcome these limitations, 
we hypothesized the use of N-succinimidyl-[4-
18F]fluorobenzoate ([18F]SFB) to be a promis-
ing alternative [19]. Using this more hydrophilic 
fluorinated Bolton-Hunter-type reagent apoB-
100, the major protein of human LDL, can be 
specifically labeled via [18F]fluorobenzoylation 
in the N-terminus or the lysine side chain resi-
dues, respectively [20]. As a very recent result, 
the total radiochemical yields, effective specific 
radioactivities, and in vitro stability of [18F]FB-
nLDL and [18F]FB-oxLDL, respectively, could 
demonstrated to be sufficiently high for both in 
vitro and in vivo investigations [20]. Impor-
tantly, only trace amounts of 18F-radioactivity 
were incorporated into the lipid moiety of the 
radiolabeled LDL particles. More than 95% of 
the 18F-radioactivity was covalently coupled to 
apoB-100, the structural protein of LDL [20, 
21]. Furthermore, our data demonstrate that 
the use of [18F]SFB for radiolabeling of LDL 
does not affect native and modified LDL 
specimen by initial or further oxidative modifi-
cation or by alteration of their biological func-
tion in vitro [20]. This has been confirmed by 
cell binding and uptake studies. Furthermore, 
determination of non-specific and specific pa-
rameters of lipid and protein oxidation, respec-
tively, prior to and after the radiolabelling pro-
cedure showed no differences between radio-
labelled LDL and their corresponding non-
radioactive counterparts [21]. We conclude 
that the use of [18F]SFB for radiolabeling of 
LDL is an attractive alternative to LDL iodina-
tion methods. Moreover, it can be applied for 
measurement of kinetics and behavior of both 
native and oxidized LDL in vivo by means of 
small animal positron emission tomography 
(PET). 
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Fluorine-18 Radiolabelling of Low Density Lipoproteins (LDL): a Potential 
Approach for Characterization and Differentiation of Metabolism of Native    
and Oxidized LDL in vivo 
J. Pietzsch, R. Bergmann, K. Rode, C. Hultsch, B. Pawelke, F. Wüst, J. van den Hoff 
 
Assessing the metabolic fate of oxidized LDL (oxLDL) in vivo with radiotracer techniques is hindered by the lack 
of suitable sensitive and specific radiolabelling methods. We evaluated an improved methodology based on the 
radiolabelling of native LDL (nLDL) and oxLDL with the positron emitter fluorine-18 (18F) by conjugation with N-
succinimidyl-4-[18F]fluorobenzoate ([18F]SFB). We investigated whether radiolabelling of LDL induces adverse 
structural modifications. Results suggest that radiolabelling of both nLDL and oxLDL using [18F]SFB causes nei-
ther additional oxidative structural modifications of LDL lipids and proteins nor alteration of their biological activity 
and functionality, respectively. Thus, radiolabelling of LDL using [18F]SFB could prove to be a promising approach 
for studying the kinetics of oxLDL in vivo. 
 
Although different radionuclides have been 
used to radiolabel LDL, investigations to 
evaluate localization, clearance, and biological 
effects of modified LDL, e.g., acetylated LDL 
and oxidized LDL, respectively, have used 
extensively radionuclides of iodine such as 
iodine-125 and iodine-131. Recently, it has 
been clearly demonstrated that most com-
monly used radioiodination methods lead to 
oxidative modification of both the lipid and the 
protein moiety of LDL, affecting their cytotoxic-
ity, interaction with LDL receptors or scavenger 
receptors, and in vivo clearance [1-3]. In con-
sequence, the use of radioiodinated LDL la-
beled via direct iodination has serious limita-
tions, particularly it does not allow to differenti-
ate kinetics and behavior of native and oxi-
dized LDL. As an attractive alternative we pre-
sent a new methodology for n.c.a. labeling of 
LDL with the positron emitter fluorine-18 (18F) 
using the Bolton-Hunter-type reagent N-
succinimidyl-[4-18F]fluorobenzoate ([18F]SFB) 
[4]. 
Isolation of LDL, LDL oxidation, measurement 
of specific oxidation parameters, radiolabelling 
of native and oxidized LDL with [18F]SFB, bio-
chemical and biological characterization of 
radiolabelled LDL were performed as pub-
lished elsewhere [4]. 
This work reports for the first time experiments 
on radiolabelling of both nLDL and oxLDL us-
ing the acylating reagent [18F]SFB (Figure 1). 
The present data indicate that radiolabelling 
with [18F]SFB did not alter biological activity 
and functionality of nLDL and oxLDL, respec-
tively (not shown in detail). 
 
 
    1 2 3 4  5 6  7 
 
Fig. 1. Representative SDS polyacrylamide gel 
electrophoresis pattern of a complete separation of 
[18F]FB-oxLDL. The figure shows radioactivity distribution 
as determined by radioluminography. Lane 7 is the 
reaction mixture, lanes 1 to 6 represent individual fractions 
obtained from DG 10 size exclusion chromatography 
column as determined in duplicate. Arrow indicates the 
apoB-100 band. 
 
This radiolabelling does not lead either to ad-
verse oxidation of nLDL particles or to addi-
tional adverse oxidative modification of oxLDL 
particles (Table 1). Thus, the present method 
is likely to provide a suitable radiotracer for 
assessment of metabolism of oxidized LDL in 
vivo by means of dynamic positron emission 
tomography (PET). 
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Table 1. Parameters of protein oxidation prior to and after radiolabeling of nLDL and oxLDL with [18F]SFB 
Parameter nLDL [18F]FB-nLDL P 
nLDL /[18F]FB-nLDL 
oxLDL [18F]FB-oxLDL P 
oxLDL/ [18F]FB-oxLDL 
P 
nLDL/oxLDL 
REM 1 1.01±0.04 ns 3.94±0.23 3.91±0.36 ns 0.000 
HAVA (mol/mol apoB-100) 0.009±0.003 0.011±0.003 ns 14.661±0.884 14.044±0.862 ns 0.000 
HACA (mol/mol apoB-100) 0.0007±0.0003 0.0007±0.0003 ns 7.82±1.62 7.86±1.45 ns 0.000 
Results are means ± SD (n=10); Mann-Whitney U tests were used for comparison of numerical variables between groups; REM, relative electrophoretic mobility; HAVA, 5-
hydroxy-2-aminovaleric acid; HACA, 6-hydroxy-2-aminocaproic acid 
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N-Arylation of Indoles with 4-[18F]Fluoroiodobenzene: a Novel Radiolabelling 
Technique in 18F Chemistry 
F. Wüst, T. Kniess 
 
The palladium-mediated N-arylation of indoles with 4-[18F]fluoroiodobenzene as novel radiolabelling method has 
been developed. Optimised reaction conditions (Pd2(dba)3/(2-(dicyclohexyl-phosphino)-2'-(N,N-dimethylamino)-bi-
phenyl, NaOBut, toluene, 100 °C for 20 min) gave radiochemical yields of up to 71 %  related to 4-[18F]fluoro-
iodobenzene. 
 
Introduction 
N-Arylindoles are central structural motifs in 
many drugs and other pharmaceutically impor-
tant compounds, and several Pd- and Cu-
mediated reactions were shown to be very 
effective for the preparation of N-arylated 
compounds including indoles [1-4]. However, 
the transition-mediated N-arylation of indoles 
has not been adapted to 18F chemistry yet.  
 
Results and Discussion 
Four different catalyst systems were tested for 
sufficient coupling of 4-[18F]fluoroiodobenzene 
with indole 1 to give 1-(4-[18F]fluorophenyl)-1H-
indole [18F]-2 (Fig. 1), being A: CuI/trans 1,2-
diaminocyclohexane; B: CuI/ethylenediamine;  
C: Pd2(dba)3/Xantphos and D: Pd2(dba)3/2-
(dicyclohexyl-phosphino)-2'-(N,N-dimethyl-
amino)-biphenyl). 
 
N
H
I
18F
N
18F
Catalyst system
[18F]-21  
 
Fig. 1. Synthesis of the labelling precursor 7. 
 
Best results were obtained with catalyst sys-
tem D containing electron-rich phosphine 
ligand 2-(dicyclohexyl-phosphino)-2'-(N,N-di-
methyl-amino)-biphenyl), whereas Cu-media-
ted reactions (entries 1-4) or the use of Xant-
phos as phosphine ligand (entries 5-10) only 
gave low to moderate radiochemical yields 
(Table 1). The reaction is strongly influenced 
by the used base and solvent. In this connec-
tion a combination of NaOBut as base and 
toluene as the solvent seems to be the best 
choice. No product formation was observed 
when DMF as a polar solvent was used (entry 
12). In contrast, high radiochemical yields were 
obtained when toluene was used as the sol-
vent (entry 13). Thus, cross-coupled product 
[18F]-2 was formed in 25 % after 10 min, and 
the radiochemical yield could be increased 
significantly to 69 % after 20 min. Extension of 
the reaction time to 30 min and 60 min did not 
further improve the radiochemical yield, being 
71 % and 70 %, respectively. Lowering the 
reaction temperature to 65 °C (entry 14) was 
accompanied with a drastic decrease of radio-
chemical yield and only 3 % of the desired 
product was formed. On the other hand, per-
formance of the reaction at 140 °C did not 
further improve radiochemical yield of product 
[18F]-2 when compared with the reaction at 
100 °C (entry 15 vs. entry 13).  
 
Table 1. N-Arylation of indole with [18F]fluoro-iodobenzene 
No 
Catalyst
system 
Base Solventc
RCY 
in %a,b
1 A K3PO4 THF/toluene 0 
2 A K3PO4 toluene 0 
3 B K3PO4 THF/toluene 7 
4 B K3PO4 toluene 36 
5 C NaOBut THF 5 
6 C KOBut THF 6 
7 C NaOBut THF/toluene 13 
8 C Cs2CO3 THF/toluene 0 
9 C K3PO4 THF/toluene 16 
10 C NaOBut toluene 28 
11 D NaOBut THF/toluene 22 
12 D NaOBut DMF 0% 
13 D NaOBut toluene 
25 (10 min) 
69 (20 min) 
71 (30 min) 
70 (60 min) 
14 D NaOBut toluene 3 %d
15 D NaOBut toluene 70 %e
a Radiochemical yield (RCY) determined by radio-HPLC representing the 
percentage of radioactivity area of cross-coupled product [18F]-2 related to 
the total radioactivity area 
b All reactions were conducted at 100 °C for 30 min.  
c Solvents in a 1:1 mixture 
d Reaction was carried out at 65 °C 
e Reaction was carried out at 140 °C 
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N-Arylation of Indoles with 4-[18F]Fluoroiodobenzene: Synthesis of 18F-Labelled 
σ2 Receptor Ligands  
F. Wüst, H. Kasper 
 
Optimised reaction conditions (Pd2(dba)3/(2-(dicyclohexyl-phosphino)-2'-(N,N-dimethylamino)-bi-phenyl, NaOBut, 
toluene, 100 °C for 20 min) for the palladium-mediated N-arylation of indoles with 4-[18F]fluoroiodobenzene were 
applied for the synthesis of 18F-labelled σ2 receptor ligands [18F]-11 and [18F]-13 in 91 % and 84 % radiochemical 
yield, respectively, related to 4-[18F]fluoroiodobenzene. 
 
Introduction 
In a previous report in this Annual Report we 
described the development of an efficient N-
arylation approach of indoles with 4-[18F]fluoro-
iodobenzene [1]. Now we report on the radio-
synthesis of two 18F-labelled σ2 receptor 
ligands [18F]-11 and [18F]-13 exhibiting an 4-
[18F]fluorophenyl-substituted indole motif by 
application of optimised reaction conditions as 
elaborated for the palladium-mediated N-
arylation of indole with 4-[18F]fluoroiodo-
benzene.  
 
Results and Discussion 
Optimised reaction conditions (Pd2(dba)3/(2-
(dicyclohexyl-phosphino)-2'-(N,N-dimethyl-
amino)-biphenyl, NaOBut, toluene, 100 °C for 
20 min) were applied for the synthesis of 18F-
labelled σ2-receptor ligands [18F]-11 and [18F]-
13 by the reaction of indoles 10 and 12 with 4-
[18F]fluoroiodobenzene. The synthesis of label-
ling precursors 10 and 12 and the synthesis of 
reference compounds 11 and 13 is shown in 
Fig. 1. 
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Fig. 1. Reagents and conditions: (i) LiAlH4, THF, 0 °C-r.t.; 
(ii) MsCl, TEA, CH2Cl2, 0 °C; (iii) 4-fluoroiodobenzene, CuI, 
ZnO, K2CO3 NMP, 160 °C; (iv) amine 8 or 9, Na2CO3, 
acetone, r.t.. 
 
The synthesis started with reduction of com-
mercially available 4-(3-indolyl)-butyric acid 3 
by means of LiAlH4 to give the corresponding 
alcohol 4 in 57 % yield. 4-(1H-Indol-3-yl)-1-
butanol 4 was converted into methanesul-
fonate ester 6 followed by N-alkylation reac-
tions with amines 8 [2] and 9 to give labelling 
precursors 10 and 12 in 59 % and 67 % yield, 
respectively, for the two steps. For the synthe-
sis of reference compounds 11 and 13 alcohol 
4 was subjected to an Ullmann arylation reac-
tion with 4-fluoroiodobenzene to give 1-(4-
fluorophenyl)-substituted compound 5 [3] in 44 
% yield prior to conversion into methanesul-
fonate ester 7. N-Alkylation was carried out 
using the same procedure as was used for the 
synthesis of labelling precursors 10 and 12 
using amines 8 [2] and 9. Following this proce-
dure reference compounds 11 and 13 could be 
obtained in 52 % and 62 % yield relative to 
methanesulfonate ester 7. 
The radiolabelling of σ2-receptor ligands [18F]-
11 and [18F]-13 via N-arylation with 4-
[18F]fluoroiodobenzene is depicted in Fig. 2.  
 
N
H
N
N
N
H
N
O
N
N
N
N
N
O
18F
18F
Catalyst system
NaOBut, toluene
 20 min, 100°C
Catalyst system
NaOBut, toluene
 20 min, 100°C
Catalyst system: Pd2(dba)3 /2-(dicyclohexyl-phosphino)-2'-(N,N-dimethylamino)-biphenyl
10
12
[18F]-11
[18F]-13
91%
84%
18F
I
18F
I
 
Fig. 2. Radiosynthesis of σ2-receptor ligands [18F]-11 and 
[18F]-13. 
 
 
Starting from labelling precursors 10 and 12 
the desired compounds [18F]-11 and [18F]-13 
could be obtained in excellent radiochemical 
yields of 91 % and 84 %, respectively, related 
to 4-[18F]fluoroiodobenzene.  
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Determination of Radiochemical Purity of [18F]3-OMFD and [18F]FDOPA by 
HPLC 
J. Zessin, B. Lipps 
 
A combination of a short polymer and a RP18 column was used for determination of the radiochemical purity of 
[18F]OMFD to improve the quantification of impurities. 
 
 
Introduction 
The radiochemical purity is an important pa-
rameter for the release of PET radiopharma-
ceuticals. This parameter can be easily deter-
mined by reserved phase HPLC. Two types of 
stationary phases are available for RP-HPLC: 
silica and styrene/divinylbenzene copolymer.  
The use of silica-based columns for the analy-
sis of 18F-labelled radiopharmaceuticals is 
restricted by the high affinity of [18F]fluoride to 
the silica matrix. A correct quantification of this 
main side product is prevented due to this 
obstacles. Polymer-based stationary HPLC 
phases do not show an irreversible binding of 
[18F]fluoride [1], but the decreased resolution 
ability implied difficulties in the quantification of 
compounds with comparable retention times. 
[18F]3-OMFD and [18F]FDOPA contain 
[18F]fluoride as well as other radioactive impur-
ities with retention times comparable to that of 
the radiopharmaceuticals. A correct determina-
tion of the radiochemical purity is impossible 
using either a silica- or a polymer-based HPLC 
column.  
In this report, we describe the improvement of 
this analysis by use of a column combination, 
which consists of a short polymer column and 
a silica-based column. 
 
Methods 
The analysis of radiochemical purity was per-
formed with an HPLC system (Series 1100) 
from Agilent consisting of an autosampler, 
pump with a low pressure gradient system, 
vacuum degasser, and a photodiode array 
detector (DAD). The gamma radioactivity 
monitor “GABI” from Raytest was used as ra-
dioactivity detector. The HPLC eluent was a 
acetonitrile/water (containing trifluoroacetic 
acid and Na2EDTA) gradient. 
Columns and detectors were arranged in the 
following order: SecurityGuard RP-1 (4x3 mm, 
Phenomenex) - radioactivity detector - Puro-
spher RP18 (125x3 mm, Merck) - radioactivity 
detector – DAD. After passing the columns, the 
compounds go through the radioactivity detec-
tor in separated loops. 
 
 
 
 
Results and Discussion 
Fig. 1 shows a typical radiochromatogram, 
which was obtained by the established HPLC 
method using a PolymerX RP1 column. This 
chromatogram demonstrates the restricted 
resolution of [18F]3-OMFD and an impurity with 
a comparable polarity. 
 
 
Fig. 1. Radiochromatogram of [18F]3-OMFD from PolymerX 
column 
 
Fig. 2 shows the radiochromatogram of the 
same [18F]3-OMFD batch, which was obtained 
from the analysis of radiochemical purity using 
a combination of a short polymer column and a 
silica-based RP18 column. The first part of the 
radiochromatogram demonstrates, that a 
polymer column with a length of 3 mm was 
sufficient enough to separate [18F]fluoride from 
the more unpolar compounds. 
 
 
Fig. 2. Radiochromatogram of [18F]3-OMFD (same batch 
as shown in Fig. 1) from SecurityGuard RP1/Purosphere 
RP18 column combination 
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After passing the radioactivity detector, the 
pre-separated HPLC sample passed a silica-
based RP18 column. As expected, [18F]fluoride 
was completely retained by this stationary 
phase, but the peaks of [18F]3-OMFD and the 
radioactive impurity were separated.  
The quantification was performed by analysis 
of the [18F]fluoride peak in the first part and the 
[18F]3-OMFD and impurity peaks in the second 
part of the radiochromatogram. These results 
were comparable to the results obtained with 
the PolymerX RP1 column. The differences of 
the [18F]fluoride amount were in the range of 
accuracy of HPLC. 
The described HPLC method is also applicable 
for the analysis of [18F]FDOPA, but a 10 mm 
polymer column (RSPak DE-G 4.6x10 mm, 
Shodex) was necessary to separate the peaks 
of [18F]fluoride and [18F]FDOPA completely. 
The longer polymer column has no influence of 
the resolution of the silica-based RP-HPLC.  
Furthermore, we tested the [18F]fluoride recov-
ery from a hybrid phase (Gemini, Phenome-
nex), which has a coating of the silica surface 
with organic residues. The [18F]fluoride recov-
ery of such a hybrid phase was in the same 
range as by use of conventional RP phase. 
Such a coating of silica do not show an advan-
tage for the HPLC determination of 
[18F]fluoride. 
 
Conclusions 
A combination of a short polymer column and 
a silica-based RP column was used for a de-
termination of the radiochemical purity of the 
PET radiotracer [18F]3-OMFD. This arrange-
ment of columns improves the resolution of 
compounds with similar retention times by a 
similar sensitivity to [18F]fluoride. 
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Synthesis of N-[6-(4-[18F]Fluorobenzylidene)aminooxyhexyl]maleimide (MHAA). 
A New SH-Reactive 18F-Labelling Agent 
M. Berndt, F. Wüst 
 
We describe the synthesis of a new 18F-labelling agent containing a thiol-reactive maleimide group. The labelling 
precursor was obtained in a three-step synthesis. Preparation of [18F]fluorobenzaldehyde from [18F]fluoride und 
subsequent conversion with the substituted maleimide led to the labelling reagent in 29-39 % radiochemical yield. 
 
 
Introduction 
For the 18F-labelling of peptides and proteines 
N-succinimidyl-4-[18F]fluorobenzoate (SFB) 
was found to be a suitable labelling reagent. 
Recently, a convenient remotely-controlled 
module radiosynthesis of SFB was developed 
in our group [1]. However, in some applications 
the use of this amine-reactive agent failed. 
Therefore further labelling strategies are 
needed. In this connection, particularly 
maleimide were shown to react efficiently and 
selectively with SH-groups under mild condi-
tions. 
 
Results and Discussion 
Toyokuni et al. recently reported the synthesis 
of a bifunctional linker containing a thiol-
reactive maleimide group and a carbonyl-
reactive aminooxy group [2]. Admittedly the 
synthetic route was quite extensive. We found 
a very efficient synthetic pathway to a related 
labelling precursor 4 with only three steps (Fig. 
1). 6-bromo-1-hexanole (1) was converted with 
tert-butyl-N-hydroxycarbamate and DBU in 
dichloromethane [3]. The maleimide group was 
introduced via Mitsunobu reaction [4]. Finally, 
the Boc-protecting group was removed using 
HCl/EtOAc and N-(6-aminooxyhexyl)maleimide 
(4) was obtained as the stable HCl salt. 
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Fig. 1. Synthesis of labelling precursor 4 and reference 
substance [19F]-5. 
 
Transformation of 4 with [19F]fluorobenzalde-
hyde led to the reference substance [19F]-5. 
Exclusively the E-isomer was formed, which 
was verified by the 1H NMR signal of the oxime 
proton [2].  
The radiosynthesis started with the preparation 
of [18F]fluorobenzaldehyde. In a one-pot pro-
cedure N-(6-aminooxyhexyl)maleimide (4) was 
added to the generated aldehyde and after-
wards N-[6-(4-[18F]fluorobenzylidene)amino-
oxyhexyl]maleimide ([18F]-5) was isolated by 
HPLC. In a typical experiment 3.88 GBq of 
[18F]fluoride could be converted to 723 MBq 
(29 %, decay corrected) [18F]-5 within 69 min, 
including HPLC purification. The specific acti-
vity was determined to be 76 GBq/µmol. 
The labelling properties of [18F]-5 were exam-
ined by using glutathione (GSH) as a SH- 
group-containing model peptide (Fig. 2). [18F]-
5 in ethanol (50 µl, 5 MBq) was added to 900 
µl of glutathione solutions (1.0 mg/ml to 10 
ng/ml) in phosphate buffer (pH = 7.2) at 20 °C. 
The conversion was monitored by radio-TLC. 
After 5 min the [18F]-5 was transferred into 
[18F]-6 completely in the vials containing 1.0 
mg/ml to 10 µg/ml. At lower concentrations of 
glutathione the conversion was incomplete (for 
1 µg/ml 95 % radiochemical yield after 1 h, for 
100 ng 20 % after 1 h, for 10 ng 5 % after 1 h).  
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Fig. 2. Coupling of [18F]-5 and glutathione (GSH). 
 
Currently we extend this labelling procedure to 
more complex biomolecules such as proteines 
and antibodies. 
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Modul-Assisted Synthesis of the Labelling Agent [18F]SFB 
P. Mäding, F. Füchtner, F. Wüst 
 
The known three-step synthesis of N-succinimidyl-4-[18F]fluorobenzoate ([18F]SFB) was adapted and transferred 
to an automated module. After optimization of the reaction conditions [18F]SFB was obtained in decay-corrected 
radiochemical yields of 34-37 % (related to [18F]fluoride; n = 8) within a synthesis time of 68 min. The radiochemi-
cal purity was in the range of 93-96 %.  
 
 
Introduction 
[18F]SFB 5 was shown to be a suitable acyla-
tion agent for labelling of peptides, proteins 
and antibodies [1-4 among others]. Such bio-
active compounds containing the [18F]fluoro-
benzoyl group can be useful radiotracers for in 
vivo studies by means of PET. 
Permanent utilisation of [18F]SFB call for a 
reliable and reproducible routine preparation of 
[18F]SFB without increased radiation exposure 
to personnel. 
Therefore we have adapted the three-step two-
pot procedure according to Fig. 1 [4] to a modi-
fied double module “TRACERlab FxFDG” from 
GE Medical Systems. 
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Fig. 1. Synthesis of [18F]SFB (5) 
 
 
Results and Discussion 
In [4] the synthesis of 4-[18F]fluorobenzoic acid 
3 was carried out within a very short reaction 
time using microwave activations (2 min for the 
[18F]fluorination step, 30 s for the saponifica-
tion step). As the use of the microwave is not 
possible in the module, the reaction vessels 
are heated conventionally. Therefore, the syn-
thesis of 3 was investigated and optimised in 
the automated synthesis module. The first 
reaction step (1 into 2) was tested using sev-
eral solvents, such as DMSO, DMF and 
MeCN, at different temperatures and reaction 
times. MeCN was the solvent of choice along 
with heating at 90 °C for 10 min. Furthermore 
diluted HCl was tested for the saponification 
step (2 into 3) to avoid the use of trifluoroacetic 
acid. It was found that 1 M HCl was suitable to 
hydrolyse the tert.-butyl ester group of 2 by 
heating at 100 °C for 5 min. After dilution of the 
acidic reaction mixture with water, 3 was puri-
fied by solid phase extraction (Chromafix HR-
P; Macherey-Nagel). 3 was eluted from the 
cartridge with MeCN in radiochemical yields of 
up to 67 % and a radiochemical purity of 97-98 
%. 
Then, 3 was converted with Me4NOH into its 
tetramethylammonium salt, which was dried. 
Addition of the activating agent O-(N-
succinimidyl)-N,N,N’,N’-tetramethyluronium-
tetrafluoroborate (TSTU; (4)) in MeCN and 
heating at 90 °C for 2 min yielded [18F]SFB 5. 
After the two purification steps using a polysty-
rene cartridge [2] (Chromafix HR-P; Macherey-
Nagel), 5 was eluted with MeCN in radio-
chemical yields of 34-37 %. The total synthesis 
time was 68 min and the radiochemical purity 
ranged between 93-96 %. Thus, in a typical 
experiment 12 GBq of [18F]fluoride could be 
converted into 2.8 GBq [18F]SFB within 68 min. 
The process flow scheme is given in Fig. 2. 
 
 
Conclusions 
A remotely-controlled procedure for the syn-
thesis of [18F]SFB 5 was developed based on a 
modified double module “TRACERlab FxFDG” 
from GE Medical Systems. In this way, 
[18F]SFB could be obtained in reproducible 
yields and purities. It was suitable for the label-
ling of peptides and proteins.  
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Fig. 2. Process flow scheme for the remotely-controlled synthesis of [18F]SFB 5. 
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Preparation of the Radiopharmaceutical [18F]NaF for Medical Use 
P. Mäding, F. Füchtner, J. Zessin, F. Wüst 
 
The preparation of sodium [18F]fluoride was developed in an automated module. The separated [18F]fluoride was 
eluted from the anion exchange cartridge using 1 ml of isotonic saline. After dilution with isotonic saline the radio-
active solution was sterilized by filtration through a 0.22 µm sterile filter. The yield of sodium [18F]fluoride was in 
the range of about 90 % within a preparation time of 6 min. 
 
 
Introduction 
The importance of sodium [18F]fluoride as a 
radiotracer for bone imaging originated from 
1962 [1]. It became the standard agent for 
bone scanning until the development of 99mTc-
labelled bisphosphonates in the 1970s [2]. In 
1992 Hawkins had introduced a kinetic model 
for [18F]fluoride in humans [3]. The use of 
[18F]fluoride for whole body skeletal PET imag-
ing in patients was published in 1993 for the 
first time [4]. Sodium [18F]fluoride is indicated 
in PET imaging to define areas of bone metas-
tases and altered osteogenic activity [2, 5, 6 
among others]. 
Therefore we have developed a simple proce-
dure for the preparation of sodium [18F]fluoride 
for medical use based on a 18F-remotely-
controlled synthesis module from GE Medical 
Systems. 
In [7] the preparation of sodium [18F]fluoride 
was carried out by dilution of the irradiated 
[18O]water with isotonic saline solution. In this 
way [18O]water can not be re-used. Non-
separated radionuclide impurities are an other 
disadvantage of this method. To avoid this 
disadvantages, Brenner et al. [2] performed a 
purification of [18F]fluoride using an anion ex-
change cartridge. Sodium [18F]fluoride was 
eluted with sodium bicarbonate solution and 
diluted with isotonic saline. 
 
Results and Discussion 
We have found that the adsorbed [18F]fluoride 
can also be eluted off the anion-exchange 
cartridge with small amounts of isotonic saline 
(about 1 ml). The use of larger amounts of 
isotonic saline will cause co-elution of radionu-
clidic impurities. Thus, we have transferred this 
procedure on a modified 18F synthesis module 
according to Fig. 1. The preparation of sodium 
[18F]fluoride was carried out as follows:  
(1) Adsorption of the [18F]fluoride on an strong 
anion exchange cartridge (AccellTM Plus QMA, 
Waters),  
(2) Elution of [18F]fluoride with 1 ml isotonic 
sodium chloride,  
(3) Dilution with 14 ml isotonic saline and ster-
ile filtration through a 0.22 µm sterile filter. The 
yield of sodium [18F]fluoride was in the range of 
90 % within a preparation time of 6 min. In this 
way a chemical and radiochemical pure prod-
uct was obtained. The radiochemical and 
chemical purity was determined by ion chro-
matography using a CarboPac PA1 column 
(250x4 mm; DIONEX) and 0.1 M sodium hy-
droxide as eluent. The radiochemical purity 
exceeds 99.5 %. The radionuclear purity, 
which was checked by gamma spectroscopy 
and measurement of the half-life, exceeds 99.9 
%. 
The maximum amounts of the residual sol-
vents acetonitrile (to activate the QMA car-
tridge) and ethanol (as cleaning solvent) are 
within the limits of the European Pharma-
copoeia. The pH of the solution varies from 7.2 
to 8.6. The product was isotonic, sterile and 
pyrogen-free. 
 
Conclusions 
A procedure for the routine production of so-
dium [18F]fluoride was developed based on a 
18F synthesis module from GE Medical Sys-
tems. The described procedure is very simple 
and robust. The final product conforms to the 
specifications for this radiopharmaceutical 
according to the monograph “sodium fluoride 
(18F) injection” of the European Pharmaco-
poeia. 
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Fig. 1. Scheme of the module for the preparation of sodium [18F]fluoride. 
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Factors Affecting the Specific Activity of [18F]Fluoride from a Water Target 
F. Füchtner, S. Preusche, P. Mäding, J. Steinbach1
1 Institut für Interdisziplinäre Isotopenforschung, Permoserstr.15, 04318 Leipzig, Germany 
 
By replacing PTFE tubes to PP tubes the contribution of the water target dispensing system to the contamination 
of [18F]/[18O]water with [19F]fluoride can be reduced by the factor of about two. 
 
 
Introduction 
The nuclear reaction 18O(p,n)18F  is the method 
of choice for routine production of n.c.a. 
[18F]fluoride to synthesise labeled compounds 
on high activity level as well as with high spe-
cific activity (SA). For quite a few PET radio-
pharmaceuticals the SA has to be high in order 
to prevent physiological response at the stud-
ied system. We found that the SA shows con-
siderable variation, as also reported in the 
literature [1-6]. The SA is an important quality 
parameter in accordance with the GMP guide-
lines and should be reproducible. The SA of 
the radiopharmaceuticals mainly depends on 
the SA of the [18F]fluoride dispensed from the 
cyclotron target system after radiation. Initial 
investigations indicated that the main origin of 
19F is the [18O]water dispensing and delivery 
system of the target and not the starting 
[18O]water itself. Detailed ion chromatographic 
investigations were carried out to determine 
the contamination sources of the 19F. 
 
Results and Discussion 
[18O]water and [18F]/[18O]water samples from 
different places of the target dispensing and 
delivery system were analyzed for [19F]fluoride 
using ion chromatography. 
The SA of the labeled receptor ligand 
[18F]ZK811460 [7] (n = 58) was determined by 
RP chromatography using a UV detector. 
The starting [18O]water is of good quality and 
contains no significant amounts of [19F]fluoride 
(0.5 nMol/8 ppb). A considerable contribution 
of the target irradiation process to the 
[19F]fluoride amount was not found. 
The [19F]fluoride amount of the dispensing 
system mainly depends on the tubing materi-
als and the radiation dose, which is exposed to 
the tube near the target/cyclotron, as well as 
on the water/tube contact time. The PTFE tube 
of the dispensing system is the main origin of 
[19F]fluoride (contamination up to 380 
nMol/5550 ppb). Avoiding PTFE tubes and 
changing to PP (polypropylene) tubes the 
[19F]fluoride amount can be decreased consi-
derably (maximum value 10 nMol/170 ppb). 
The average value and its standard deviation 
of the cold amount | SA of the [18F]ZK811460 
using PP tubes (n = 36) in the target dispens-
ing system in contrast to PTFE tubes (n = 22) 
could improved from 66±32 nMol | 56±35 
GBq/µMol (PTFE) to 38±15 nMol | 126±38 
GBq/µMol (PP) (see Fig.). 
On the other hand: In our experience PTFE 
tubes of the target water delivery system 
have the best transport properties related to 
the [18F]/[18O]water bolus. In general, its contri-
bution to the [19F]fluoride amount (contamina-
tion up to 20 nMol/300 ppb) is minor. If very 
high SA is required repeated rinsing of the 
whole delivery system with ultra pure water 
becomes necessary. 
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Synthesis of a 11C-Labelled Nonsteroidal Glucocorticoid Receptor Ligand for 
Imaging Brain Glucocorticoid Receptors (GR) 
F. Wüst, T. Kniess, R. Bergmann 
 
The radiosynthesis of a 11C-labelled nonsteroidal GR ligand 11 is described as an alternative approach for imag-
ing brain GR by means of PET. Compound 11 could be synthesised in 30-40 % radiochemical yield at an specific 
radioactivity of 20 GBq/µmol within 40-45 min. Preliminary biodistribution studies in Wistar rats showed promising 
brain uptake of 1.5 % ID/g after 5 min p.i., which decreased to 0.65 % ID/g after 60 min.  
 
Introduction 
The development of GR ligands which are 
appropriately labelled with short-lived positron-
emitting radioisotopes would allow the non-
invasive in vivo imaging and mapping of brain 
GRs by means of PET. For this purpose, vari-
ous steroidal glucocorticoids have been la-
belled with the positron emitter 18F. However, 
none of the investigated compounds were 
suitable for in vivo visualization of brain GRs 
with PET [1-3].
An alternative approach is based on the dis-
covery of structurally novel, nonsteroidal small 
molecules, which show high binding to the GR 
in the nanomolar range [4-5]. The ben-
zopyrano quinoline-based structure of these 
GR-binding compounds bears a methoxy 
group, which is a potential site for radio-
labelling with [11C]methyl iodide starting from 
the corresponding desmethyl labelling precur-
sor 10. 
 
Results and Discussion 
The preparation of compound 10 commenced 
with commercially available 2,6-dimethoxy-
phenylboronic acid 1 and involves a multi-step 
synthesis sequence as shown in Fig. 1 [5].
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Fig. 1. Synthesis of labelling precursor 10. 
 
The reaction of phenol 10 with [11C]methyl 
iodide was performed in an automated synthe-
sis module (Nuclear Interface, Münster). 
[11C]Methyl iodide was prepared via the “wet” 
chemistry route, involving LiAlH4 reduction of 
[11C]CO2 and subsequent treatment with HI (57 
%). 
[11C]Methyl iodide was trapped in a DMF solu-
tion containing labelling precursor 2 and NaOH 
as the base (Fig. 2).  
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Fig. 2. Radiolabelling of 10 with [11C]MeI. 
 
The methylation reaction was accomplished 
within 5 min at 100 °C, and the product was 
purified by semi-preparative HPLC. The total 
synthesis time including [11C]methyl iodide 
preparation, synthesis of 11C-labelled com-
pound 11 and HPLC-purification was 40-45 
min. Compound 11 was obtained in a radio-
chemical yield of 30-40 % (decay-corrected, 
related to [11C]CO2). Starting from 20 GBq 
[11C]CO2, specific radioactivities ranging from 
15 to 20 GBq/µmol were reached at the end of 
the synthesis. The radiochemical purity of 11 
exceeded 98 %.  
Preliminary biodistribution studies of com-
pound 11 in Wistar rats demonstrated a brain 
uptake of 1.5 % ID/g after 5 min p.i., which 
decreased to 0.65 % ID/g after 60 min.  
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Synthesis of [11C]CH3I by Iodination of [11C]CH4 in a Synthesis Module 
T. Kniess, F. Wüst  
 
The synthesis procedure of [11C]CH3I via [11C]CH4 using the remotely controlled synthesis module TRACERlab 
FXC is described. 
 
Introduction 
[11C]CH3I is an important labelling precursor in 
11C-chemistry. It is usually prepared by the 
“wet chemistry route” involving reduction of 
cyclotron produced [11C]CO2 with LiAlH4 to 
[11C]CH3OH, followed by hydrolysis and iodina-
tion with hydrogen iodide. In general this pro-
cedure suffers from low specific activity of 
[11C]CH3I since LiAlH4 readily adsorbs CO2 
from air. Thus, LiAlH4 has to be handled with 
great care in suitable glove boxes prior use to 
avoid any potential CO2 contamination from 
air. Moreover, the aqueous iodination with HI 
requires careful and laborious cleaning and 
drying procedures of the synthesis module, 
which limits the number of [11C]CH3I syntheses 
to not more than one per day.  
To circumvent these obstacles an alternative 
gas phase iodination of [11C]CH4 has been 
developed [1, 2]. An automated synthesis 
module for [11C]CH3I preparation employing 
this principle has been commercially available 
recently by GE Medical Systems. The PET 
Center Rossendorf is operating such a 
TRACERlab FXC module since 2004, and first 
experiences of operation are reported herein. 
 
Results and Discussion 
The scheme of [11C]CH3I production is shown 
in Fig. 1, which also serves as operation panel 
for the synthesis module. [11C]CO2 produced 
via 14N[p,α]11C nuclear reaction is con-
verted into [11C]CH4 by reduction with hydro-
gen on a Ni-catalyst at 400 °C. 
The produced [11C]CH4 is trapped on Car-
bosphere under liquid nitrogen cooling at -140 
°C for purification and concentration. Uncon-
verted [11C]CO2 and formed H2O are trapped 
on Ascarite (NaOH). The purified [11C]CH4 is 
than allowed to react with iodine at 720 °C to 
form [11C]CH3I in a gas circulating process 
system, where formed HI is trapped in an addi-
tional Ascarite trap. [11C]CH3I is trapped on a 
Porapak Q trap at room temperature while 
unconverted [11C]CH4 re-enters the circulation 
process. At the end of the circulation process 
the collected [11C]CH3I is released from the 
Porapak Q trap in a stream of He at 190 °C 
and distilled into the reaction vessel to perform 
the labelling reaction. 
In a typical experiment 8.0 GBq of [11C]CO2 
could be converted into 5.3 GBq of [11C]CH4 
and 3.0 GBq of [11C]CH3I after 15 minutes. The 
radiochemical yield of [11C]CH3I synthesis is  
60 % (decay-corrected). 
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Fig. 1. [11C]CH3I production scheme.  
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Synthesis of 11C-Methylated Mercaptoimidazole Piperazinyl Derivatives as 
Potential Radioligands for Imaging 5-HT1A Receptors by PET 
T. Kniess, R. Garcia1, A. Paulo1, I. Santos1, R. Bergmann, F. Wüst 
1Instituto Tecnologico e Nuclear (ITN), Sacavem, Portugal 
 
Two novel 5-HT1A receptor binding 2-mercaptoimidazole derivatives 1 and 2 were labelled with 11C through me-
thylation of the thioketone functionality with [11C]CH3I in radiochemical yields of 20-30 % within 40 min including 
HPLC-purification in 99 % radiochemical purity. The brain uptake of the radioligands was determined by prelimi-
nary biodistribution studies. 
 
Introduction 
Central 5-HT1A receptors are implicated in the 
pathophysiology of major neuropsychiatric 
diseases such as schizophrenia, anxiety and 
depression. The functional imaging of the 5-
HT1A receptors by PET represents an innova-
tive approach for a non-invasive assessment 
of those disorders. The identification of WAY-
100635 as a potent and selective antagonist 
for the 5-HT1A receptor was accompanied by 
attempts to label the compound with 11C [1, 2]. 
The replacement of the piperazinyl amide 
group by fragments of the mercaptoimidazole 
type would allow straightforward alkylation of 
thioketone functionality with [11C]CH3I. Herein 
we report on the radiosynthesis and biodis-
tribution of two 11C-methylated mercaptoimida-
zole piperazinyl derivatives 3 and 4. 
 
Results and Discussion 
The synthesis of labelling precursors 1 and 2 
was accomplished by multi-step procedures 
starting from 4-[(2-methoxyphenyl)-1-piperaz-
inyl]-butylamine [3]. Corresponding reference 
compounds were synthesised by the reaction 
of thioketones 1 and 2 with methyl iodide in 
ethanolic solution in the presence of NaOH at 
room temperature.  
S-Methylation of thioketones 1 and 2 with 
[11C]CH3I was performed by means of an 
automated synthesis module to give the de-
sired radiolabelled compounds 3 and 4, re-
spectively (Fig. 1). 
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Fig. 1 
 
[11C]CH3I was synthesised in a 11C-methylation 
synthesis module (GE-Medical Systems) by 
reduction of cyclotron produced [11C]CO2 with 
LiAlH4 followed by hydrolysis and iodination 
with HI.  
After distillation of approximately 3700 MBq of 
[11C]CH3I into a second reaction vessel con-
taining 1.0-1.5 mg of labelling precursor in 
ethanol the methylation was carried out at 80 
°C for 6 min. Afterwards, radioligands 3 and 4 
were purified by semi-preparative HPLC using 
isocratic elution with acetonitrile/aqueous NEt3 
(70/30). Under these conditions 3 and 4 could 
nicely be separated from excess of precursor 
and very low amount of non-reacted [11C]CH3I. 
Typically, 900 MBq of the radioligand were 
obtained in radiochemical yields of 20-30 % 
within 40 min.  
Biodistribution studies of 3 and 4 were per-
formed in male Wistar rats to evaluate brain 
uptake and brain radioactivity retention. Table 
1 summarizes the biodistribution data. 
 
Table 1 
% ID/g 
[11C]3 [11C]4 
 
Organ 
5 min 60 min 5 min 60 min 
Blood 0.11 ± 0.02 0.10 ± 0.03 0.12 ± 0.03 0.04 ± 0.00
Cerebellum 0.82 ± 0.13 0.14 ± 0.03 0.29 ± 0.04 0.14 ± 0.01
Brain 1.14 ± 0.11 0.18 ± 0.04 0.37 ± 0.04 0.16 ± 0.01
Pancreas 4.16 ± 0.51 5.85 ± 0.84 3.34 ± 0.57 1.86 ± 0.13
Spleen 1.48 ± 0.26 0.92 ± 0.19 1.27 ± 0.17 0.51 ± 0.07
Adrenals 3.77 ± 1.03 1.11 ± 0.16 7.95 ± 3.09 7.32 ± 0.75
Kidneys 2.85 ± 0.43 0.81 ± 0.16 2.56 ± 0.32 1.09 ± 0.15
Heart 0.49 ± 0.08 0.19 ± 0.03  0.41 ± 0.08 0.10 ± 0.01
Lung 1.68 ± 0.19 0.48 ± 0.06 1.14 ± 0.17 0.33 ± 0.07
Liver 0.80 ± 0.18 1.37 ± 0.35 1.33 ± 0.28 2.75 ± 0.72
 
Both compounds 3 and 4 were able to cross 
the blood brain barrier showing an initial brain 
uptake after 5 min of 1.14 and 0.37 % ID/g, 
respectively. However, a drastically reduced 
level of radioactivity in the brain was observed 
after 60 min. 
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A Novel Approach for 11C-C Bond Formation: Hydrozirconation/11C-Methylation 
of Prop-1-ynyl-benzene with [11C]MeI 
F. Wüst, P. Mäding 
 
The hydrozirconation/11C-methylation of prop-1-ynyl-benzene 1 with [11C]MeI as novel approach for 11C-C bond 
forming reactions is described.  
 
Introduction 
Distinct 11C-C bond forming reactions via vari-
ous transition metal-mediated reactions have 
been in the focus of radiochemical research for 
more than one decade [1-3]. Many metal-
mediated reactions known from synthetic or-
ganic chemistry have successfully been intro-
duced into 11C chemistry, and research on 
novel 11C-C bond formations is still of great 
interest.  
In this report we describe the palladium-
mediated reaction of alkenyl-zirconium deriv-
atives with [11C]MeI as a novel synthetic route 
for 11C-C bond formations.  
 
Results and Discussion 
The α, α`-dimethyl alkene group is a common 
structural motif in many biological active com-
pounds, namely phenyl group-containing mole-
cules. The isotopic substitution of one of the 
two methyl groups present in α,α`-dimethyl 
alkene groups with a [11C]methyl group repre-
sents an interesting approach to form corre-
sponding 11C-labelled compounds. 
A commonly employed strategy to form α,α`-
disubstituted alkenes comprises the formation 
of alkenylzirconium(IV) complexes by the cis-
insertion of a C-C triple bond into the Zr-H 
bond of Schwartz`s reagent [Cp2Zr(H)Cl] fol-
lowed by metal-mediated C-C bond formation 
with electrophiles under retention of the con-
figuration of the C-C double bond [4-5].  
The principle feasibility of the approach was 
elaborated by the synthesis of 2-[11C]methyl-
propenyl benzene 3 via hydrozirconation/11C-
methylation of prop-1-ynyl-benzene 1 with 
[11C]MeI as a model reaction (Fig. 1).  
 
Cp2ZrHCl
Zr
Cl
*
   [11C]MeI
M(PPh3)4
M = Pd, Pt, Ni
1 2
3
 
 
Fig. 1. 11C-labelling via hydrozirconation/11C-methylation  
Prop-1-ynyl-benzene 1 was treated with 1.2 
equiv. of Schwartz reagent in THF at room 
temperature. Formation of alkenylzirconium(IV) 
complex 2 could be monitored by formation of 
a clear orange-coloured solution. Alkenyl-
zirconium(IV) complex 2 was treated with 5 
mol % M(PPh3)4 (M = Ni, Pd, Pt) prior distilla-
tion of [11C]MeI into the solution. The reaction 
mixture was heated at 60 °C for 5 min. The 
results are summarised in Table 1. 
 
Table 1. Radiochemical yields of transition metal-mediated 
reaction of alkenyl-zirconium(IV) complex 2 with [11C]MeI  
Transition metal 
complex Radiochemical yield [%]
Ni(PPh3)4 4  
Pd(PPh3)4 70  
Pt(PPh3)4 11  
 
The radiochemical yields were determined by 
radio-HPLC representing the percentage of 
radioactivity area of 11C-labelled product 3 
related to the total radioactivity area. 
The results clearly show that the use of transi-
tion metal complex Pd(PPh3)4 is superior to 
Ni(PPh3)4 and Pt(PPh3)4, respectively. Thus, 
sufficient radiochemical yields of 70 % could 
be obtained when Pd(PPh3)4 was used as the 
metal complex in the cross-coupling reaction. 
 
Conclusion 
The palladium-mediated cross-coupling reac-
tion of in-situ-generated alkenyl-zirconium(IV) 
complexes with [11C]MeI as novel method for 
11C-C bond formations was developed. The 
extension of this labelling approach toward 
phenyl group-containing compounds with bio-
logical relevance is currently in progress. 
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Metabolism of [11C]SMe-ADAM in the Rat 
B. Pawelke, R. Bergmann, J. Zessin 
 
The blood kinetics and metabolisation of the radiotracer N,N-dimethyl-2-(2-amino-4-[11C]methylthiophenylthio)-
benzylamine ([11C]SMe-ADAM) was evaluated in rats.  
 
 
Introduction 
Alterations of serotonin transporters (SERT) 
are implicated in a large number of psychiatric 
disorders. The first generation radiotracer for 
SERT imaging by PET techniques was 
(+)-[11C]McN 5652 [1]. New compounds should 
exhibit lower nonspecific binding in the brain, 
higher plasma free fraction, and faster plasma 
clearance and brain uptake kinetics, enabling 
measurement of SERT parameters in a shorter 
scanning time. The purpose of this study was 
to evaluate the blood kinetics and metabolism 
in rats of the new PET radioligand for the 
SERT, N,N-Dimethyl-2-(2-amino-4-[11C]methyl-
thiophenylthio)benzylamine ([11C]SMe-ADAM). 
The tracer was synthesized from its thiophenol 
precursor by reaction with [11C]methyl iodide 
[2]. 
 
Results and Discussion 
Blood kinetics 
The 11C-activity clearance from rat blood was 
evaluated by arterial blood samples and by 
measurements of the time activity distribution 
in a region of interest (ROI) over the heart. 
After an initial, rapid distribution phase, plasma 
activity stabilized at relatively constant levels 
for the tracer.  
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Fig. 1. Time-activity curve extracted from a heart ROI of 
dynamic microPET images after single intravenous 
injection of [11C]-SMe-ADAM in a rat. 
 
Metabolic investigations 
Metabolisation of the radioligand [11C]-SMe-
ADAM was investigated in blood and brain of 
rats after i.v. application. A quite fast peripheral 
metabolism of the radiotracer was stated. 10 
min after administration the main portion of 
radioactivity in plasma samples was assigned 
to hydrophilic metabolites whereas less than 
18 % of the activity represented the un-
changed radiotracer. 60 min after injection the 
portion of the non-metabolized tracer had 
dropped to only 2 %.  
In contrast to these observations, only the 
signal of the original compound [11C]-SMe-
ADAM was detected in brain sections 60 min 
after tracer application (striatum + thalamus, 
cerebellum) revealing that no passage of me-
tabolites through the blood-brain-barrier occurs 
(for examples, see Fig. 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. RadioHPLC of the tracer before injection, plasma 
10 min p.i. and brain homogenate (striatum + thalamus)  
60 min p.i. (from top). 
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Animal PET Studies with [11C]SMe-ADAM 
R. Bergmann, J. Zessin 
 
Biodistribution of [11C]SMe-ADAM was studied by animal PET and showed suitable characteristics for imaging 
SERT in the living brain. 
 
 
Introduction 
The serotonin transporter (SERT) regulates the 
entire serotoninergic system and its receptors 
via modulation of extracellular fluid serotonin 
concentrations. Differences in SERT expres-
sion and function show associations with mul-
tiple human disorders and with side effects 
during treatment with antidepressant SERT 
antagonists, namely, the serotonin reuptake 
inhibitors (SRIs). Therefore, the in vivo distribu-
tion and kinetics of specific SERT binding 
radiotracers could give important information 
about the functional expression of the SERT. 
The biokinetics of the SERT binding radio-
tracer [11C]SMe-ADAM was studied in rat brain 
to evaluate the potential of this compound to 
image the SERT in vivo.  
 
Biodistribution and microPET imaging 
studies  
Kinetic biodistribution studies were done in 
male Wistar rats by tail vein injection of 
[11C]SMe-ADAM followed by brain dissection 
and tissue counting. 
PET imaging was performed with a microPET® 
P4 primate model scanner (CTI Concorde 
Microsystems Inc. Knoxville, TN). No correc-
tion for recovery and partial volume effects was 
applied.  
The brain distribution of the radiotracer 
showed a increasing specific accumulation in 
the striatum and thalamus, as regions with high 
SERT concentrations (Table 1, Fig. 1).  
 
Table 1. Regional brain uptake and specific binding of the 
radiotracer [11C]SMe-ADAM in male Wistar rats a
Time (min) Striatum Thalamus 
5 3.16 ± 0.51 3.59 ± 0.41 
 (1.72 ± 0.10) (1.94 ± 0.73)
10 2.43 ± 0.39 3.04 ± 0.58 
 (1.81 ± 0.30) (2.28 ± 0.19)
30 2.41 ± 0.48 3.58 ± 0.40 
 (2.73 ± 0.27) (4.03 ± 1.50)
60 1.78 ± 0.30 2.86 ± 0.20 
 (4.15 ± 0.17) (6.74 ± 0.95)
 
a Regional brain uptake is represented as %ID/g (mean ± 
SD, 3 animals per group); specific binding (in parentheses) 
is expressed as ratio of activity in the tissues to that of the 
cerebellum. 
 
 
 
 
Fig. 1. Coronal (A), sagittal (B), and transversal (C) images 
of rat brain at 30 min after injection of 11 MBq of [11C]SMe-
ADAM (15 min acquisition). 
 
The corresponding time-activity curves de-
scribing the kinetics of [11C]SMe-ADAM binding 
in thalamus and cerebellum are presented in 
Fig. 2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2: Representative time activity curves of the [11C]SMe-
ADAM distribution in the rat brain measured with 
microPET®. Points represent the activities measured in the 
thalamic region (open circles), in the cerebellum (open 
triangles) and the activity relation between thalamus and 
cerebellum (closed squares) in one experiment. 
 
The radioactivity concentration in the SERT-
rich region thalamus increased during the first 
25 min, peaked between 30 and 50 min, and 
decreased slowly after this time. The specific 
binding of [11C]SMe-ADAM expressed as the 
ratio of radioactivity concentration in the SERT 
rich region thalamus and the reference region 
cerebellum increased up to 90 min to a plateau 
of 1.5 thereafter remains constant. This sug-
gests a saturable specific binding of [11C]SMe-
ADAM, which is a favourable feature for quan-
titative analysis of PET images. Additionally, as 
the metabolism analysis showed, the meas-
ured activity was identical with the [11C]SMe-
ADAM compound, so that estimations of the 
SERT in vivo should be possible.  
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Evaluation of 18F-Labelled Annexin V: Apoptosis Imaging in Mice 
R. Bergmann, C. Hultsch, B. Pawelke, J. Pietzsch, S. Bergmann1, S. Zijlstra2, J. Gunawan2, 
W. Burchert2, J. van den Hoff  
1Universitätsklinikum Dresden, 2Herz- und Diabeteszentrum Bad Oeynhausen 
 
The biodistribution of 18F-labelled annexin V and 18F-labelled albumin in mice was analysed and compared in a 
model system of apoptosis. The distribution of both proteins in apoptotic regions was similar. Only at high liver 
destruction the accumulation of 18FB-annexin was higher than that of 18FB-albumin. 
 
 
Apoptosis imaging with PET plays an increas-
ing role in various medical fields like oncology, 
cardiology, transplant rejection, and inflamma-
tion, but the radiotracer distribution in the tis-
sues is influenced by various mechanisms. In 
this study a recombinant annexin-V derivative 
and human serum albumin (HSA) were radio-
labelled using N-succinimidyl-4-18F-fluoro-
benzoate (SFB) [1], and characterised. 
Mechanism and specificity of both 18F-annexin-
V and 18F-HSA biodistribution and accumula-
tion were examined in rodents.  
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Accumulation of 18FB-HSA and 18FB-Annexin in the Mouse Liver after Induction of 
Apotosis by Fas-Antibodies
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Recombinant annexin-V derivative and HSA 
were radiolabelled using SFB and the products 
were confirmed by size exclusion chromatog-
raphy and SDS-PAGE. The radiotracer distri-
butions in animals were studied in rats and 
mice ex vivo by organ extraction, autoradio-
graphy, and in vivo with animal PET. For apop-
tosis imaging, 18F-annexin-V or 18F-HSA were 
intravenously applied in 4 groups of mice that 
received either intraperitoneal 100 µl Anti-Fas 
antibody in 200 µl isotonic NaCl or 200 µl iso-
tonic NaCl 2 hours before the radiotracer. The 
degree of liver apoptosis was characterised by 
plasma (Alanine-Amino-Transferase) ALAT 
and (Aspartat-Amino-Transferase) ASAT activ-
ity measurements. 
 
The radiochemical yield was in the range of 10 
to 30 % (corrected for decay) with a specific 
activity of more than 20 GBq/µmol.  
The accumulation of 18F-annexin-V and 18F-
HSA, respectively in the apoptotic livers (4–16 
%ID/g) were correlated to the ASAT and in-
creased up to 4 times in comparison to control. 
The biodistribution of the tracers were compa-
rable except for the renal elimination of 18F-
annexin-V, which was up to 3 times higher 
than of 18F-HSA.  
 
The blood clearance of 18F-annexin-V was 
faster than the elimination of 18F-HSA from the 
blood. 
 
 
18F-annexin-V seems to be a PET-tracer for 
apoptosis imaging. The increasing accumula-
tion of 18F-HSA (Fig. 1) with increasing liver 
destruction in the used model could be inter-
preted as a degradation of the blood vascula-
ture in the acute apoptosis, induced by the 
anti-Fas antibodies. Thus, in PET measure-
ments of apoptosis, using 18F-annexin V tissue 
reactions should be taken into account. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Accumulation of 18FB-HAS and 18FB-annexin in the 
mouse liver after induction of apoptosis by Fas-antibodies. 
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Molecular and Biochemical Characterisation of Neurotensin Receptor-1 (NTR-1) 
in Different Tumour Cell Lines 
C. Haase, R. Bergmann  
 
The enhanced expression of Neurotensin Receptor-1 (NTR-1) mRNA in different tumour cell lines could be used 
as a specific diagnostic marker, e.g. in pancreatic cancer. The functional expression of the NTR-1 was studied on 
the mRNA and protein level in HT-29 and FaDu cells by RT-PCR and 2D-electrophoresis followed by Western 
blot. 
 
Introduction 
The human NTR-1 consists of 418 amino acids 
and belongs to a large superfamily of receptors 
coupled to G-proteins with seven transmem-
brane spanning regions (Fig. 1). The increas-
ing interest for peptide receptors in cancer is 
the possibility of receptor targeting. It has al-
ready be shown that these receptors are only 
overexpressed in cancer, in comparison to 
their expression in normal tissue. To achieve 
better insight into the disease mechanism, it is 
important to better understand the molecular 
characteristics of pancreatic cancer [1, 2]. 
 
Fig. 1. Schematic drawing of the NTR in the three-
dimensional space. Blue: helix 1; light blue: helix 2 + 
extracellular loop 1 + helix 3; red: helix 4 + extracellular 
loop 2 + helix 5; brown: helix 6 + extracellular loop 3 + 
helix 7. 
 
Results and Discussion 
For preparation of total RNA from HT29/WiDr 
(colorectal adenocarcinoma) and FaDu 
(squamous cell carcinoma) cells, an RNA iso-
lation kit was used. The purity and integrity of 
RNA were analysed by measuring the absorb-
ance ratio at A260/A280 as well as by electropho-
resis on a 1 % agarose gel. RT-PCR was per-
formed with mRNA as template and 5´and 
3´PCR primer specific for the human NTR-1 
sequence. Products were analysed on a 1,5 % 
agarose gel. 
As shown in Fig. 2, the 893-bp product result-
ing from primers against NTR-1 sequence was 
amplified from FaDu (1), HT29 (2) and WiDr 
cells (3). All three cell lines express the NTR 
sequence at high level. With the use of these 
two primers no more possible isoforms could 
be detected. Further studies will be done for 
RNA quantification in these cells and in differ-
ent tumour mouse models.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Base pairs 
2,645 
1 2 3 
1,605 
1,198 
Fig. 2. RT-PCR with human specific NTR-1 primers 
(1 FaDu cells, 2 HT29 cells and 3 WiDr cells) 
 
For Western blot and 2D-gel electrophoresis 
membrane proteins were extracted from FaDu, 
HT29 and WiDr cells by detergent based pro-
tein extraction utilizing the selective solubilisa-
tion of proteins afforded by detergents. 
Immunoblot analysis of NTR-1 expression with 
human polyclonal NTR-1 antibody was detect-
able in all three cell lines with a molecular 
range of 48-50 kDa. The analysis of 2D-
elctrophoresis (Fig. 3a) with following im-
munoblot (Fig. 3b) resulted in two apparent 
spots (Fig. 2). 
For further studies of the protein structure 
(splice forms [3] or protein modifications) the 
spots from membrane were used for MALDI-
MS analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. 2D-gel and Western blot analysis of HT29 cells 
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Prediction of Alternative Spliceforms of the Neurotensin Receptor-1 
S. Heymann1, R. Bergmann 
1Humboldt University Berlin, Institute of Computer Science 
 
Possible alternative spliceforms of the neurotensin receptor-1(NTR-1) were predicted and an extracellular peptide 
sequence was identified, which could be important in receptor function regulation. 
 
 
Introduction 
Pancreatic cancer is an extremely aggressive 
malignant disorder with a definitely poor prog-
nosis. The clinical characteristics of pancreatic 
cancer are much influenced by many different 
mechanisms and signals, like growth factors, 
growth factor receptors, apoptosis-inhibiting 
genes. Neurotensin is a neurotransmitter, 
which can also induce growth stimulation me-
diated via NTR. Autoradiographic binding 
analysis in resected pancreatic cancer re-
vealed the presence of high levels of NTR-1 
binding sites in 75 % of pancreatic cancers, 
suggesting that gastrointestinal hormones and 
neurotransmitters might also be involved in the 
regulation of pancreatic cancer cell behaviour 
[1]. It seems to be surprising that by NTR-1 
autoradiography, only pancreatic cancer sam-
ples and not chronic pancreatitis (CP) samples 
exhibited increased NT binding. Wang [1] dis-
cussed, that it is probable that in CP NTR-1 
mRNA is not translated into protein, which may 
result in low NTR-1 binding capacity, and al-
ternatively, it is possible that in CP, most of the 
NTRs are occupied and thereby masked by 
endogenous NT, which is increased in the 
serum, and that this does not happen in pan-
creatic cancer, in which the serum levels of NT 
are lower. 
We hypothesized that the discrepancy be-
tween mRNA and functional NTR-1 could be 
also a result of alternative spliceforms of the 
NTR-1. In this project, possible alternative 
spliceforms of the NTR-1 were predicted using 
a protein domain homology method [2]. 
 
Method 
Alternative splicing can yield manifold different 
mature mRNAs from primary transcripts. Nu-
merous studies revealed that alternative splic-
ing occurs much more often than previously 
assumed. In particular, various protein se-
quences obtained from cDNA libraries of ma-
lignant tissues turned out to be aberrant splice-
forms [3]. Computerized alternative spliceform 
simulation aims at biological knowledge acqui-
sition [2], addressing a protein diversity prob-
lem. Applied to NTR-1, putative spliceforms 
were screened for effects on ligand binding. 
The yellow peptide in Fig. 2 is common to 
known and aberrant spliceforms, but differen-
tially affected (Fig. 1) by a distant domain. 
Fig. 1 illustrates how sensitive a hormone re-
ceptor responds to the loss of a small portion 
due to alternative splicing: Because of this 
loss, the important disulphide bridge could not 
be formed. 
 
Fig. 1. Alternative spliceform prediction for cell surface 
protein studies 
 
 
Results 
The analysis of the NTR-1 genes showed a 
splicing sensitive peptide sequence (Fig. 2), 
which could be used as signal in further func-
tional analysis of the NTR-1 using receptor 
binding assays, aptamers, 2D-electrophoresis 
and MALDI-MS [4]. 
 
 
Fig. 2. Target peptide sequence on NTR-1 
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Preparation of [86Y]YCl3 Solution for Labelling of Functionalised Biomolecules  
S. Seifert, St. Preusche, J. Schlesinger, U. Schwarz1, F. Wüst 
1AEA Technology QSA GmbH, Braunschweig  
 
The metallic positron emitter 86Y has been produced using the solid target system at the Rossendorf CYCLONE 
18/9 cyclotron. A separation protocol was developed to obtain 86Y suitable to meet the high quality standard for 
labelling appropriately functionalised biomacromolecules like proteins and peptides.  
 
Introduction 
86Y is a potentially better suited radionuclide 
than 111In for the estimation of an absorbed 
dose in 90Y therapy. The positron emitter 86Y 
(T1/2 = 14.7 h) is produced via the 86Sr(p,n)86Y 
nuclear reaction using enriched 86SrCO3 as the 
target material. Two of the most crucial as-
pects for successful application of radiometals 
in any targeted radiotherapy or imaging appli-
cation are related to the radionuclear and 
chemical purity of the radioisotope. The pres-
ence of metal contamination diminish labelling 
efficiencies, which may even lead to a com-
plete radiolabelling failure of chelate conju-
gated biomolecules. Thus, elaboration of a 
simple, rapid, and highly efficient purification 
method is of paramount importance. To meet 
these requirements, we have established a 
separation/purification method developed in 
collaboration with AEAT. Moreover, a recycling 
procedure for sufficient target material recov-
ery was elaborated. 
 
Results and Discussion 
In 2004 a total number of 18 irradiations of 
86SrCO3 were performed. Using 70 mg of the 
enriched target material pressed into a Pt tar-
get holder (Fig. 1), a 14 MeV proton beam with 
a beam current of 8 µA, and an irradiation time 
of 80 min, 1.7–1.8 GBq of 86Y could be pro-
duced at EOB.  
 
  
 
 
Fig. 1. Pt target holder with 86SrCO3 
 
After dissolution of the irradiated target mate-
rial in hydrochloric acid, the separation of yt-
trium from the strontium solution is achieved by 
a chromatographic material supplied by AEAT. 
About 40 % of the starting 86Y activity can fi-
nally be recovered in 1 N HCl. The solution is 
evaporated, and the residue is heated up to 
400 °C in a heating block. After cooling the 86Y 
activity is re-dissolved in 500 µl of 0.04 N HCl. 
The final solution is analysed for chemical and 
radionuclear impurities by ICP-MS, γ-spectro-
metry, and a DTPA binding test.   
It could be shown that 86Y solutions of high 
purity are obtained when ultrapure chemicals, 
carefully purified vials and other devices are 
used to prevent any metal contamination. The 
found M3+ impurities (Al3+, Fe3+) are in the 
range of 20 - 25 µg/l when the irradiated target 
material 86SrCO3 is removed from the Pt target 
holder using a special “dry” ejection method 
which circumvents the contact of the Pt target 
holder with hydrochloric acid.  
The low M3+ concentrations are confirmed by 
positive results of the DTPA binding test, which 
was developed by AEAT. The test is performed 
with 0.1 ml each of two concentrations of 
DTPA (10 µg/ml and 0.1 µg/ml) in neutral solu-
tion buffered with potassium acetate. The ra-
diolabelling yield is determined by TLC [sili-
cagel//0.1 M potassium acetate pH 6/10 % 
ammonia (50/50)]. The 86Y-DTPA complex 
moves with the solvent front while non-bound 
86Y remains at the origin. The final [86Y]YCl3 
solution exhibits DTPA-binding of >95 % when 
0.1 ml of DTPA solution (0.1 µg/ml) is used. 
The results of γ-spectrometric analyses show 
that only 0.04 % of the long-lived isotop 88Y 
are formed under the irradiation conditions 
mentioned above.  
 
86Y   (t1/2 = 0.608 d):  98.20 % 
87Y   (t1/2 = 3.346 d):    0.48 % 
87mY (t1/2 = 0.583 d):    1.31 % 
88Y   (t1/2 = 106.63 d):   0.04 % (n = 5) 
 
The costly target material 86SrCO3 has to be 
recycled. That succeeds by precipitation of the 
strontium chloride solutions with ammonium 
carbonate. We found that high concentrations 
of ammonium chloride in the strontium solution 
may prevent sufficient precipitation of SrCO3. 
For that reason the strontium carbonate pre-
cipitation should be performed seperately from 
each eluate. Thus, too high amounts of ammo-
nium chloride, which are obtained by pooling 
the eluates, can be avoided.  
86SrCO3 Target closed 
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Yttrium-86 Labelling of Neurotensin(8-13) Derivatives  
J. Schlesinger, R. Bergmann, F. Wüst 
 
Several 86Y complexes with functionalised neurotensin NT(8-13) derivatives were prepared. The radiochemical 
yield was determined dependent on the amount of functionalised peptide used. 
 
 
Introduction 
The application of appropriately radiolabelled 
neurotensin(8-13) derivatives should open an 
innovative approach for diagnosis and therapy 
of pancreas carcinomas, for 75 % of all pan-
creas tumours were found to overexpress the 
neurotensin receptor [1]. For radiolabelling the 
β--emitter yttrium-90 and the β+-emitter yttrium-
86 represent an interesting “matched pair” 
enabling both, therapy and diagnosis, respec-
tively.  
The present work is aimed at acquiring basic 
radiochemical knowledge on labelling of sev-
eral functionalised neurotensin(8-13) deriva-
tives with cyclotron-produced n.c.a. yttrium-86 
[2]. In this report we describe the fuctionalisa-
tion of neurotensin(8-13) (NT(8-13)) with DTPA 
and DOTA as suitable chelators for forming 
stable complexes with yttrium and subsequent 
radiolabelling with yttrium-86.  
 
Results and Discussion 
Preparation of DOTA- and DTPA-
functionalised NT(8-13) derivatives (Fig. 1) 
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Fig. 1. DOTA- and DTPA-functionalised neurotensin(8-13) 
derivatives. 
 
The preparation of DOTA-NT(8-13) 1 was car-
ried out by the reaction of DOTA(But)3 with 
NT(8-13) in the presence of HATU as activat-
ing agent providing DOTA-NT(8-13) conjugate 
1 in 31 % yield. Significantly higher yields were 
obtained when bifunctional chelating agents p-
SCN-bz-DOTA and SCN-bz-DTPA were linked 
to NT(8-13) via formation of a thiourea func-
tionality, being 49 % (DOTA-bz-NT(8-13) 2) 
and 92  % (DTPA-bz-NT(8-13) 3), respectively.  
 
 
However, in contrast to compound 1 com-
pounds 2 and 3 were shown to be fairly unsta-
ble under acidic conditions due to EDMAN deg-
radation. 
The IC50 values of non-radioactive yttrium 
complexes toward the neurotensin receptor 1 
were determined to be 4.7 nM for complex 4 
and 4.3 nM for complex 5 using a radiometric 
binding assay with 3H-labelled NT(8-13) as 
tracer (IC50 3H-NT(8-13): 0.7 nM). Complexes  
Y-DOTA-NT(8-13) 4 und Y-DOTA-bz-NT(8-13) 
5 were prepared in 68 % and 73 % yield after 
HPLC-purification (Fig. 2). 
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Fig. 2. Synthesis of yttrium-complexes 4 and 5. 
 
86Y-labelling 
The radiolabelling of DOTA- and -DTPA func-
tionalised NT(8-13) derivatives 1, 2 and 3 with 
n.c.a. yttrium-86 was studied using different 
amounts of chelator. The radiochemical yields 
(RCYs) strongly depend on the amount of 
DOTA-NT(8-13) 1, DOTA-bz-NT(8-13) 2 and 
DTPA-bz-NT(8-13) 3, which were subjected to 
the radiolabelling procedure (0.4 M NH4OAc 
buffer, 95 °C, 25 min.). The RCYs were deter-
mined by means of radio-TLC using RP-18 
plates and MeOH/10 % NH4OH (9:1) as eluent.  
The RCYs were 91-100 % for [86Y]Y-DOTA-
NT(8-13) when 35-250 µg of DOTA-NT(8-13) 1 
were used. Lower RCYs were found in the 
case of thiourea conjugates 2 and 3, being 65-
70 % (25-250 µg of DOTA-bz-NT(8-13) 2) and 
48-95 % (40-330 µg of DTPA-bz-NT(8-13) 3), 
respectively. 
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Technetium and Rhenium Complexes with Modified Fatty Acid Ligands             
7. Synthesis and Biological Evaluation of a New Type of Technetium-Labelled 
Fatty Acids for Myocardial Metabolism Imaging 
M. Walther, C. M. Jung, R. Bergmann, J. Pietzsch, K. Rode, W. Kraus1, H.-J. Pietzsch, 
H. Spies 
1Bundesanstalt für Materialforschung und –prüfung, Berlin 
 
Technetium-99m ‘4+1’ fatty acid complexes were synthesised and investigated in vivo. 
 
Introduction 
To develop technetium-labelled fatty acid ana-
logues for myocardial metabolism imaging, 
rhenium model complexes and their 99mTc 
analogues were synthesised according to the 
‘4+1’ mixed-ligand approach and investigated 
in vitro and in vivo. 
To estimate the diagnostic value of the 99mTc-
labelled fatty acids the compounds were inves-
tigated in cell-uptake experiments and in bio-
distribution studies using male Wistar rats (5–6 
weeks old, body weight 151±15 g). 
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Results and Discussion 
The formation of the rhenium models was ac-
complished by ligand exchange reactions us-
ing different pre-formed rhenium precursors. 
The rhenium model complexes were 
completely characterised by NMR, IR, MS, EA 
and by single crystal X-ray analyses for the 
C15-derivative in order to determine the geo-
metrical impact of the chelate unit on the fatty 
acid structure (Fig. 1).  
 
 
Fig.1. Molecular structure of the ReNS3C15-fatty acid. 
 
The new fatty acid tracers contain the metal 
core in the oxidation states +3, well-wrapped in 
a trigonal-bipyramidal coordination moiety 
which is attached at the omega position of a 
fatty acid chain. The compounds differ in their 
chain lengths with 10 or 11 methylene groups 
and in the insertion of a sulphur atom into the 
chain. This structural feature is considered to 
be a good imitate of the well-established 
iodinated phenyl fatty acids. 
Noticable heart uptake of the 99mTc tracers 
being in the order of 3.7 % ID/g 5’ p.i. and 
accompanied by a good heart to blood ratio 
(Fig. 2) confirms the remarkably results of the 
perfused heart experiments [1]. 
While the tracers are superior to other de-
scribed Tc-fatty acid imitates [2, 3] with regard 
to good heart to blood ratios, heart to liver ratio 
has to be improved.  
For this, chemical modifications will be per-
formed at the chelating part as well as at the 
alkyl chain. 
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Technetium and Rhenium Complexes with Modified Fatty Acid Ligands            
8. Myocardial Extraction of a New Type of Technetium-Labelled Fatty Acids 
M. Walther, C. M. Jung, S. Stehr1, A. Heintz1, G. Wunderlich1, H.-J. Pietzsch, J. Kropp1, 
A. Deussen1, H. Spies 
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Technetium-99m ‘4+1’ fatty acid complexes and well-known iodine labelled fatty acids like IPPA were compared 
concerning their heart uptake on perfused guinea pig heart studies. 
 
Introduction 
Newly developed technetium-labelled fatty acid 
analogues are promising agents for myocardial 
metabolism imaging. 
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M = Re, 99mTc, X = C, S, n = 1 -7  
The myocardial extraction of eight 99mTc ana-
logues of rhenium model complexes synthe-
sised according to the ‘4+1’ mixed-ligand ap-
proach [1] have been tested in a guinea pig 
heart-LANGENDORFF model. 
 
Results and Discussion 
All substances showed extraction rates in the 
region of 5 to about 40 %. In particular, 
experiments with fatty acid analogues C11 
(39.8 %), but also C12 (14.8 %) and C11S   
(17.1 %) showed values superior to that of 
‘3+1‘ Tc-fatty acid derivatives described before 
[2].  
When compared with extraction rates for 
[123I]iodophenylpentadecanoic acid (IPPA) 
determined with the same set-up, extraction for 
the C11 and C11S compounds is 3 fold and 1.3 
fold, respectively (Fig. 1).  
These results confirm our hypothesis that the 
″4+1″ Tc(III) chelate unit is a promising tool for 
the Tc-labelling of fatty acids. Further experi-
ments with different species are planned to 
elucidate exact myocardial uptake mecha-
nisms. 
Derivatives that show high extraction rates in 
the isolated constant-flow-perfused guinea pig 
heart model will be involved to characterise in 
vivo patterns in mice and guinea pigs. 
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Fig. 1. Extraction rates of the new ‘4+1’ mixed-ligand Tc complexes in comparison with IPPA. 
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99mTc-Labelled RGD-Peptide Using the “4+1” Mixed-Ligand Chelate System 
J.-U. Kuenstler, S. Seifert, R. Bergmann, H.-J. Pietzsch 
 
A new 99mTc-labelling method for the RGD-peptide c(RGDyK) via a "4+1" mixed-ligand complex is described, 
enabling labelling of about 0.1 mg peptide with 1 GBq in a yield of 70 %. For identity confirmation of the 99mTc-
labelled RGD-peptide the analogous Re compound was prepared. Biodistribution studies with 99mTc-labelled 
c(RGDyK) were performed. 
 
Introduction 
Radiolabelled RGD-derived compounds show-
ing a large potential for imaging of tumour-
induced angiogenesis have already been de-
scribed and studied in vivo with a large variety 
in both the labelling system and the RGD-
motive [1]. 
In this report we present a new 99mTc-labelling 
procedure for the RGD-peptide c(RGDyK) 
according to the "4+1" mixed-ligand approach 
[2]. The 99mTc-labelled c(RGDyK) is investi-
gated in biodistribution studies. 
 
Results and Discussion 
The RGD-peptide c(RGDyK) was modified by 
introducing an isocyanide group using the bi-
functional coupling agent CN-BFCA [3]. This 
reacted with the ε-amino group of lysine to give 
CN-c(RGDyK). A two-step procedure was per-
formed to obtain the 99mTc-labelled compound 
99mTc(NS3)(CN-c(RGDyK) (Fig. 1). At first 
99mTc-EDTA was formed, which reacted in a 
second step with CN-c(RGDyK) and the tet-
radentate ligand N(CH2CH2SH)3 [3]. This pro-
cedure enabled 99mTc-labelling of 0.1 mg CN-
c(RGDyK) with up to 1 GBq and a radiochemi-
cal yield of 70 %. To verify the identity of the 
99mTc-labelled c(RGDyK) an analogous "4+1" 
Re compound Re(NS3)(CN-c(RGDyK) (Fig. 1) 
was synthesised. The obtained compounds 
were characterized by RP-HPLC (Fig. 2) and 
ESI-MS. 
 
NH
N
H NH
NHNH
O
O
O
O
O
NH
OH
OH
O
NH
NH2
NH
O
N
M
S
S
S
N
 
 
Fig. 1. Prepared "4+1" complex bearing RGD-peptide,  
M = 99mTc: 99mTc(NS3)(CN-c(RGDyK),  
M = Re: Re(NS3)(CN-c(RGDyK). 
 
Biodistribution studies of 99mTc(NS3)(CN-
c(RGDyK) in rats and tumour-bearing mice 
exhibited a high liver and kidney uptake (Table  
1). The tumour uptake was relatively low, re-
flecting the lack of specific receptor (αvβ3) up-
take. The receptor state of the tumour is not 
known. 
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Metabolic Stability and Biodistribution of Model Compounds Based on the 
99mTc “4+1” Mixed-Ligand Chelate System 
B. Pawelke, S. Seifert, R. Bergmann 
 
The metabolic stability of model compounds bearing a Tc(III) NS3/isonitrile mixed-ligand chelate unit was investi-
gated in rats and discussed in connection with biodistribution examinations. 
 
 
Introduction 
Trigonal-bipyramidal “4+1” Tc complexes con-
taining the NS3/isonitrile ligand system have 
been developed as versatile building blocks for 
labelling of biomolecules. A number of these 
complexes have been investigated and re-
ported to be stable against ligand exchange in 
glutathione challenge experiments as well as 
in vitro in whole blood and plasma of rats.[1] 
Therefore, they are considered promising can-
didates for further development. Recently, an 
improved procedure for their preparation was 
introduced [2]. In order to evaluate the behav-
iour in vivo we investigated the biodistribution 
and metabolic pattern of the model compounds 
1-4 in Wistar rats. 
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Results and Discussion 
Metabolic stability  
Arterial blood samples, urine, organ homoge-
nates and content of intestine of rats were 
analysed after i.v. injection of 99mTc labelled 
compounds 1-4. For compounds 3 and 4 bear-
ing a carboxyl group, the presence of a hydro-
philic main metabolite was stated in plasma, 
organ homogenates as well as in rinsing fluid 
of intestine (for an example, see Fig. 1). The 
compounds without carboxyl group did not 
show a comparably consistent metabolic pat-
tern in the different samples but instead a con-
siderably increased amount of activity bound to 
plasma proteins. It was concluded that the 
metabolic attack at compounds 3 and 4 occurs 
mainly at the carboxyl group. Compounds 1 
and 3 show a more complex degradation 
mechanism compared to 2 and 4, respectively, 
which is attributed to a higher metabolic sus-
ceptibility of the monodentate ligand (not 
shown in detail). 
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Fig. 1. Radiochromatograms of compound 4 in rats: 
injected compound, plasma and liver homogenate  
60 min p.i. (from top). 
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Fig. 2. Biodistribution of compounds 1-4 in rats (n = 4). 
 
Biodistribution 
A higher accumulation in liver and intestine 
was observed for compounds 1 and 2 whereas 
3 and 4 seem to undergo mainly renal excre-
tion (Fig. 2). The lower accumulation in liver 
and intestine of compounds 3 and 4 may be 
discussed in terms of a lower lipophilicity of the 
parent compounds with carboxyl group them-
selves as well as of the influence of the hydro-
philic metabolites described above. 
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Inhibition of Thymidine Phosphorylase as one Approach in Tumour 
Chemotherapy 
M. Grote, St. Noll, B. Noll 
 
Thymidine phosphorylase (TP, EC 2.4.2.4) is one of the key enzymes involved in the salvage biosynthesis path-
way and catabolism of pyrimidine 2’-deoxynucleosides. Several new pyrimidine derivatives were tested concern-
ing their inhibitory effect on E. coli TP. 
 
 
The enzyme thymidine phosphorylase (TP) 
converts thymidine (dT) to thymine and α-D-2-
deoxy-ribose-1-phosphate in a reversible reac-
tion. TP expression is enhanced in several 
types of human tumour tissues (e.g. in 
mamma, ovarian or colon carcinomas) [1]. 
To clarify the role TP is playing in this process 
inhibitors are necessary to prevent this enzy-
matic activity. Specific inhibitors will disturb the 
salvage pathway and diminish the clearance of 
thymidine and 2’-deoxynucleosides leading to 
cell death. The monitoring of this process re-
quires suitable radiotracers acting as inhibitors.  
A first step of this approach was to study 
whether a number of novel acyclic nucleoside 
derivatives [2] (Fig. 1) are potential inhibitors of 
thymidine phosphorylase, derived from E. coli. 
The sequences of this enzyme correspond to 
about 70 % with human TP.  
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Fig. 1. 
 
 
 
The inhibition assays contained 250 µM 
3H-thymidine, 10 mM Tris*HCl pH 7.4, 2 mM 
KH2PO4 and 1 % HSA in a final volume 
of 15 µl [3]. The inhibitory effect was tested 
with various amounts of inhibitor. Aliquots of 
2 µl were withdrawn at several time points and 
spotted to a TLC plate to determine the en-
zyme reaction. Plates were developed in 
CH2Cl2/MeOH (10:1) and scanned with a TLC 
scanner. The inhibition of TP was expressed 
as ratio of 3H-thymine formed without and with 
the respective compound (Table 1). 
Table 1. Inhibition of thymidine phosphorylase by uracil 
derivatives. 
  % inhibitory 
Comp. Conc. 
[µM] 
5 min 10 min 15 min 
1 1000 45 35 32 
 500 18 15 14 
2 1000 30 24 22 
 500 24 19 18 
3 1000 83 76 74 
 500 26 21 19 
4 1000 38 36 45 
 500 15 8 12 
5 1000 30 67 76 
 500 19 36 46 
6 1000 59 62 60 
 500 47 45 52 
 
 
All substances tested offer a more or less in-
hibitory effect on TP. Particularly compounds 3 
and 5 revealed a significant inhibition and ap-
pear to be capable for further more experi-
ments with isolated human TP and with human 
cell lines.  
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Synthesis and 18F-Labelling of Novel Acyclic Purine Nucleosides 
B. Noll, St. Noll 
 
The synthesis and 18F-labelling of two novel acyclic purine nucleosides for monitoring gene expression of herpes 
simplex virus type 1 thymidine kinase gene (HSV1-tk) is described. 
 
Introduction 
Monitoring thymidine kinase expression should 
be possible by using 18F-labelled nucleosides. 
Thus, two new precursors have been synthe-
sised followed by 18F-labelling to get new po-
tential substrates 1 and 3 for monitoring gene 
expression of herpes simplex virus type 1 
thymidine kinase gene (HSV1-tk). 
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Synthesis 
To brominate the acyclonucleosides ganci-
clovir 2 and penciclovir 4 a standard procedure 
was used yielding 5 and 6 [1]. For that 2 and 4 
were dissolved in 0.5 M sodium acetate buffer. 
A saturated solution of bromine-water was 
then added and the reaction mixture was al-
lowed to stir at 22 °C for several hours. The 
brominated compounds were purified by col-
umn chromatography on Sephadex G10 and 
water as eluent. 
Our strategy to label the nucleosides at the 
acyclic side chain with 18F requires the protec-
tion of the second hydroxyl group and of the 
amino group at position 2. Therefore 8-bromo-
ganciclovir 5, and 8-bromo-penciclovir 6 were 
treated with p-anisyl-chlorodiphenyl-methane 
in dimethyl formamide. Triethylamine and 
traces of dimethylamino pyridine were added 
and the mixture was allowed to react for 2 
hours at 55 °C. Thus, the protected com-
pounds 7 and 8 were formed in a yield of about 
65 %. 
 
X
OH
OH
NH
N N
N
O
NH2 Br
X
O
OH
NH
N N
N
O
NHMTr
MTr
Br
5: X = O
6: X = CH2 
MTrCl / TEA
DMF
7: X = O
8: X = CH2 
 
The once-tritylated and the threefold tritylated 
compounds being occurred as by-products in 
the synthesis were separated by column 
chromatography on silica gel and dichloro-
methane/methanol 10:1 as eluent. 
The introduction of the p-toluenesulphonyl 
group into 7 and 8 as leaving group for the 
fluorination was carried out with p-toluene-
sulphonyl chloride in a five-fold molar excess 
in anhydrous pyridine for 6 hours at room tem-
perature. The precursors 9 and 10 were puri-
fied by column chromatography on silica gel 
and dichloromethane/methanol 15:1 as eluent 
of about 55 %. 
All substances synthesised were identified by 
elemental analysis and 1H NMR spectroscopy. 
 
X
O
OH
NH
N N
N
O
NHMTr
MTr
Br
X
O
O
NH
N N
N
O
NHMTr
MTr
Ts
Br
7: X = O
8: X = CH2
TsCl / pyridine
9: X = O
10: X = CH2  
 
18F-Labelling 
An [18F]KF/K2.2.2 complex was received after 
azeotropic distillation with acetonitrile, krypto-
fix 2.2.2 and potassium carbonate. This com-
plex was allowed to react with the precursors 9 
and 10 (5 mg), dissolved in acetonitrile, for 
25 min at 160 °C. Then, the reaction mixture 
was given over a silica Sep-pak cartridge and 
eluted with dichloromethane/methanol (85/15 
v/v). The cartridge holds back K2CO3, kryptand 
and non-converted [18F]KF whereas the de-
sired [18F]F-labelled tracers 1 and 3 were 
eluted. 
The labelling yield amounted to about 55 % 
(50 min reaction time). HPLC analysis (Phe-
nomenex C18, PBS/MeCN 80:20) of the reac-
tion mixture after Si Sep-pak elution yielded a 
radiochemical purity >98 %. 
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N
O
NH2 Br
9: X = O
10: X = CH2
K18F / Krypt.
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Biodistribution of  18F-Labelled Acyclic Guanosine and Thymine Derivatives 
B. Noll, St. Noll, M. Grote, R. Bergmann 
 
The biodistribution of 18F-labelled acyclic guanine and thymine derivatives has been studied in Wistar rats con-
cerning their behaviour as potential substrates of HSV-1 thymidine kinase for monitoring gene therapy. 
 
 
Recently the syntheses of novel acylic 
pyrimidine nucleosides [1], acyclic purine nu-
cleosides [2] and the corresponding precursors 
have been reported. The 18F-labelled acyclic 
guanine and thymine derivatives were devel-
oped as potential substrates of the HSV1 TK to 
monitor gene expression. The labelling with 
fluorine-18 was carried out according to an 
optimised procedure with variation in reaction 
time and temperature. The general procedure 
is described in [2]. 
All tracers were purified by HPLC on RP18 
column and water/ethanol (90/10 up to 97/3) 
as eluent. The biodistribution in male Wistar 
rats 5 and 120 min after i.v. injection is de-
picted in Figs. 1 and 2 as % dosis/organ.  
The following 18F-labelled compounds 1-4 were 
tested.  
 
 
NN
NN
O
NH2
OH
F18
R1
NN
NNH
O
NH2
O
OH
F18
R1
1. R1 = H,     FHBG
2. R1 = CH3, FMHBG
3. R1 = H, FHPG
4. R1 = Br, BrGCV  
 
 
As acyclic thymidine derivatives the 18F-
labelled tracers 5-7 were taken into account: 
 
 
N
NH
O
O
R1
R2
O
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OH
5. R1 = I, R2 = H,      Iodacyclur
6. R1 = I, R2 = CH3,  Iodmetacyclur
7. R1 = H, R2 = H,    Acyclur  
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Fig. 1. Biodistribution of acyclic nucleosides in Wistar rats 
after 5 min. 
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Fig. 2. Biodistribution of acyclic nucleosides in Wistar rats 
after 120 min. 
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Biodistribution of  18F-Labelled Acyclic Guanine and Uracile Derivatives 
B. Noll, St. Noll, M. Grote, R. Bergmann 
 
The biodistribution of 18F-labelled acyclic guanine and uracile derivatives has been studied in Wistar rats concern-
ing their behaviour as potential subtrates of HSV-1 thymidine kinase for monitoring gene therapy. 
 
 
Recently, the syntheses of novel acylic pyrimi-
dine nucleosides [1], acyclic purine nucleosi-
des [2] and the corresponding precursors have 
been reported. The 18F-labelled acyclic gua-
nine and uracile derivatives were developed as 
potential substrates of the HSV-1 TK to moni-
tor gene expression. The labelling with fluo-
rine-18 was carried out according to an opti-
mised procedure with variation in reaction time 
and temperature. The general procedure is 
described in [2]. 
All tracers were purified by HPLC on RP18 
column and water/ethanol (90/10 up to 97/3) 
as eluent. The biodistribution in male Wistar 
rats 5 and 120 min after single i.v. injection is 
depicted in figures 1 and 2 as % injected 
dose/organ.  
 
The following 18F-labelled compounds 1-5 were 
tested.  
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O
NH2
OH
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1. R1 = H,     R2 = H   FHBG
2. R1 = CH3, R2 = H   FMHBG
5. R1 = Br,    R2 = H   BrPCV
3. R1 = Br,  R2 = H    BrGCV
4. R1 = H    R2 = H     FHPG
 
 
 
As acyclic uridine derivatives the 18F-labelled 
tracers 6-8 were taken into account: 
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8. R1 = H, R2 = H,      Acyclur  
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Fig. 1. Biodistribution of acyclic nucleosides in Wistar rats 
5 min p.i.. 
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Fig. 2. Biodistribution of acyclic nucleosides in Wistar rats 
120 min p.i.. 
 
 
As expected, all compounds showed a fast 
blood clearance. The biliary elimination was 
correlated with the lipophilicity of the com-
pounds tested. After 60 min most of the activity 
was found in intestine and urine. The fast ex-
cretion of the tracer seems to be a pre-
requisite for high target/non target ratio for 
monitoring gene expression. 
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Hydrophilic Rhenium-188 Complexes for Attaching the Metal to Biomolecules 
4. Synthesis and Characterisation of Hydroxymethyl Phosphine Containing 
‘4+1’ Complexes 
E. Schiller, W. Kraus1, H.-J. Pietzsch, H. Spies 
1Bundesanstalt für Materialforschung und –prüfung, Berlin 
 
A synthetic route for the preparation of hydroxymethyl phosphines is presented. Model complexes of these 
ligands were prepared to evaluate their use in the design of ‘4+1’-type complexes.  
 
Introduction 
Synthesis of hydrophilic species is an impor-
tant aim in the development of rhenium-188 
complexes of the ‘4+1’ mixed ligand approach 
[1]. Katti and co-workers reported on water-
soluble tetradentate ligands containing 
phosphines with hydroxymethyl substituents 
[2]. Sulfur or nitrogen heteroatoms in the 
phosphine’s backbone are responsible for their 
high stability against oxidation. These 
phosphines are considered as appropriate 
synthons in the design of radiopharmaceuticals 
of favourable biodistribution. We wanted to 
adapt the published synthesis strategy to the 
development of monodentate ligands for the 
‘4+1’ approach. 
 
Results and Discussion 
Hydroxymethyl phosphonium salts were syn-
thesised according to Scheme 1. Resulting PN 
and PS phosphonium salts 3 and 4, respec-
tively, can be converted to their corresponding 
tertiary phosphines by addition of triethyl-
amine. 
 
Scheme 1. Syntheses of hydroxymethyl-functionalised PN 
(3) and PS (4) ligands. 
 
P
+
NH
+
OH
OH
OH
 
P
O
Br
EtO
EtO
P
O
R
EtO
EtO
P
+
OH
OH
OH
S
 
Cl Cl
1. LiAlH4 / Et2O
2. HC(O)H / EtOH / HCl
2
+ NEt2 or HSPr 1 R = NEt2
2 R = SPr
3 4  
 
First diethylamine or 1-propanethiol was alky-
lated with commercial available diethyl  
2-bromoethyl phosphonate. Then the phos-
phonates 1 and 2 were reduced with LiAlH4. 
The resulting primary phosphines were reacted 
without isolation with formaldehyde in acidic 
solution, yielding the phosphonium salts as 
colorless viscous oils. 
‘4+1’ complexes Re1 and Re2 were prepared 
by heating a methanol/triethylamine solution of 
[Re(tu)6]Cl3 (tu = thiourea) and equimolar 
amounts of the phosphine ligand and tris(2-
mercaptoethyl)amine (NS3) for two hours un-
der reflux. 
Phosphonium salts as well as the ‘4+1’ com-
plexes were characterized by means of multi-
nuclear NMR and elemental analysis. Com-
plexes were additionally investigated by UV/vis 
spectroscopy and X-ray structure analysis. 
Crystal structures are displayed in Fig. 1.  
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Re
S1
S2
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S4
 
S2
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S3
Re
P
O1
O2
N2
N1
 
 
 
 
 
 
 
 
Fig. 1. Crystal structures of Re1 (left) and Re2 (right). 
 
Re1 showed high stability in organic solvents 
at room temperature whereas Re2 was con-
verted to a more hydrophilic species under 
these conditions. The final product of this con-
version (Re3) was isolated by column chroma-
tography. Mass spectrometry, IR spectroscopy 
and X-ray structure analysis (Fig. 2) indicated 
the oxidation of the sulfur atom in the 
phosphine’s backbone to the corresponding 
sulfoxide. Therefore only PN ligands are inves-
tigated furtherly [3]. 
 
 O3
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P
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S3
N
S1
 
 
 
 
 
 
Fig. 2. Crystal structure of Re3. 
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Hydrophilic Rhenium-188 Complexes for Attaching the Metal to Biomolecules 
5. Determination of in Vitro Stabilities 
E. Schiller, S. Seifert, F. Tisato1, F. Refosco1, H.-J. Pietzsch 
1ICIS-CNR, Padova, Italy 
 
Looking for suitable candidates for the development of rhenium-188 radiotherapeutics we determined in vitro 
stabilities of various complexes with tetradentate/monodentate (‘4+1’) coordination. Influences of the nature of the 
ligands on the in vitro stability are discussed. 
 
 
Introduction 
According to the so-called ‘4+1’ approach [1] 
we have synthesised a series of rhenium-188 
model complexes using a method recently 
described by Seifert and co-workers [2]. We 
determined in vitro stabilities of these com-
pounds by incubating 2-3 MBq of each com-
plex in phosphate buffer, human plasma and 
rat plasma, followed by checking the amount of 
188ReO4- formed after 1 h, 24 h and 48 h by 
thin layer chromatography. 
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Fig. 1. In vitro stabilities of 188Re complexes Re1–
Results and Discussion 
In vitro stabilities of rhenium-188 ‘4+1’ com-
plexes were found to be strongly dependent on 
the nature of the monodentate phosphorus(III) 
ligands (see Re1 – Re5 in Fig. 1). The most 
hydrophilic complex bearing a hydroxymethyl 
phosphine [3] Re1 was not stable giving large 
amounts of perrhenate. Conversely, more lipo-
philic compounds Re4 and Re5 were found to 
produce only little amounts of perrhenate. 
Obviously, only complexes bearing a bulky 
phosphorus co-ligand which generates along 
with the three thiolate sulfurs of the NS3 ligand 
a lipophilic area around the rhenium are of 
high in vitro stability. This lipophilic area pre-
vents the Re(III) center from hydrolysis and re-
oxidation to perrhenate. 
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2 The initial aim to develop hydrophilic rhenium-
188 complexes of high in vitro stability can be 
achieved by preserving the lipophilic core in 
the inner coordination sphere and introduction 
of hydrophilic functional groups either at the 
NS3 framework and/or at the monodentate 
ligand. Therefore, complexes having a car-
boxyl group containing tetradentate NS3 ligand 
[2, 4] or a derivative thereof are an appropriate 
approach. Complexes of this formulation (Re6, 
Re7) exhibited higher hydrophilicity (Re6 >> 
Re7 > Re5) but comparable in vitro stability 
than their unsubstituted analogue Re5. There-
fore we consider these agents as promising 
candidates for the development of rhenium-
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188Re-EDTA – a Suitable Precursor for Preparing 188Re(V) Complexes 
S. Seifert 
 
The 188Re(III) complex with ethylene diamine tetraacetic acid (EDTA) was found to be a suitable precursor for 
preparing 188Re complexes of the same or higher oxidation states. That was tested by ligand exchange reactions 
with ligands forming Re(V)oxo complexes like ECD, EC, another N2S2 ligand, or DMSA. 
 
 
Introduction 
99mTc(III)-EDTA and the analogue 188Re com-
plex has been successfully used to prepare 
‘4+1’ complexes containing the tetradentate 
NS3 ligand and a phosphine or isonitrile as the 
monodentate ligand [1]. The reduction of 
Tc(VII) or Re(VII) to the oxidation state 3+  
succeeds at room temperature, also in the 
case of perrhenate generator eluate and al-
lows the gently preparation of M(III) com-
plexes. Considering the tendency of carrier-
free 188Re complexes of lower oxidation states 
to re-oxidise in solution, it should be possible 
to prepare 188Re complexes of higher oxidation 
states by ligand exchange reaction of 188Re-
EDTA with ligands forming such kinds of com-
plexes. Therefore, corresponding studies were 
performed using tetradentate N2S2 ligands like 
ECD, its acid form EC, KET 397 or dithiol 
ligands like DMSA (Fig. 1).  
 
HS
COOEtEtOOC
N N
SH  
L,L-ECD (L,L-ethylene dicysteine diethyl ester) 
 
HS
NH N N
OH
N
SH  
KET 397 
 
SH
SH
COOH
COOH  
DMSA 
   
Fig. 1. Ligands used for re-oxidation studies 
 
 
Results and Discussion 
The preparation of 188Re(V) complexes was 
carried out in two steps. At first, the 188Re-
EDTA was prepared by reconstitution of a kit 
containing 5 mg EDTA, 5 mg mannitol, and 1 
mg SnCl2 with 2–5 ml of acidic perrhenate 
eluate as described in [1]. In a second step, 1 
ml of the 188Re-EDTA solution was added to 
the aqueous/ethanolic solution of 0.5–1.0 mg 
of the appropriate ligand. After slight heating to 
40–50 °C for 30 min the desired Re(V) com-
plexes were formed with yields of 50–80 % of 
the starting activity (reaction conditions were 
not optimised up to now). Generally, the reac-
tion succeeds in a neutralised 188Re-EDTA 
solution. Fig. 2 shows as an example the re-
oxidation of 188Re-EDTA in an ECD solution. 
The comparison of retention times of the 
formed 188Re-ECD complex and a “kit-like” 
99mTc-ECD preparation confirms the identity of 
the final complex. 
 
0 2 4 6 8 10
Time (min)  
188Re-ECD 
 
0 2 4 6 8 1
Time (min)
0
 
99mTc-ECD 
 
Fig. 2. Comparison of HPLC analyses of 188Re-ECD and a 
“kit-like” 99mTc-ECD preparation. 
 
 
In Table 1 the results of the presented studies 
are summarised. 
 
Table 1. Yields and reaction conditions for the preparation 
of 188Re(V) complexes 
Complex formed Yield 
[%] 
Reaction 
conditions 
188Re-ECD 80 1 mg ligand, rt, 45 min
188Re-KET 397 50 same 
188Re-DMSA 56 30 min 
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In Vitro Stability of 188Re Complexes  
S. Seifert, C. Jentschel 
 
The in vitro stability of 188Re complexes of various oxidation states and coordination spheres was studied in phos-
phate buffer, rat plasma and human plasma.  
 
Introduction 
The aim of this study was to determine the rate 
of re-oxidation of various 188Re(III) and  
188Re(V) complexes to perrhenate in phos-
phate buffer and plasma solutions. The influ-
ence of chemical nature of the monodentate 
ligand in ‘4+1’ 188Re(III) complexes of the type 
[188Re(NS3)(isonitrile)] was investigated using 
tert. butylisonitrile (TBI), cyclohexylisonitrile 
(CHI), and triphenylmethylisonitrile (TPMI).The 
stabilities were compared with those of 
188Re(V)-MAG3 and 188Re(V)-DMSA.    
 
Results and Discussion 
The ‘4+1’ 188Re(III) complexes were prepared 
according to the described method using the 
two-step procedure via 188Re-EDTA [1]. 
188Re(V)-MAG3 was prepared according to [2] 
and for the preparation of 188Re(V)-DMSA a 
commercial kit was reconstituted at 100 °C 
with 1.0 ml of perrhenate eluate [3].   
For stability studies the preparations were 
purified by semi-preparative HPLC and 0.1 ml 
of the complex solution (2-5 MBq) were added 
to 0.4 ml of 0.01 M phosphate buffer of pH 7.4, 
a mixture of 0.2 ml buffer and 0.2 ml human 
plasma, as well as a mixture of 0.2 ml buffer 
and 0.2 ml rat plasma. The yield of perrhenate 
formed by incubation at room temperature was 
determined by TLC [RP-18//acetonitrile/water 
(80/20)] at three times (after 1, 24, and 48 h). 
The results are presented in Figs. 1 and 2. 
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Fig. 1. Stabilities of ’4+1’ 188Re complexes  
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Fig. 2. Stabilities of 188Re-MAG3 and 188Re(V)-DMSA in 
phosphate buffer (PBS), human plasma (HP), and rat 
plasma (RP). 
 
The remarkable high stability of the ‘4+1’ com-
plex [188Re(NS3)(TPMI)] confirms results ob-
tained with various phosphine ligands [3]. Ob-
viously, ‘4+1’ complexes with a phenyl-groups 
bearing monodentate ligand are well-shielded 
and more stable against re-oxidation. Such 
types of 188Re(III) complexes are much more 
stable than 188Re(V) complexes. The high sta-
bility of 188Re(V)-DMSA in human plasma was 
also found by Blower et al. [4].  
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Novel and Efficient Preparation of Precursor [188Re(OH2)3(CO)3]+ for the 
Labelling of Biomolecules 
S. H. Park1, S. Seifert, H.-J. Pietzsch 
1Division of Radioisotope Production and Application, Korea Atomic Energy Research Institute, 
Daejeon, Republic of Korea 
 
A novel and efficient method for preparing 188Re(I) tricarbonyl precursor [188Re(OH2)3(CO)3]+ has been developed 
by reacting [188Re]perrhenate with Schibli’s kit in the presence of borohydride exchange resin (BER) as an addi-
tional reducing agent. The precursor was produced in more than 90 % yield by reacting 3 mg BER, 3 mg 
BH3·NH3, and 3 mg K2[BH3CO2], dissolved in saline, with a solution of Na188ReO4 and concentrated phosphoric 
acid (85 %, 8 µl) at 60  oC for 15 min.  
 
Introduction 
The 99mTc(I) and 188Re(I) tricarbonyl precursors 
[M(OH2)3(CO)3]+ have been shown to be excel-
lent starting materials for the synthesis of fur-
ther 99mTc(I) and 188Re(I) tricarbonyl complexes 
as well as radiolabelling of target specific bio-
molecules [1]. Recently, a user-friendly kit 
formulation (IsoLinkTM) was developed using 
potassium boranocarbonate, K2[BH3CO2], for 
preparation of the 99mTc precursor complex. 
This solid reagent serves both as a source of 
CO as well as a reductant for technetium. It 
was also used by Schibli and co-workers for 
the preparation of the corresponding 188Re 
precursor complex [2]. [188Re]perrhenate elu-
ate (1 ml) was reduced in neutral solution with 
3 mg K2[BH3CO2] and 5 mg BH3@NH3 by incu-
bation at 60 °C for 15 min. The amount of re-
ducing agents and acid (concentrated phos-
phoric acid) was carefully balanced, to avoid 
fast hydrolysis of the boranes and to maintain 
a sufficient low pH to stabilize reduced rhe-
nium intermediates. The preparations resulted 
in yields >85 % of the desired precursor com-
plex, remaining perrhenate (7±3 %), colloidal 
188ReO2 (<5 %), and a by-product of unknown 
composition.  
To overcome the moderate yields we used the 
recently described borohydride exchange resin 
(BER) as an additional reducing agent [3]. For 
preparation of BER the chloride-form resin 
(Amberlite® ion exchange resin, 12.5 g) was 
slurry-packed with water into a 30 ml fritted 
glass funnel mounted on a filter flask. Then, an 
aqueous sodium tetrahydroborate solution 
(200 ml, 0.25 M) was slowly passed through 
the resin over a period of 30 min. After wash-
ing with distilled water and ethanol, the tetra-
hydroborate-form anion exchange resin was 
partially air-dried by removing ethanol on the 
surface of the BER.  
 
Results and Discussion 
Optimal yields of the precursor complex were 
obtained using the following preparation condi-
tions: To a vial containing a mixture of 3 mg 
K2[BH3CO2], 3 mg BH3@NH3, and 3 mg BER, 
1.0 ml of [188Re]perrhenate eluate and 8 µl 
phosphoric acid (85 %) were added. The vial 
was incubated at 60 °C for 15 min. Pressure 
from the evolving H2 gas was balanced with a 
20 ml syringe. 90–95 % of the desired 
[188Re(OH2)3(CO)3]+ complex were found by 
HPLC and TLC analyses. The assay for the 
formation of the 188Re(I) tricarbonyl precursor, 
reduced-hydrolyzed 188Re, and [188Re]perrhen-
ate was achieved by investigating their posi-
tions using an instant thin-layer chromatogra-
phy (silicagel//MeOH/HCl (95/5). 188Re(I) tri-
carbonyl precursor: 90-95 % (Rf = 0.4); re-
duced-hydrolyzed 188Re: less than 3 % (origin); 
[188Re]perrhenate ion: 5-8 % (Rf = 0.8). The 
identity of the precursor was confirmed by 
reaction with histidine. The retention time of 
188Re(I) tricarbonyl histidine was compared to 
that of 99mTc(I) tricarbonyl histidine and found 
to be identical. 
According to the present study, employing the 
borohydride exchange resin (BER) as a novel 
reducing agent, 188Re(I) tricarbonyl precursor 
having high radiochemical purity as well as 
high labelling efficiency can be prepared with-
out nitrogen gas flushing and ice bath cooling.  
The BER is advantageous in terms of being 
stable over a wide range of pH (2-11) and ap-
plicable to biologically active molecules, as 
well as being easily removable through filtra-
tion when being administrated. 
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Biological Evaluation of 64Cu-Labelled Tetrapropionitrile Derivatized 
Macrocyclic Ligands 
P. McQuade1, M. Wüst1, M. Welch1, F. Wüst
1Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis 
 
Three tetrapropionitrile-containing azamacrocycles have been labelled with 64Cu. Biological evaluation of the 64Cu 
complexes comprised in vitro uptake studies in EMT-6 cells and biodistribution studies on BALB/c mice bearing 
EMT-6 tumours. 
 
Introduction 
The positron-emitting isotope 64Cu has found 
use as both a diagnostic agent by utilizing the 
high sensitivity of PET imaging, and also as a 
radiotherapy agent. As a result alternative 
approaches to targeted radiotherapy may be 
developed from studies on novel 64Cu-labelled 
derivatized macrocyclic ligands, by improving 
on the efficiency and clearance properties of 
known radiopharmaceuticals.  
One such family of macrocyclic ligands con-
taining propionitrile groups have been shown 
to cause DNA damage in P388 and BEL-7404 
cell lines [1].  
 
Results and Discussion 
Macrocyclic ligands containing nitrile groups 
have been synthesised by the Michael addition 
of acrylonitrile to the corresponding macrocy-
cle to give cyclen-N,N',N'',N'''-tetrapropionitrile 
(Cyclen-TPN), cyclam-N,N',N'',N'''-tetrapropio-
nitrile (Cyclam-TPN) and cyclo15-N,N',N'',N'''-
tetrapropionitrile (Cyclo15-TPN) (Fig. 3).  
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Fig. 1: Macrocycles Cyclen-TPN, Cyclam-TPN and 
Cyclo15-TPN. 
 
 
Labelling of these compounds with 64Cu was 
achieved at 85 °C at pH 5.5 (0.1 M NH4OAc) 
for 60 minutes, with specific activities of 500 
mCi/mg typically being obtained. All three 
Cu(II) complexes are hydrophilic with log P 
values of  -1.47±0.1, -2.17±0.1 and -0.71±0.05, 
and were shown to be stable in vitro by incu-
bating at 37 °C in rat serum for 2 h. The in vitro 
uptake of these complexes in EMT-6 cells was 
investigated. 64Cu(II)-Cyclen-TPN had an up-
take of 6.67±0.81 % after 15 minutes, which 
then increased to around 20 % after 2 h, be-
fore reaching a plateau. Both complexes 
64Cu(II)-Cyclam-TPN and 64Cu(II)-Cyclo15-
TPN showed similar uptake in this cell line.  
Biodistribution studies on these complexes 
have also been obtained on BALB/c mice 
bearing EMT-6 tumours. 64Cu(II)-Cyclen-TPN 
had a tumor uptake of 3.96±0.56 %ID/g after 
only 5 minutes, which increased to 4.72±0.74 
after 4 h. 64Cu(II)-Cyclam-TPN and 64Cu(II)-
Cyclo15-TPN had a tumour uptake of 
4.80±0.30 %ID/g and 2.11±0.29 %ID/g after 5 
min, respectively. Tumour uptake of 64Cu(II)-
Cyclam-TPN dropped to 2.18±0.29 %ID/g 
after 4 h, whereas an increased uptake of 
3.28±0.36 %ID/g was found for 64Cu(II)-
Cyclo15-TPN. The tumour uptakes are sum-
marized in Table 1. 
 
Table 1. Tumour (T) uptake for 64Cu-labelled Cyclen-TPN, 
Cyclam-TPN and Cyclo15-TPN in BALB/c mice implanted 
with EMT-6 tumours. (Data presented as %ID/g ± sd (n=4). 
Tumour/Blood (T/B) and Tumour/Muscle (T/M) ratios ± sd.) 
 Cyclen-TPN Cyclam-TPN Cyclo15-TPN 
 5 min 4 h 5 min 4 h 5 min 4 h 
T 3.96±0.60 4.72±0.74 4.80±0.30 2.18±0.29 2.11±0.29 3.28±0.36
T/B 0.70±0.19 1.37±0.16 0.71±0.22 1.37±0.16 1.16±0.09 1.83± .29
T/M 1.68±0.34 4.44±0.98 1.79±0.14 5.14±0.69 3.80±0.57 4.70±0.97
 
 
Conclusion 
In vivo studies on these tetrapropionitrile 
ligands show that tumour uptake is observed 
and that compounds of this type may be of use 
as both a diagnostic or radiotherapy agent.  
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Formation of Stable Cu(II)-Complexes with Dendritic Oxybathophenanthroline 
Ligands 
H. Stephan, G. Geipel1, G. Bernhard1, U. Hahn2, F. Vögtle2 
1Institut für Radiochemie, 2Universität Bonn 
 
Hydrophobic dendritic oxybathophenanthroline ligands (generation 0 to 4) have been synthesised. The complexa-
tion behaviour towards Cu(II) has been studied using liquid-liquid extraction experiments and time-resolved laser-
induced fluorescence spectroscopy (TRFLS). The formation of 1:3 complexes (metal:ligand) having high stability 
has been proven in organic media.  
 
Introduction 
Derivatives of 1,10-phenathroline and their 
metal complexes are of considerable interest 
in bioinorganic chemistry, biology and medi-
cine [1]. In this nexus, dendritic modification 
(Scheme 1) is gaining in importance opening 
the way of tailoring complexation and solubility 
behaviour. Ruthenium(II) complexes contain-
ing dendritic 4,7-bis(benzyloxy)-1,10-phen-
anthroline show interesting luminescence and 
redox properties [2]. Octahedral assemblies 
can be obtained by coordination of phenan-
throline ligands having branched units in the 
3,8-position with certain metal ions [3]. Re-
cently, bischelates of dendritic 2,9-disubs-
tituted phenanthroline derivatives with cop-
per(I) have been described [4]. 
 
Scheme 1. Suitable positions for dendritic modification of 
1,10-phenanthroline 
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Here we want to report the complexation be-
haviour of dendritic oxybathophenanthroline 
ligands towards copper(II). 
 
Results and Discussion 
Dendritic oxybathophenanthroline ligands from 
zero to the fourth generation (cf. Scheme 2; 
only generation 1 is shown) were synthesised 
by addition of 2 equiv. of the corresponding 
dendritic benzylbromides to 1 equiv. depro-
tonated 4,7-bis(4´-hydroxyphenyl)-1,10-phen-
anthroline (NaH) dissolved in DMF.  
 
Scheme 2. Dendritic oxybathophenanthroline ligand 
(generation 1) 
O
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Liquid-liquid extraction studies in the system 
Cu(NO3)2/MES-NaOH buffer (pH = 5.3)//ligand/ 
CHCl3 using 64Cu for the determination of cop-
per concentration have been performed. The 
higher the generation of the dendritic ligand 
the higher the extraction efficiency of Cu(II) 
clearly indicating a dendritic effect. The results 
obtained from liquid-liquid extraction point to 
fast kinetics of complexation and the formation 
of 1:3 complexes (Cu(II):ligand) in the organic 
phase. This finding has been  corroborated by 
spectroscopic investigations using TRLFS 
experiments. Spectroscopic titration of den-
dritic ligands with copper(II) gives the evidence 
of clear 1:3 complex formation for all dendritic 
ligands investigated. It can be seen from Fig.1 
that the intensity of the emitted fluorescence 
signal of the dendritic ligand (excitation wave-
length: 266 nm) is reduced with increasing 
copper concentration. At the stoichiometry of 
1:3 (Cu(II):ligand) the fluorescence of the 
ligand is almost disappeared and clearly visible 
in a spectral shift. This points to the formation 
of highly stable Cu(II) complexes in the organic 
media. 
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Fig. 1. Time resolved fluorescence spectra of oxybatho-
phenanthroline ligand (generation 1) in dependence of 
Cu(CF3SO3)2 concentration in CHCl3. 
 
The results obtained for the copper complexa-
tion with hydrophobic dendritic ligands have 
encouraged us to develop water-soluble ana-
logues having PEG arms as branching units in 
view of binding the diagnostically and thera-
peutically relevant radioisotopes 64Cu and 
67Cu.   
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Remarkable Enhancement of Cell Uptake for [Ti2W10PO40]7- in the Presence of 
Chitosan 
H. Stephan, R. Bergmann, K. Rode, A. Röllich, W. Kraus1, K. Inoue2, L. Jelínek3,  Z. Matějka3 
1BAM Berlin, 2Saga University, Japan, 3Institute of Chemical Technology Prague 
 
The Keggin type metal oxygen anion cluster [Ti2W10PO40]7- forms stable particles of defined stoichiometry with the 
polysaccharide chitosan. Cell uptake studies with [Ti2W10PO40]7- using the tumour cell line HT-29 showed that the 
tungsten amount inside the cells is remarkably enhanced in the presence of chitosan. 
 
Introduction 
Certain polyoxometalates (POMs) have been 
recognized to efficiently penetrate into tumour 
cells and to act as anti-tumour agents [1]. 
However, many derivatives have a poor hydro-
lytic stability under physiologically relevant 
conditions leading to non-reproducible results. 
K7[Ti2W10PO40] has been found as a very sta-
ble compound even at higher pH [2]. Thus, this 
tungsten oxygen cluster has been chosen for 
cell uptake experiments. 
 
Results and Discussion 
K7[Ti2W10PO40] was prepared according to [3]. 
This polyoxotungstate has a high water solubil-
ity (>0.05 M), and it crystallizes from aqueous 
solution as K4H3[Ti2W10PO40]⋅15H2O having a 
tetragonal structure (Fig. 1).  
 
Fig. 1. Crystal packing of K4H3[Ti2W10PO40]⋅15H2O 
 
The polyanion is surrounded by potassium 
cations and water molecules that form a hy-
drogen bond network with terminal and point-
bridged oxygens from the cluster anion leading 
to a highly symmetric structure. Knowing that 
aminosaccharides can form stable complexes 
with metal oxoanions [4], the potassium cation 
was replaced by glucosamine and water-
soluble chitosan (Mr ~ 10.000 g/mol; Fig. 2), 
respectively.  
 
Fig. 2. Chemical structure of chitosan 
After mixing an aqueous solution of 
K7[Ti2W10PO40] (c = 10-4 M) with chitosan 
(0.5…2 g/l), the formation of stable nanometer-
sized particles has been observed [5]. Interest-
ingly, the stoichiometry of the particles formed 
of chitosan and [Ti2W10PO40]7- in the pH-range 
= 5.0…7.6  was always 1:5 independently from 
the initial chitosan concentration. 
Cell uptake studies of [Ti2W10PO40]7- has been 
performed using HT-29 cell line (adenocarci-
noma). Thus, ~5⋅104 HT-29 cells were incu-
bated for 24 h at 37 °C under 5 % CO2 using 
McCoy’s 5A medium (24-well plates, 4 repli-
cates for each concentration) in the presence 
of various [Ti2W10PO40]7- concentrations (0–
500 µM). In order to study the influence of 
aminosaccharides on the cell uptake of the 
polyoxotungstate two additional test series in 
the presence of glucosamine (10-4 M) and 
chitosan (1 g/l) have been carried out. Glycoly-
sis studies using 18F-labelled FDG point to a 
low toxicity of [Ti2W10PO40] and [Ti2W10PO40]/ 
glucosamine mixtures in the HT-29 cell line. 
On the other hand, glycolysis activity is re-
markably decreased in the case of applying 
[Ti2W10PO40]/chitosan particles. This finding 
may be explained on the basis of a considera-
bly higher tungsten content found in cells con-
tacted with nanoparticles formed of 
[Ti2W10PO40]7- with chitosan (Table 1). 
 
Table 1. Tungsten content in HT-29 cells 
Conditions µg W / mg cell protein 
100 µM [Ti2W10PO40] 1.3± 0.7 
100 µM [Ti2W10PO40] 
+ 100 µM glucosamin 
1.3± 0.8 
100 µM [Ti2W10PO40] 
+ 1 g/l chitosan 
30.5± 2.9 
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Colloid-Chemical Characterisation of Nanoparticles Formed by [Ti2W10PO40]7- 
and Chitosan 
W. Richter1, H. Zänker1, P. Krotká2,  Z. Matějka2, A. Röllich, H. Stephan 
 1Institut für Radiochemie, 2Institute of Chemical Technology Prague 
 
Nanoparticles formed of the Keggin type cluster anion [Ti2W10PO40]7- with the polysaccharide chitosan have been 
characterised by photon  correlation  spectroscopy, scanning electron microscopy, filtration and centrifugation 
experiments. Experiments reveal that the size of the particles formed are in the range of 40 to 300 nm. 
 
Introduction 
Organic modification of polyoxometalates 
(POMs) appears highly attractive to develop 
metallic drugs [1]. Thus, starch and liposome 
encapsulated POMs show suitable biocom-
patibility, enhanced chemical stability and im-
proved antitumoural activity [2, 3]. Recently, 
we found that [Ti2W10PO40]/chitosan associates 
have been efficiently taken up into tumour cells 
[4]. Chitosan is a linear polysaccharide com-
posed of randomly distributed ß-(1-4)-linked D-
glucosamine (deacetylated unit) and N-acetyl-
D-glucosamine (acetylated unit). Low molecu-
lar weight chitosan is well-soluble in water. But 
when K7[Ti2W10PO40] (POM1) is added, nano-
particles may be formed. In this paper, we 
want to report the colloid-chemical characteri-
zation of these particles.  
 
Experimental 
Chitosan (YC-100, Mr ~ 10.000 g/mol) was 
supplied by YDC company (Seoul, South Ko-
rea). The experiments were done with two 
solutions: solution A (50 mg/l chitosan and 
1·10-4 M POM1) and solution B (500 mg/l chi-
tosan and 1·10-4 M POM1). Both solutions 
were diluted with water in the ratio 1:10. These 
solutions were investigated with the following 
techniques: photon correlation spectroscopy 
(PCS), filtration, centrifugation, and scanning 
electron microscopy. The centrifugates, filtra-
tes and filter cakes were analysed by ion 
chromatography and ICP-MS. 
 
Results and Dicussion 
The filtration experiments of the solutions sug-
gested that all particles are smaller than 1 µm. 
Fig. 1 shows an SEM micrograph of the depos-
its on a 100-nm filter confirming the existence 
of particles in the 100-nm size range. PCS 
measurements in the solution revealed the 
presence of colloid particles of 40 to 300 nm in 
diameter. Fig. 2 shows the particle size distri-
bution from solution A received by PCS meas-
urement analysed by CONTIN method [5]. 
Centrifugation experiments have been per-
formed with both solutions: Solution A with an 
excess of POM1 and solution B with an excess 
of chitosan. As can be seen from Table 1, 
comparable size distribution of particles has 
been found. This finding points to the formation 
of well-defined associates between chitosan 
and POM1. 
 
Fig. 1. Scanning electron micrograph of [Ti2W10PO40]/ 
chitosan associates (filter pores = 100nm) 
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Fig. 2. Particle size distribution as obtained by photon 
correlation spectroscopy (PCS) for solution A 
 
Table 1. Particle size distribution as obtained by centrifu-
gation (average density of the particles = 1,1 g/cm3) 
Particle size [nm] Solution A Solution B 
               >370 0,8 % 2,1 % 
      370 ... 224 9,7 % 2,4 % 
      224 ... 132 18,1 % 18,2 % 
      132 ...   52 25,6 % 37,3 % 
      <52 45,8 % 40,0 % 
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Estimation of Partition Coefficient (log P) with Molecular Modelling of Rhenium 
and Technetium Complexes 
K. Yoshizuka1, H. -J. Pietzsch, H. Stephan  
1 University of Kitakyushu, Japan 
 
A novel molecular modelling method for Re and Tc complexes combined with the molecular mechanics and the 
molecular dynamics has been developed for estimating log P of these complexes between water and 1-octanol.  
 
Introduction 
Lipophilicity of 99mTc and 188Re tracers is an 
important parameter for the prediction of ab-
sorption and distribution of these tracers in 
biosystems. 
We are now developing an estimation method 
of log P of Re and Tc complexes combined 
with the molecular mechanics (MM) and the 
molecular dynamics (MD). In this paper, we 
describe the MM and the MD in binary system 
of water/1-octanol of Re- and Tc-DMSA model 
complexes as shown in Fig. 1. 
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Fig. 1. Re- and Tc-DMSA complexes  
(mixtures of isomeres) 
 
Calculation methods 
The MM calculations were performed with the 
strain minimization program MOMEC97 [2]. 
Within the molecular mechanics frame work, 
the structure of a molecule is modified in order 
to minimize its total strain energy (Utotal) con-
sisting of bond length deformation (Eb), va-
lence angle deformation (Eθ), torsion angle 
deformation (Eφ) and non-bonded interaction 
(Enb), as expressed by eq.(1).  
Utotal = Σ( Eb + Eθ + Eφ+ Enb)  (1) 
No symmetry restrictions were imposed on the 
local coordination sphere, and non-bonded 
interactions involving the metal center were 
neglected. Input coordinates were obtained 
from X-ray crystal structure data in literatures. 
The constant values of force field parameters 
were adjusted until an optimal agreement be-
tween calculated and observed structures was 
obtained throughout the entire range of avail-
able structures.  
The MD simulations were performed using the 
MD program WinMASPHYC Pro. The potential 
parameters for MD calculations were trans-
ferred from those of MM described above. 
 
Results and Discussion 
Fig. 2 illustrates RMS overlays of the calcu-
lated lowest energy structures of Re-DMSA 
calculated by MOMEC97 with crystal structure 
cited in Cambridge Structure Database. Since 
both structures are in good agreement with 
corresponding (RMS = 0.24 Å), we consider 
that this force field parameters are also adapt-
able in order to obtain the calculated structures 
of these complexes. 
Fig. 2. Overlay of computed MOMEC and X-ray 
structures of Re-DMSA. 
 
Fig. 3 shows the MD snap shot of Re-DMSA in 
water/1-octanol binary system (1.5×1.5×6 nm) 
after 100 ps. Using the calculated internal en-
ergies of the binary systems of both the com-
plex in 1-octanol (Uo) and that in water (Ua), 
the energy difference (∆U = Uo-Ua ) can be 
obtained. Since ∆U directly reflects the energy 
difference between non-bonded interaction of 
the complex and solvent, we are attempting 
the quantitative structure-property relationship 
(QSPR) between ∆U and experimental values 
of log P. 
Both experimental and calculated values poin-
ted to a higher lipophilicity of the Tc complexes 
in comparison with the Re analogues. 
Fig. 3.  MD simulation of Re-DMSA complex in water/ 
1-octanol binary system 
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Biodistribution and Catabolism of 18F-Labelled Amadori Product 
Fructoselysine 
C. Hultsch, M. Hellwig1, R. Bergmann, B. Pawelke, T. Henle1
1Institute of Food Chemistry, TU Dresden 
 
After synthesis of an 18F-labelled analogue of fructoselysine by conjugation with N-succinimidyl-4-
[18F]fluorobenzoate, biodistribution and catabolism of this labelled compound were studied. 
 
Introduction 
Amadori products are formed in food via Mail-
lard reaction. This reaction takes place when 
components like reducing sugars and amino 
acids or proteins react together. It occurs in 
most foods during heating. Thereby up to 50 % 
of the lysyl moieties may be modified because 
the ε-amino group of lysine is especial suscep-
tible to reactions with sugars [1]. 
Therefore one of the most important Amadori 
products is fructoselysine. Several studies 
concering bioavailability of fructoselysine show 
that at most 1 to 3 % of alimentary adminis-
tered fructoselysine is excreted to the urine. 
Because recovery in faeces is also only 1 to 2 
%, the fate of 95 % fructoselysine remains 
unclear [2]. For this reason, biodistribution, 
catabolism and elimination of 18F-labelled fruc-
toselysine were investigated.  
 
Results and Discussion 
N-succinimidyl-4-[18F]fluorobenzoate was used 
to modify fructoselysine at its α-amino group. 
The coupling reaction resulted in the respec-
tive 4-[18F]fluorobenzoylated derivative (Fig. 1), 
which was separated by semipreparative 
HPLC.  
 
 
 
Fig. 1. Conjugation of fructoselysine with [18F]SFB 
 
Firstly in vitro testings were accomplished. 
Thereby the [18F]fluorobenzoylated fructose-
lysine remained almost unchanged in all exam-
ined tissue homogenates (brain, liver, kidney, 
pancreas, heart and spleen from male Wistar 
rats) as well as in plasma and whole blood. 
Only in lysed whole blood the formation of a 
metabolite (m1) could be observed. The forma-
tion of this metabolite could be inhibited by 
addition of 1-deoxy-1-morpholinofructose, a 
specific inhibitor of the enzyme fructosamine 3-
kinase [3]. Furthermore, the metabolite m1 was 
completely transformed to [18F]fluoro-benzoyl-
ated fructoselysine after addition of the en-
zyme alkaline phosphatase. Therefore m1 
should be a phosphate ester which is formed 
by a fructosamine kinase.  
In in vivo experiments the metabolite m1 was 
also found. In plasma the appearance of m1 
could not be observed till 60 min p.i.. Then 10 
% of total radioactivity were derived from m1. In 
urine 60 min p.i. a second metabolite (m2) 
could be found. m2 was identified as 
[18F]fluorobenzoylated lysine. However, alto-
gether m1 and m2 represented less than 8 % of 
the total radioactivity. Furthermore, 60 min p.i. 
in the kidney sample 16 % of unmodified 
[18F]fluorobenzoylated fructoselysine were left. 
The portion of m1 was about 82 %. m2 was 
found to 2 %. 
Moreover, biodistrubtion of the fructoselysine 
derivative was investigated. The results are 
presented in Figs. 2 and 3. For comparison the 
biodistribution results of [18F]fluorobenzoyl-
ated lysine are also shown. 
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Fig. 2. Biodistributions (5 min p.i.) 
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Fig. 3. Biodistributions (60 min p.i.) 
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After intravenous application the [18F]fluoro-
benzoylated fructoselysine was fast taken up 
into the kidneys. 5 min p.i. over 30 % of the 
administered dose could be found in the kid-
neys. Also 60 min p.i. still more than 30 % of 
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whole radioactivity were localised in the kid-
neys. However, in comparison to [18F]fluoro-
benzoylated lysine the [18F]fluorobenzoylated 
fructoselysine showed a stronger accumulation 
in the kidneys and a delayed excretion into the 
urine.  
Because the studies of the in vivo stability 
showed the existence of large amounts of m1 – 
a phosphate ester of [18F]fluorobenzoylated 
fructoselysine – in the kidneys, the accumula-
tion of radioactivity seems to result from this 
phosphate ester. Recapitulatory, it should be 
noticed that amost half of the administered 
[18F]fluorobenzoylatedfructose lysine was ex-
creted to the urine nearly unchanged within 60 
min p.i..  
Consequently, the main part of the lysine, 
which was fructosylated during food process-
ing, remains unusable in spite of the activity of 
renal fructosamine kinase. 
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Radiolabelled Flavonoids and Polyphenols                                                     
III. Synthesis of an 18F-Labelled Resveratrol Derivative 
S. Gester, J. Pietzsch, F. Wüst 
 
The Wittig-Horner-Emmons carbonyl olefination was employed as the key step in the synthesis of 5-[(E)-2-(4-
[18F]fluorophenyl)ethenyl]-1,3-benzenediol (3,5-dihydroxy-4’-[18F]fluoro-trans-stilbene) [18F]-1. In a typical experi-
ment, starting from 5.75 GBq [18F]fluoride, 215 MBq of [18F]-1 could be obtained within a total synthesis time of 
120-130 min. 
 
Introduction 
As reported earlier we set up a synthesis of 
18F-labelled resveratrol derivative 5-[(E)-2-(4-
[18F]fluorophenyl)ethenyl]-1,3-benzenediol 
[18F]-1 to evaluate the radiopharmacological 
profile by means of PET [1]. However, the use 
of methoxy groups as protecting groups in the 
18F-labelled stilbene compound proved to be 
not suitable due to low yields observed in the 
deprotecting step. Therefore we now describe 
a modified synthesis of 5-[(E)-2-(4-[18F]fluoro-
phenyl)ethenyl]-1,3-benzenediol [18F]-1 using 
MOM-ether protecting groups. 
 
Results and Discussion 
The syntheses of novel labelling precursor 4c 
and reference compound 1 are given in Fig. 1.  
 
R O OR
O OMe
R O OR
R
R O
OR
F
F
OHC
2: R1 = H
3: R1 = MOM
5
2
1 1 1 1
1
1
a
b
c
d
e
f
4a: R1 = MOM, R2 = OH
4b: R1 = MOM, R2 = Br
4c: R1 = MOM, R2 = PO(OEt)2
6: R1 = MOM
1: R1 = H  
 
Reagents and conditions: (a) MOMCl, DIPEA, THF, reflux, 100 %; 
(b) LiAlH4, Et2O, 0°C-RT, 92 %; (c) NBS, PPh3, DMF, 60 °C, 56 %; 
(d) P(OEt)3, 160 °C, 65 %; (e) 4c, KOtBu, DMF, 100 %; (f) MeOH, 
HCl, 93 %. 
 
Fig. 1. Synthesis of the labelling precursor 4c and 
reference compound 1 
 
The labelling precursor 4c was obtained in four 
steps starting from commercially available 
methyl 3,5-bis(methoxymethoxy)benzoate 2. 
The phenolic OH-groups in 2 were protected 
as MOM-ether groups, and MOM-ether 3 was 
reduced with LiAlH4 to give [3,5-bis-
(methoxymethoxy)phenyl]methanol 4a in 92 % 
yield according to Sun et al. [2]. Subsequent 
bromination of the benzyl alcohol 4a with 
NBS/PPh3 in DMF gave 1-(bromomethyl)-3,5-
bis(methoxymethoxy)benzene 4b in 56 % yield 
[3]. Finally, a Michaelis-Arbuzov reaction of the 
bromide 4b with an excess of triethyl phosphite 
at 160 °C gave diethyl-[3,5-bis-(methoxymeth-
oxy)benzyl]phosphonate 4c in 65 % yield. The 
Wittig-Horner-Emmons carbonyl olefination of 
the phosphonate 4c with 4-fluorobenzaldehyde 
5 under basic conditions (KOtBu, DMF) led to 
the formation of 1-[(E)-2-(4-fluorophenyl)-
ethenyl]-3,5-bis(methoxymethoxy)benzene 6 in 
quantitative yield. Treatment of MOM-ether 6 
with HCl provided reference compound 1 in   
93 % yield.  
The radiosynthesis of [18F]-1 was carried out 
by coupling phosphonic acid diester 4c in the 
presence of KOtBu with readily available 4-
[18F]fluorobenzaldehyde [18F]-5 according to a 
Wittig-Horner-Emmons carbonyl olefination 
protocol (Fig. 2).  
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Reagents and conditions: (a) [18F]F-, K2CO3/Kryptofix222, DMF,   
120 °C, 15 min; (b) 4c, KOtBu, DMF, 60 °C, 15 min; (c) 3 N HCl,  
60 °C, 20 min. 
 
Fig. 2. Synthesis of 18F-labelled resveratrol derivative 
 [18F]-1 
 
The resulting coupling product [18F]-6 was 
treated with 3 N HCl to remove MOM-ether 
protecting groups. Subsequent final semi-
preparative HPLC purification gave compound 
[18F]-1 in decay-corrected radiochemical yield of 
9 % and at a specific activity of 90 GBq/µmol 
within 120-130 min. The radiochemical purity 
exceeded 95 %. The radiopharmacological 
evaluation of [18F]-1 is currently in progress. 
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Operation of the Rossendorf PET Cyclotron "CYCLONE 18/9" in 2004 
St. Preusche, F. Wüst 
 
 
Routine operation 
The radionuclides produced in routine opera-
tion in 2004 were F-18, C-11, O-15 available 
as [18F]F-, [18F]F2, [11C]CO2, and [15O]H2O. 
There were no demands for production of 13N. 
The production of the non-standard radionu-
clide 86Y became routine operation in 2004. 
Table 1 gives an overview of the 2004 ra-
dionuclide production. 
Due to an increasing demand of radiopharma-
ceuticals (FDOPA, OMFD) and radiotracers 
the daily operating time of the CYCLONE 18/9 
increased by 30 % with regard to the maximum 
value of 2001 and varied now between three 
and five hours. It is the first time that the num-
ber of deuterons beam hours exceeds those of 
the protons significantly. 
 
Table 1. Radionuclide production in 2004 
Radionuclide production  
RN Number of 
Irradiations 
    SumAEOB 
GBq 
[18F]F- 274 9002 
[18F]F2  303*) 1837 
11C 106 2900 
15O 88 1940 
86Y 18 20.1 
56Co 4 0.002 
*) including pre-irradiations  
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Fig 1a, b. Number of irradiations of radionuclides 
produced. 
Fig. 1 shows the number of irradiations of our 
radionuclides and Fig. 2 the total amount of 
activity produced over the last seven years 
(1998 to 2004). 
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Fig. 2a, b, c. Total amount of activity produced.  
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Improvements at the cyclotron 
An improved version of the Rossendorf solid 
target system [1, 2] was designed, assembled 
and tested. Thus, the yield of 86Y produced 
could be increased by 50 % using similar irra-
diation conditions. 
 
 
Maintenance and service 
- Stripper foils 
Serious problems with the carbon stripper foils 
occurred in 2004 and led to a number of cyclo-
tron openings that exceeded the average an-
nual value by a factor of 3. The stripper foils 
tore at the front edge of the fork or at any other 
edges and curled. Thus, stable extraction con-
ditions were not possible any more. We also 
observed this effect with stripper foils that were 
not in the ion beam. Comprehensive investiga-
tions were carried out and led to the result that 
these effects could be explained by the bad 
quality of the stripper foils. Since the end of 
2004 we have tested carbon foils of other sup-
pliers. 
 
- Cathodes for the ion sources 
Since 2004 the cathodes for both ion sources 
are manufactured in the FZR (Dept. of Re-
search Technology). With the new Ta cath-
odes the ion sources need less arc current to 
achieve a certain ion beam current and work 
more stable over period of use. 
 
- Annual check of the cyclotron 
The annual check of the CYCLONE 18/9 facil-
ity by the TÜV Sachsen organization (TÜV = 
Association for Technical Inspection) under  § 
66 (2) of the Radiation Protection Regulation 
was carried out in the second half of Septem-
ber. There were no objections to the further 
operation of the cyclotron.  
 
 
Radiation protection 
- Emission of radionuclides with the exhaust air 
The emission of radionuclides with the exhaust 
air is routinely monitored. As shown in Table 2, 
it is well below the limit of 2.0E11 Bq.  
 
 
 
 
 
 
 
 
 
 
Table 2. Emission of radionuclides with the exhaust air in 
2004 as a result of cyclotron operation  
Radionuclide Emission [Bq/a] 
41Ar  1.7E10 
18F  6.3E09 
Sum 2.3E10 
Percentage of the 
annual limit 
11.7 
 
 
- Exposure to radiation of the cyclotron staff 
The cyclotron staff belong to category A of 
occupational exposed persons. The average 
exposure to radiation of the cyclotron staff over 
the years is shown in Table 3. The increase in 
2004 is due to the strongly increased number 
of cyclotron openings to replace destroyed 
stripper foils and to more maintenance work as 
result of an increased number of beam hours 
and related to it an increased wear. 
 
Table 3. Average exposure  to radiation  of the cyclotron 
staff 
Year Exposure [mSv] 
1997 1.8 
1998 2.9 
1999 3.5 
2000 6.2 
2001 4.6 
2002 1.7 
2003 2.6 
2004 5.2 
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Improved Version of the Rossendorf Solid Target System  
St. Preusche, N. Dohn, H. Roß 
 
An improved version of the Rossendorf solid target system was designed, assembled and tested. 
 
 
Introduction 
Originally, the Rossendorf solid target system 
(STS) [1, 2] consisted of an irradiation cham-
ber to irradiate targets with rectangular shape 
(rectangle targets) and a module connected to 
the chamber to irradiate targets with circular 
shape (disk targets).  
During the test period of STS in 2003 it be-
came obvious that very sensitive target mate-
rials will not be used in the next future and thus 
there will be no reasons for using the irradia-
tion chamber with the rectangle targets.  
The focus of interest changed to the use of the 
disk target system only. 
 
Technical feature 
The irradiation chamber was completely re-
moved from STS and new adapter flanges to 
match the disk target system to the external 
beam transport line were designed, manufac-
tured and tested.  
Fig. 1 shows the new disk target system. 
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The disk target holder with the target is electri-
cally driven from the load position into the irra-
diation position and there it is fixed by a spring. 
The target holder is water cooled at the rear, 
the target surface is He cooled by a special 
nozzle inside the He cooling flange (see Fig. 1, 
position 2) and in this way the vacuum window 
is also cooled. The collimator insert (see Fig. 
1, position 3) is water cooled. 
 
Water and He interlocks for the disk target are 
connected to the cyclotron’s internal interlock 
system. They act only in the case when the 
vacuum valve of the external beam transport 
line is open.  
 
 
Results 
The new disk target system has been working 
for half a year in the predicted way. Without 
the long irradiation chamber and its low He 
overpressure inside there are less energy 
losses of the ion beam on the target resulting 
in higher production yields of e.g. 86Y. With 
comparable irradiation parameters it is now 
possible to achieve 50 % more 86Y activity [3]. 
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Production of 86Y and 56Co at the Rossendorf PET Cyclotron “CYCLONE 18/9”  
St. Preusche, F. Wüst, K.D. Schilling1, N. Dohn, H. Roß 
1FZR, Institut für Kern- und Hadronenphysik 
 
Additional to the routine production of 18F, 15O, 13N and 11C the positron emitting radionuclides 86Y and 56Co are 
produced using the Rossendorf solid target system. 
 
 
Introduction 
The number of radionuclides produced at the 
Rossendorf CYCLONE 18/9 cyclotron was 
increased in 2004. Additional to the routine 
production of 18F, 15O, 13N and 11C the positron 
emitting radionuclides 86Y (T1/2 = 14.7 h) and 
56Co (T1/2 = 77.3 d) are produced using the 
Rossendorf solid target system [1, 2]. 
86Y as potentially better radionuclide than 111In 
for the estimation of an absorbed dose in 90Y 
therapy is produced via the 86Sr(p,n)86Y nu-
clear reaction using enriched 86SrCO3 as target 
material [3]. 
56Co is produced via the 56Fe(p,n)56Co nuclear 
reaction using natural Fe as target material. 
The Institut für Kern- und Hadronenphysik of 
the FZR uses 56Co as a very convenient 
gamma calibration source for HPGe detectors 
applied in measurements of characteristic γ-
radiation in nuclear resonance fluorescence [4] 
and photo-activation [5] experiments at the 
Rossendorf ELBE Radiation Source. 
 
 
Results and Discussion 
86Y 
The enriched target material (70 mg) is 
pressed into a platinum target holder and cov-
ered by a thin platinum foil for protection. 
Typical irradiation parameters are: 
Ion beam on the target: (6.5 – 8) µA 
Irradiation time:  (80 – 110) min 
 
With these parameters (1.3 – 2.2) GBq of 86Y 
could be achieved at end of bombardment 
(EOB). 
In 2004 18 irradiations of 86SrCO3 were carried 
out and a total amount of 21 GBq of 86Y activity 
(EOB) was produced. 
The results of γ-spectrometric analyses show 
that only 0.04 % of the long-lived radionuclide 
88
Y (T1/2 = 106.6 d) are formed under the irra-
diation parameters mentioned above [3]. 
 
 
 
 
 
 
 
 
56Co 
The first tests to find suitable irradiation pa-
rameters for the production of 56Co were car-
ried out with a target area of 12 mm in diame-
ter (natural Fe: 54Fe/5,8 %, 56Fe/91,7 %, 
57Fe/2.2 %, 58F/0.3 %). Using an ion beam on 
the target of (1 – 2) µA and irradiation times of 
(2 – 20) min  (0.08 – 1.8) MBq of 56Co could be 
achieved at EOB. 
The results of γ-spectrometric analyses show 
that less than 1 % of the long-lived radionu-
clides 57Co (T1/2 = 271.8 d)  and 58Co  
(T1/2 = 70.8 d) are formed under these irradia-
tion parameters [6]. 
The 56Co activity of 80 kBq had to be reduced 
due to the very sensitive detector systems. A 
new target design became necessary: a re-
movable Fe insert of only 16 mm2 in cross 
section as target surface is now fixed in the 
target holder disk. 
Using an ion beam current of 1 µA on the tar-
get and irradiation times of (2 – 3) min 12.5 – 
15.7 kBq of 56Co could be achieved at EOB. 
These 56Co activities enable an effective cali-
bration of the HPGe detectors. 
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K. Knop 
Entwicklung eines neuen Radiotracers zur Charakterisierung von Transglutaminasen in vivo. 
Fachhochschule Zittau/Görlitz, 27.01.2004. 
 
J. Langner 
Development of a parallel computing optimised head movement correction method in positron emis-
sion tomography. 
Hochschule für Technik und Wirtschaft Dresden, 19.02.2004 
 
A. Höhne 
Synthese von 18F-markierten Cyclooxygenase-2-Inhibitoren als Radiotracer für die Positronen-
Emissions-Tomographie. 
Technische Universität Dresden, 30.06.2004. 
 
J. Schlesinger 
Yttrium-86 Markierung von Neurotensin (8-13)-Derivaten. 
Technische Universität Dresden, 15.07.2004. 
 
S. Juran 
Synthese und Charakterisierung von Kupferkomplexen mit Bispidin-Liganden. 
Fachhochschule Lausitz, Senftenberg, 10.12.2004. 
 
 
PhD THESIS 
 
J.-U. Künstler 
Beitrag zur Präparation und Charakterisierung technetiummarkierter Antikörper und Peptide. 
Technische Universität Dresden, 05.11.2004. 
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III. COLLABORATIONS, FUNDED 
PROJECTS AND FINANCIAL 
SUPPORT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 COLLABORATIONS  
 
The Institute sustains a number of valuable collaborations with other research institutions and is en-
gaged in joint projects funded by federal and trans-national authorities and research initiatives as well 
as by the industry. 
 
Naturally, the Technical University of Dresden continues to be an important partner in our cooperative 
relations. Cooperations exist with various groups in the Department of Chemistry and the Faculty of 
Medicine. Common objects of radiopharmacological and medical research link the Institute with the 
University Hospital in Dresden, above all with its Department of Nuclear Medicine (Prof. Kotzerke) 
which contributes to the staff of the jointly operated PET Centre Rossendorf. Application of the posi-
tron emission tomography technique has been successfully extended to new questions in collabora-
tion with the Institute of Food Chemistry (Prof. Henle). Fruitful collaborations on the development of 
novel PET radiotracers have been established with the Institute of Organic Chemistry (Prof. Metz) and 
the Institute of Biochemistry (Prof. van Peè). Bioinorganic research activities are closely linked with the 
Department of Coordination Chemistry (Prof. Gloe). 
 
 
On the national and international level, there exist a number of collaborations. 
 
The identification of common objects in PET radiopharmacy has led to collaborative research with the 
Institute of Interdisciplinary Isotope Research at the University of Leipzig (Prof. Steinbach). Both insti-
tutes constitute an alliance of research in radiopharmaceutical sciences. 
 
Cooperation in PET tracer chemistry and radiopharmacology has been established with the Turku 
Medical PET Center (Prof. Solin), Washington University, School of Medicine in St. Louis (Prof. Welch 
and Prof. Anderson), Harvard School of Medicine in Boston (Dr. Neumeyer), Northeastern University 
Boston (Prof. Hanson), University of Illinois in Champaign-Urbana (Prof. Katzenellenbogen) and the 
Instituto Tecnológico e Nuclear in Sacavèm (Dr. Santos). 
 
Cooperation in the field of peptide chemistry and receptor research exists with the University of Leip-
zig (Prof. Beck-Sickinger) and the Free University of Brussels (Prof. Tourwe).  
 
Cooperation in technetium and rhenium chemistry exists with the University of Ferrara (Prof. Duatti), 
CNR Padova (Dr. Tisato, Dr. Refosco), with the Korean Research Centre KAERI (Dr. Park), as well as 
with the University of Kitakyushu, Japan (Prof. Yoshizuka) and, more recently, the University of Mis-
souri-Columbia (Dr. Smith). The Institute works with the University of Heidelberg (Prof. Comba) and 
with University Hospital Leipzig (Dr. Laub, Prof. Emmrich), on radioimmunoscintigraphy. 
 
Very effective cooperation exists with the Federal Material Research Institute in Berlin (Dr. Reck, Mr. 
Kraus), whose staff members carried out X-ray crystal structure analysis of new technetium and rhe-
nium complexes. 
 
In the field of supramolecular chemistry, successful cooperation exists with the Kekulé Institute of Or-
ganic Chemistry and Biochemistry (Prof. Vögtle) of the University of Bonn. 
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 PUBLIC FUNDED PROJECTS 
 
The Institute is part of the Research Center Rossendorf, which is financed by the Federal Republic of 
Germany and the Free State of Saxony on a fifty-fifty basis. 
 
 
The Institute participated in the following networks supported by Commission of the European Com-
munities: 
 
Radiotracers for in vivo assessment of biological function 
COST B12 
in collaboration with Sweden, Italy and Switzerland. 
02/1999 – 04/2005. 
 
Since 2004, the Institute is engaged in the SIXTH FRAMEWORK PROGRAMME PRIORITY 1 FP6-
2002 LIFESCIHEALTH, in the project BioCare, Molecular Imaging for Biologically Optimized Cancer 
Therapy, Contract no.: 505785. The Institute contributes to the work packages: WP 3 - Molecular im-
aging of radiation therapy induced alteration of tumour cell proliferation and functional receptor ex-
pression, WP 4 - Aptamer based PET and SPECT tracers for molecular tumour imaging, together with 
partners from the Technical University of Dresden, Universitair Ziekenhuis Gasthuisberg, Université 
Catholique de Louvain, and University of Hamburg. 
04/2004-10/2008. 
 
The Institute further contributes to POL-RAD-PHARM (MARIE CURIE TRANSFER OF KNOWLEDGE 
FELLOWSHIP). Project full title: Chemical Studies for Design and Production of New Radiopharma-
ceuticals. The project aims at commencing and intensifying research in radiopharmaceutical chemistry 
– a new discipline for the host institution. For this purpose the host institution, located in Poland, has 
established partnership with other seven European laboratories.  
The research part of the project includes:  
(1) learning and/or mastering methods for obtaining novel potential radiopharmaceuticals labelled with 
99mTc (diagnostic) and with 188Re (therapeutic);  
(2) developing a method for labelling biomolecules with 211At by formation of stable heteroleptic com-
plexes between astatide (At-) and chelates of soft metal cations;  
(3) developing methods for obtaining selected radionuclides of potential use in manufacturing radio-
pharmaceuticals, including metallic PET nuclides and alpha-emitters;  
(4) developing analytical methods for purity control and stability studies of the novel radiopharmaceuti-
cals.  
07/2004-06/2008 
 
 
On the national level, two research projects concerning tracer design, biochemistry and PET radio-
chemistry were supported by the Deutsche Forschungsgemeinschaft (DFG): 
 
Molecular encapsulated 188Re complexes: Development of robust and tunable radioactive rhenium 
complexes on the basis of novel chelators derived from dimercaptosuccinic acid (DMSA) 
PI 255/5-1 (H.-J. Pietzsch) 12/2002 – 11/2004. 
 
F-18 labelled corticosteroides as ligands for imaging brain glucocorticoid-receptors by means of PET 
WU 340/1-1 (F. Wüst) 11/2004 – 10/2006. 
 
 
The Sächsisches Staatsministerium für Wissenschaft und Kunst provided support for the following 
projects: 
 
Development and characterization of nanoscale metal-based drugs targeting tumours 
SMWK-No. 4-7531.50-03-0370-01/4, 06/2001 – 12/2004. 
 
MeDDrive 2002 
 01/2004 – 12/2004 
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 The Bundesministerium für Bildung und Forschung supported cooperation with  
 
Czech Republic: Polyoxometallo compounds 
WTZ, 08/2002 – 07/2005 
 
Russia: Polynuclear metallo drugs 
WTZ, 07/2003 – 09/2004 
 
 
The Bundesministerium für Wirtschaft und Arbeit supported research projects on: 
 
Preparation of 86Y  
08/2003 - 01/2005 
 
Radioimmunodiagnostics of inflammation 
05/2004 - 06/2007 
 
 
Several laboratory visits were supported by the “Deutscher Akademischer Austauschdienst” (DAAD). 
 
VIGONI-Project with Padova (Italy): 
Labelling Dithiol Ligands with a TcN-Synthon 
01/2005 – 12/2006 
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 FINANCIAL SUPPORT BY THE INDUSTRY 
 
The following projects were supported by cooperations with the industry: 
 
ABX advanced biomedical compounds GmbH Dresden 
Cooperation in functional diagnostics  
  04/2001 - 11/2004 
 
ABX advanced biomedical compounds GmbH Dresden 
Synthesis of precursors for PET radiopharmaceuticals  
01/2003 – 12/2004 
 
ABX advanced biomedical compounds GmbH Dresden  
PET surrogate parameters 
10/2003 - 06/2006 
 
Apogepha Arzneimittel GmbH  
Cooperation in pharmakokinetics and metabolism of propiverin 
07/2003 – 03/2005 
 
A.R.T. Hersching  
Cooperation in movement tracking for PET 
09/2002 – 12/2005 
 
Bayer AG Leverkusen  
Cooperation in drug development 
05/2002 – 06/2005 
 
Bruker BioSpin MRI GmbH 
MPI/PET-Coupling 
11/2003 – 12/2005 
 
Nihon-Medi-Physics (Japan/USA) 
Development and evaluation of technetium-99m-labelled fatty acids 
01/2003 – 12/2005 
 
ROTOP Pharmaka GmbH 
Agent syntheses 
 06/2004 – 12/2006 
 
Schering AG Berlin  
Cooperation in drug development 
1/2004 – 06/2005 
 
Schering AG Berlin 
Cooperation in nuclear diagnostics 
07/1996 – 12/2004 
 
 Schering AG Berlin 
  Pharmaceutical research 
  01/2002 - 12/2006 
 
 Schering AG Berlin 
  Metal chelates 
  05/2003 - 12/2006 
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 LABORATORY VISITS 
 
Dr. F. Wüst 
McLean Hospital, Boston, USA 
16.-19.01.2004 
 
Dr. S. Seifert 
Korea Atomic Energy Research Institute (KAERI), HANARO, Div. of Radioisotope Production, Korea 
21.-28.04.2004 
 
A. Röllig 
Institute of Chemical Technology, Prag, Czech Republik 
23.-30.05.2004 
 
E. Schiller 
Forschungszentrum Padua, Italy 
07.-16.07.2004 
 
Dr. F. Wüst 
School of Medicine, St. Louis, USA 
23.09.-14.10.2004 
 
T. Heinrich 
Universität Ferrara, Italy 
02.-26.11.2004 
 
Dr. H.-J. Pietzsch 
IAEA, Wien, Austria 
14.-20.11.2004 
 
 
GUESTS 
 
S. Raji 
Kwame Nkrumah University of Science and Technology, Kumasi 
01.10.2003 – 28.03.2004 
 
F. Aggrey 
University of Cape Coast (U.C.C.) 
15.10.2003 – 11.04.2004 
 
Dr. R. Garcia 
Instituto Technologico e Nuclear, Sacavem, Portugal 
12.-30.01.2004 
 
M. R. Zainol Abidin 
University Malaya Medical Centre, Kuala Lumpur, Malaysia 
01.03. – 26.03.2004 
 
A. M. Zain 
University Malaya Medical Centre, Kuala Lumpur, Malaysia 
01.03. – 26.03.2004 
 
Dr. S. Park 
Korea Atomic Energy Research Institute, Daejeon, Korea 
15.06. – 14.09.2004 
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 X. Chen 
Shanghai Jiao Tong University, China 
19.07. – 18.09.2004 
 
Prof. V. Fedorov 
Siberian Branch of the Russian Academy, Novosibirsk, Russia 
01.09. – 10.09.2004 
 
Dr. T. Suzuki 
University of Kitakyushu, Kitakyushu, Japan 
01.09. – 11.10.2004 
 
Prof. K. Yoshizuka 
University of Kitakyushu, Japan 
01.09. – 16.10.2004 
 
Dr. Zhang Chunfu 
Shanghai Institute of Applied Physics, China 
04.10. – 29.10.2004 
 
P. Krotka 
Institute of Chemical Technology Prague, Czech Republic 
16.10. – 31.10.2004 
 
K. Brylev 
Russian Academy of Science Siberian Branch, Novosibirsk, Russia 
18.10.2004 – 16.12.2004 
 
Prof. Z. Matejka 
Institute of Chemical Technology Prague, Czech Republic 
13.12. – 15.12.2004 
 
P. Krotka 
Institute of Chemical Technology Prague, Czech Republic 
13.12. – 18.12.2004 
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 MEETINGS ORGANIZED 
 
1. Workshop “Positronen-Emissions-Tomographie in der Lebensmittelforschung” 
Forschungszentrum Rossendorf/Technische Universität Dresden 
17.05.2004 
 
1. “List Mode User Meeting“ 
Forschungszentrum Rossendorf/Siemens Erlangen, CTI Knoxville, USA 
18.05.2004 
 
 
TEACHING ACTIVITIES 
 
Summer term 2004 
 
B. Johannsen, H.-J. Pietzsch 
One term course on Metals in Biosystems (Introduction into Bioinorganic Chemistry) 
 
J. Pietzsch 
Lipoproteine and Atherogenese 
 
 
Winter term 2004/2005 
 
F. Wüst 
One term course on Radiopharmaceutical Chemistry 
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IV. SEMINARS 
 
  
 
 
 
 
 TALKS OF VISITORS 
 
Dr. N. Schramm, Forschungszentrum Jülich, Zentrallabor für Elektrotechnik 
Erste Ergebnisse eines hochauflösenden Multi Pinhole Spect an Mäusen 
02.03.2004 
 
Prof. C. E. Müller, Universität Bonn, Pharmazeutisches Institut 
Purinrezeptoren als Zielstrukturen in der Wirkstoff-Forschung 
15.04.2004 
 
Prof. K. Yoshizuka, University of Kitakyushu 
Selective recovery of lithium ion in seawater using a λ-MnO2 adsorbent 
23.09.2004 
 
Dr. T. Suzuki, University of Kitakyushu 
Speckle image observations using high coherent X-ray beams focused by Fresnel Zone Plate 
23.09.2004 
 
Prof. K. Inoue, Saga University 
Remediation of polluted environment by using biomass wastes 
12.10.2004 
 
Prof. F. Vögtle, Universität Bonn 
Funktionelle Dendrimere – Synthesen, Eigenschaften und Anwendungen in den Material- und Le-
benswissenschaften 
28.10.2004 
 
Prof. S. Waldvogel, Universität Bonn, Kekulé-Institut für Organische Chemie 
Synthese, Eigenschaften und Anwendungen von künstlichen Koffeinrezeptoren 
09.12.2004 
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 INTERNAL SEMINARS  
 
Dr. B. Noll 
Monitoring Gentherapie 
24.03.2004 
 
A. Höhne 
18F-Markierung von COX-2-Inhibition 
07.04.2004 
 
Dr. B. Beuthien-Baumann 
Parkinson-Diagnostik mit PET 
28.04.2004 
 
J. Schlesinger 
86Y-Markierung von Neurotensin (8-13) 
19.05.2004 
 
T. Heinrich 
Entwicklung von stabilen und anpassbaren Re-Komplexen mit verbrückten DMSA-Chelatoren 
09.06.2004 
 
E. Schiller 
Stabile Re-188-Komplexe mit Phoshin-Liganden 
30.06.2004 
 
S. Gester 
Markierung von Polyphenolen und Flavonoiden mit PET-Radioisotopen 
25.08.2004 
 
D. Möckel 
Validierung von Methoden zur Bewegungskorrektur bei PET 
06.10.2004 
 
J. Langner 
Entwicklung einer parallelisierten Methode zur Bewegungskorrektur bei Hirnuntersuchungen in der 
Positronen-Emissions-Tomographie 
27.10.2004 
 
Dr. C. Haase 
Modulation der Tau-Protein-Eigenschaften durch Pseudophosphorylierung 
15.12.2004 
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V. PERSONNEL 
 
  
 Director (provisional) 
Prof. Dr. van den Hoff, J.   
 
 
Administrative Staff 
Forker, S. Neubert, G.  
 
 
Scientific Staff 
Dr. Berndt, M.* Dr. Noll, B. Dr. Spies, H.* 
Dr. Bergmann, R. Dr. Noll, S. Dr. Stephan, H. 
Dr. Füchtner, F. Dr. Pawelke, B.* Dr. Strobel, K.* 
Dr. Grote, M.* Dr. Pietzsch, H.-J. Dr. Walther, M.* 
Dr. Haase, C.* Dr. Pietzsch, J. Dr. Will, E. 
Dr. Knieß, T. Preusche, S. Dr. Wüst, F. 
Künstler, J.-U.* Dr. Rother, A.* Dr. Zessin, J. 
Mäding, P. Dr. Seifert, S.  
 
 
Technical Staff 
Barth, M.* Jährig, P.* Lenkeit, U. 
Dohn, N. Kasper, H. Lipps, B. 
Gläser, H. Kolbe, U. Lücke, R.* 
Görner, H. Krauß, E. Rode, K.* 
Große, B. Krauß, T.* Roß, H. 
Hentges, A. Kreisl, B. Sterzing, R. 
Herrlich, R. Landrock, K. Suhr, A.** 
Herzog, W. Lehnert, S.  
 
 
PhD Students 
Gester, S. Just, U. Schiller, E. 
Hecht, M. Langner, J. Schlesinger, J. 
Heinrich, T. Pötzsch, C. Steiniger, B. 
Hultsch, C.   
 
 
Former Personnel 
(who left during the period covered by the report) 
 
Scientific Staff: Kretzschmar, M. Dr. Pönisch, F* 
 
 
* term contract ** on maternity leave 
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